

# ANDROGEN RECEPTOR GENE MUTATIONS DATABASE

**Curator:** Dr. Bruce Gottlieb  
 Lady Davis Institute for  
 Medical Research  
 3755 Cote Ste Catherine  
 Rd, Montreal, Quebec  
 H3T 1E2, Canada

Telephone: 514-340-8260  
 FAX: 514-340-7502  
 E-Mail: bruce.  
 gottlieb@mcgill.ca  
 Internet: <http://www.androgendb.mcgill.ca>

Date of this version: 1st Nov 2010

Accession # Phenotype	Mutation type	Proven Pathogenicity	CpG hot spot	Exon Domain	Position Base	Change Amino acid	Androgen Binding			Comments	Sex of rearing	External Genitalia	Family history	Reference
							Amino acid	Exon 1 tracts	Thermolabile					
								Poly Gln #	Poly Gly #	Bmax	Kd	k		
0001	PAIS	Substitution	1 Nterm *	002	Glu $\Rightarrow$ Lys <u>GAA</u> $\Rightarrow$ <u>AAA</u>					high				Choong et al; J Clin Invest. 98: 1423-1431, 1996
0960	CAIS	Substitution	1 Nterm	002	Glu $\Rightarrow$ Lys <u>GAA</u> $\Rightarrow$ <u>AAA</u>	27	13	low	high					Audi et al. J Clin Endocrinol Metab 95:1876-1888, 2010
0751	CAIS	Deletion	1 Nterm	007	Leu $\Rightarrow$ 0 $\Delta$ CTG $\Rightarrow$									Barbaro et al. Clin Endocrinol 66:822-826, 2007
0963	CAIS	Insertion	1 Nterm	015	Pro $\Rightarrow$ Ala CCG $\Rightarrow$	20	9							Audi et al. J Clin Endocrinol Metab 95:1876-1888, 2010
0624	CAIS	Deletion	1 Nterm	039	Pro $\Rightarrow$ 0 $\Delta$ CCC $\Rightarrow$									Jung et al. Human Genetics 114: 222, 2004
0836	CAIS	Deletion	1 Nterm	040	Arg $\Rightarrow$ 0 $\Delta$ AGG $\Rightarrow$									Decaestecker et al; Fertility & Sterility 89: 1260 e3-7, 2008
0910	Prostate cancer	Substitution	1 Nterm	043	Glu $\Rightarrow$ Gly <u>GAG</u> $\Rightarrow$ <u>GGG</u>									Steinkamp et al; Cancer Res 69:4434-4442, 2009
0002	CAIS	Deletion	1 Nterm	051	Gly $\Rightarrow$ 0 <u>GGAC</u> $\Rightarrow$		zero							Boehmer et al; J Clin Endocrinol & Metab 86: 4151-4160, 2001
0003	Prostate cancer	Substitution	1 Nterm	054	Leu $\Rightarrow$ Ser <u>TG</u> $\Rightarrow$ <u>TCG</u>									Tilley et al; Clinical Cancer Res. 2: 277-285, 1996
0004	Laryngeal cancer	Deletion	1 Nterm	057	$\Rightarrow$ $\Rightarrow$									Urushibata et al; 10th. Int. Cong. Endocrinol Abstr. P3-706, 1996
0815	Testicular cancer	Deletion	1 Nterm	057	Leu $\Rightarrow$ 0 CTG $\Rightarrow$									Garolla et al. Encodrine Related Cancer 12:645-655, 2005
0808	Liver cancer	Substitution	1 Nterm	057	Leu $\Rightarrow$ Gln <u>CTG</u> $\Rightarrow$ <u>CAG</u>									Yeh et al. Int J Cancer 120:1610-1617, 2007
0005	Prostate cancer	Substitution	1 Nterm	057	Leu $\Rightarrow$ Gln <u>CTG</u> $\Rightarrow$ <u>CAG</u>									Tilley et al; Clinical Cancer Res. 2: 277-285, 1996
0786	MAIS	Insertion	1 Nterm	057	$\Rightarrow$ <u>531</u>									Ferlin et al. Clin Endocrinol 65:606-610, 2006
0411	Mental Retard.	Deletion	1 Nterm	058	$\Rightarrow$ $\Rightarrow$	8	normal	normal						Kooy et al; Am J Med Genet. 85: 389-393. 1999
0612	MAIS ?	Substitution	1 Nterm	058	Gln $\Rightarrow$ Leu <u>CAG</u> $\Rightarrow$ <u>CTG</u>									Lund et al; Fertility and Sterility 79(suppl 3): 1647-148, 2003
0897	CAIS	Insertion	1 Nterm	058	Gln $\Rightarrow$ <u>535</u>									Philibert et al; Fertility & Sterility 2009
0006	Kennedy Syndrome	Insertion	1 Nterm	058-078	$\Rightarrow$ $\Rightarrow$	> 40								LaSpada et al; Nature 352:77, 1991
0007	Prostate cancer	Deletion	1 Nterm	058-078	$\Rightarrow$ $\Rightarrow$	18								Schoenberg et al; Bioch. & Biophys Res Comm 198: 74-80 1994
0324	Prostate cancer	Deletion	1 Nterm	058-078	$\Rightarrow$ $\Rightarrow$	22								Watanabe et al; Jpn J Clin Oncol 27: 389-393, 1997
0325	Prostate cancer	Insertion	1 Nterm	058-078	$\Rightarrow$ $\Rightarrow$	22								Watanabe et al; Jpn J Clin Oncol 27: 389-393, 1997
0495	Prostate cancer	Deletion	1 Nterm	058-078	$\Rightarrow$ $\Rightarrow$	18								Wallin et al; J Pathology 189: 559-653, 1999

Accession #	Mutation type	Exon Domain	CpG hot spot	Position Base	Change Amino acid Base	Exon 1 tracts				Androgen Binding			Comments	Sex of rearing	External Genitalia	Family history	Reference
						Poly Gln #	Poly Gly #	Bmax	Kd	Thermolabile k							
0692	CAIS	Substitut	1 Nterm	059	Gln⇒ Stop <u>CAG</u> ⇒ TAG			zero						Female	Normal		Holterhus et al; J Mol Med 2005
0008	CAIS	Substitut	1 Nterm *	060 540	Gln⇒ Stop <u>CAG</u> ⇒ TAG			low	normal	high				Female	Normal	neg	Zoppi et al; J Clin Inv 19:1105, 1993
0671	CAIS	Substitut	1 Nterm *	060 540	Gln⇒ Stop <u>CAG</u> ⇒ TAG									Female	Normal		Bouvattier et al; J Clin Endocrinol & Metab 87: 29-32, 2002
0409	CAIS	Insertion or deletion	1 Nterm	060 540	Gln⇒ Gln <u>CAG</u> ⇒ CAAG									Female	Normal		Zhu et al; J Clin Endocrinol & Metab 84: 1590-1594, 1999
0009	Prostate cancer	Substitut	1 Nterm	064 550	Gln⇒ Arg <u>CAG</u> ⇒ CGG									Male	Normal		Tilley et al; Clinical Cancer Res. 2: 277-285, 1996
0846	CAIS	Substitut	1 Nterm	067 558	Gln⇒ Stop <u>CAG</u> ⇒ TAG									Female	Normal		Cheikhelard et al. J Urol 180:1496-1501, 2008
0894	CAIS	Substitut	1 Nterm	070 569	Gln⇒ Stop <u>CAG</u> ⇒ TAG									Female	Normal	neg	Philibert et al; Fertility & Sterility 2009
0881	MAIS ?	Substitut	1 Nterm	070 570	Gln⇒ Arg <u>CAG</u> ⇒ CGG	20,21 .23								Male	Normal		Hose et al; Fertility & Sterility 92: 390e9-e11, 2009
0787	PAIS?	Substitut	1 Nterm	073 579	Gln⇒ Stop <u>CAG</u> ⇒ TAG									Female	Normal		Mueller et al. Hum Genet 119:681, 2006
0895	CAIS	Substitut	1 Nterm	076 588	Gln⇒ Stop <u>CAG</u> ⇒ TAG									Female	Normal	pos	Philibert et al; Fertility & Sterility 2009
0961	CAIS	Substitut	1 Nterm	076 588	Gln⇒ Stop <u>CAG</u> ⇒ TAG		18							Female	Normal	neg	Audi et al. J Clin Endocrinol Metab 95:1876-1888, 2010
0902	CAIS	Deletion	1 Nterm	076 589	Gln⇒ CA <u>A</u> G⇒CAC									Female	Normal	neg	Philibert et al; Fertility & Sterility 2009
0807	Liver cancer	Substitut	1 Nterm	078 593	Gln⇒ Gln CAA⇒CAG									Male	Normal		Yeh et al. Int J Cancer 120:1610-1617, 2007
0962	CAIS	Insertion	1 Nterm	079 596	Glu⇒ Arg GAG⇒	21	18							Female	Normal	pos	Audi et al. J Clin Endocrinol Metab 95:1876-1888, 2010
0901	CAIS	Deletion	1 Nterm	080 600	Thr⇒ AA <u>CTAG</u> ⇒									Female	Normal	pos	Philibert et al; Fertility & Sterility 2009
0965	CAIS	Deletion	1 Nterm	082	Pro⇒ Ser CCC⇒	20	18	zero	zero					Female	Normal	pos	Audi et al. J Clin Endocrinol Metab 95:1876-1888, 2010
0964	CAIS	Substitut	1 Nterm	084 612	Gln⇒ Stop <u>CAG</u> ⇒ TAG	20		low	high					Female	Normal	pos	Audi et al. J Clin Endocrinol Metab 95:1876-1888, 2010
0416	CAIS	Insertion	1 Nterm	085 615	Gln⇒ Gln CAG⇒ CAAG	25		zero						Female	Normal		Gottlieb et al; Hum Mutat. 14: 527-539, 1999
0796	CAIS	Substitut	1 Nterm	086 618	Gln⇒ Stop <u>CAG</u> ⇒ TAG			zero						Female	Normal		Jaaskelainen et al. Hum Mutat 27:291, 2006
0882	Prostate Cancer	Deletion	1 Nterm	086 618	Gln⇒ O Δ <u>CAG</u> ⇒						+Q58L,T438P,G456S flutamide treatment			Male	Normal		Steinkamp et al; Cancer Res 69:4434-4442, 2009
0672	CAIS	Substitut	1 Nterm	088 624	Gln⇒ Stop <u>CAG</u> ⇒ TAG									Female	Normal		Bouvattier et al; J Clin Endocrinol & Metab 87: 29-32, 2002
0806	Liver cancer	Substitut	1 Nterm	089 629	Gln⇒ His <u>CAG</u> ⇒ CAT									Male	Normal		Yeh et al. Int J Cancer 120:1610-1617, 2007
0529	CWR22R Prost. CA Cell line	Substitut	1 Nterm	091 635	Glu⇒ Asp ⇒	27	19							Male	Normal		Chelnski et al. The Prostate 47: 66-75, 2001
0805	Liver cancer	Substitut	1 Nterm	100 661	Arg⇒ Lys AGA⇒ AAA									Male	Normal		Yeh et al. Int J Cancer 120:1610-1617, 2007
0417	CAIS	Deletion	1 Nterm	102 668	Pro⇒ Pro CC <u>AC</u> ⇒ CCG	12	25	zero						Female	Normal	neg	Gottlieb et al; Hum Mutat. 14: 527-539, 1999

Accession #	Mutation type	Exon Domain	CpG hot spot	Position Base	Change Amino acid Base	Exon 1 tracts				Androgen Binding			Comments	Sex of rearing	External Genitalia	Family history	Reference
						Poly Gln #	Poly Gly #	Bmax	Kd	Thermolabile k							
0898	CAIS	Insertion	1 Nterm	107 682	Val⇒ GTC⇒GATC									Female	Normal	neg	Philibert et al; Fertility & Sterility 2009
0010	Prostate cancer	Substitution	1 Nterm	112 698	Gln⇒His CAG⇒CAT								AlsoTrp798Stop (TGG to TGA) mut. Somatic mutation	Male	Normal		Tilley et al; Clinical Cancer Res. 2: 277-285, 1996
0418	CAIS	Substitution	1 Nterm	113 699	Gln⇒Stop <u>CAA</u> ⇒TAA	25	27							Female	Normal		Gottlieb et al; Hum Mutat. 14: 527-539, 1999
0802	CAIS	Substitution	1 Nterm	118 714	Gln⇒Stop <u>CAG</u> ⇒TAG							1 affected sister	Female	Normal	pos	Berg et al. J Pediatr 150:434-438, 2007	
0631	CAIS	Substitution	1 Nterm	119 718	Ser⇒Stop <u>TCG</u> ⇒TAG	25						gonads located in inguinal canal. Same family as 0830	Female	Normal	pos	Melo et al; J Clin Endocrinol & Metab 88: 3241-3250, 2003	
0830	CAIS	Substitution	1 Nterm	119 718	Ser⇒Stop <u>TCG</u> ⇒TAG							gonads located in inguinal canal. Same family as 0631	Female	Normal	pos	Melo et al; Arq Bras Endocrinol Metab 49:87-97, 2005	
0911	Prostate cancer	Substitution	1 Nterm	119 719	Ser⇒Ser <u>TCG</u> ⇒							Silent mutation Both treated and untreated Occurred in 2 cases	Male	Normal		Steinkamp et al; Cancer Res 69:4434-4442	
0417	CAIS	Deletion	1 Nterm	125 738	Pro⇒Pro <u>CCAC</u> ⇒CCG	23	24	zero				Int. deletion causing frameshift and stop at codon 172	Female	Normal		Gottlieb et al; Hum Mutat. 14: 527-539, 1999	
0011	CAIS	Deletion	1 Nterm	127 743	Arg⇒Arg <u>AGAA</u> ⇒AGG			zero				1 nt deletion causing frameshift & stop in Codon 172	Female	Normal	neg	Batch et al; Hum Mol Genet 1: 497, 1992	
0436	CAIS	Deletion	1 Nterm	127 743	Arg⇒Arg <u>AGAA</u> ⇒AGG							1 nt deletion causing frameshift & stop in Codon 172	Female	Normal		Ahmed et al; J Clin Endocrinol & Metab 85: 658-665, 2000	
0012	CAIS	Deletion	1 Nterm	140	⇒ ⇒							Deletion of Codons 140-148 Stop in Codon 154	Female	Normal		Hiort et al; Am J Med Genet. 63: 218-222, 1996	
0837	CAIS	Substitution	1 Nterm	141 784	Lys⇒Stop <u>AAG</u> ⇒ATG							Sertoli-Lydig tumor	Female	Normal		Jazabeck et al; Gynecol Endocrinol 23:499-504, 2007	
0694	Prostate Cancer	Substitution	1 Nterm *	142 787	Gly⇒Val <u>GGG</u> ⇒GTG	16		normal	normal			Increased response to DHT	Male	Normal		Chen et al; The Prostate 63:395-406, 2005	
0516	CAIS	Substitution	1 Nterm	153 819	Glu⇒Stop <u>GAG</u> ⇒TAG								Female	Normal		Copelli et al; Asian J Androl 1: 73-77, 1999	
0523	CAIS	Substitution	1 Nterm	153 819	Glu⇒Stop <u>GAG</u> ⇒TAG								Female	Normal		Gacobini et al. Hum Genet. 108; 176, 2001	
0788	PAIS	Substitution	1 Nterm	157 831	Ala⇒Thr <u>GCT</u> ⇒ACT											Mueller et al. Hum Genet 119:681, 2006	
0627	Prostate Cancer	Substitution	1 Nterm	166 858	Gly⇒Ser <u>GGC</u> ⇒AGC							Orch + bicalutamidine treatment Gleason 10 Somatic. mutation	Male	Normal		Haaplaa et al. Lab Invest. 81:1647-1651, 2001	
0838	CAIS	Deletion	1 Nterm	166 858	Gly⇒0 <u>AGC</u> ⇒							Frameshift and stop in codon	Female	Normal		Jeske et al; J Pediatr Endocrinol Metab 20:893-908, 2007	
0013	CAIS	Substitution	1 Nterm	172 877	Leu⇒Stop <u>TTA</u> ⇒TGA								Female	Normal		Hiort et al; Am J Med Genet. 63: 218-222, 1996	
0316	PAIS	Substitution	1 Nterm	172 877	Leu⇒Stop <u>TTA</u> ⇒TGA	low		normal				Somatic mosaic mut. causes partial virilization	Female	Ambiguous		Holterhus et al; J Clin Endocrinol. 82: 3584-3589, 1997	
0420	CAIS	Substitution	1 Nterm	172 877	Leu⇒Stop <u>TTA</u> ⇒TGA	26	24	zero					Female	Normal	neg	Gottlieb et al; Hum Mutat. 14: 527-539, 1999	
0566	Prostate cancer	Substitution	1 Nterm	176 190	Ser⇒Ser <u>TCC</u> ⇒TCT							Som Mut. Exposed to Estrogen treat. Also Leu744Leu Silent	Male	Normal		Hyttinen et al; Lab Invest. 82: 1591-1598, 2002	
0014	Prostate cancer	Substitution	1 Nterm	180 901	Lys⇒Arg <u>AAA</u> ⇒AGA							Somatic mutation	Male	Normal		Tilley et al; Clinical Cancer Res. 2: 277-285, 1996	
0912	Prostate cancer	Substitution	1 Nterm	192 936	Leu⇒Phe <u>CTT</u> ⇒TTT							Treated with anti-androgens Occurred in 2 cases	Male	Normal		Steinkamp et al; Cancer Res 69:4434-4442	
0913	Prostate cancer	Substitution	1 Nterm	192 937	Leu⇒Arg <u>CTT</u> ⇒CGT							Treated with anti-androgens	Male	Normal		Steinkamp et al; Cancer Res 69:4434-4442	

Accession #	Mutation type	Exon Domain	CpG hot spot	Position Base	Change Amino acid Base	Exon 1 tracts				Androgen Binding			Comments	Sex of rearing	External Genitalia	Family history	Reference
						Poly Gln #	Poly Gly #	Bmax	Kd	Thermolabile k							
0319	CAIS	Substitut	1 Nterm	194 943	Gln⇒Arg CAA⇒CGA					Also 1 nt deletion in Codon 597 causing a stop	Female	Normal		Komori et al; J Obstetrics & Gynocol. 23: 277-81, 1997			
0551	Prostate cancer	Substitut	1 Nterm	198 955	Glu⇒Gly GAA⇒GGA					Treated with bicalutamide - somatic mutation	Male	Normal		Taplin et al; 37th meeting ASCO 20: Abstr, 1738 2001			
0015	CAIS	Insertion	1 Nterm	202	Glu⇒ ⇒	zero				4 nt insertion causing frameshift & stop in Codon 232	Female	Normal	neg	Batch et al; Hum Mol Genet 1:497, 1992			
0549	Prostate cancer	Substitut	1 Nterm	202 968	Glu⇒Glu GAA⇒GAG					Treated with bicalutamide - silent mutation- somat. mut.	Male	Normal		Taplin et al; 37th meeting ASCO 20: Abstr, 1738 2001			
0395	Normal	Substitut	1 Nterm	205 977	Ser⇒Arg AGC⇒AGG					Homosexual individual	Male	Normal		Macke et al; Am J Human Genetics 53: 844-852, 1993			
0437	CAIS	Deletion	1 Nterm	208 985	Arg⇒Lys AΔGA⇒AAG	zero				Frameshift & stop in codon 232 ?	Female	Normal		Ahmed et al; J Clin Endocrinol & Metab 85: 658-665, 2000			
0376	MAIS	Substitut	1 Nterm	210 992	Arg⇒Arg AGG⇒AGA					Silent mutation	Male	Normal		Wang et al; Clinical Genetics 54: 185-192, 1998			
0328	Normal	Substitut	1 Nterm	211 995	Glu⇒Glu GAG⇒GAA					Silent mutation - polymorphism detected in 8% popul.	Male	Normal		Batch et al; Hum Mol Genet 1:497, 1992			
0329	Normal	Substitut	1 Nterm	211 995	Glu⇒Glu GAG⇒GAA					Silent mut.polymorph -detected in 14% of X chromosomes	Male	Normal		Hiort et al; Eur J Pediatr 153: 317-321, 1994			
0330	Normal	Substitut	1 Nterm	211 995	Glu⇒Glu GAG⇒GAA					Silent mutation polymorphism	Male	Normal		Lu et al; Clinical Genetics 49: 323-324. 1996			
0377	Normal	Substitut	1 Nterm	211 995	Glu⇒Glu GAG⇒GAA					Silent mutation polymorphism	Male	Normal		Wang et al; Clinical Genetics 54: 185-192, 1998			
0396	Normal	Substitut	1 Nterm	211 995	Glu⇒Glu GAG⇒GAA					Silent mut.polymorph detected in 10% of X chromosomes	Male	Normal		Macke et al; Am J Human Genetics 53: 844-852, 1993			
0378	MAIS	Substitut	1 Nterm	211 995	Glu⇒Glu GAG⇒GAA					Silent mutation polymorphism - 4 patients with	Male	Normal		Wang et al; Clinical Genetics 54: 185-192, 1998			
0421	CAIS	Substitut	1 Nterm	211 995	Glu⇒Glu GAG⇒GAA	22	24	v low		Silent mutation - negligible level of mRNA & hAR	Female	Normal		Gottlieb et al; Hum Mutat. 14: 527-539, 1999			
0422	CAIS	Substitut	1 Nterm	211 995	Glu⇒Glu GAG⇒GAA	21	23	normal	normal	Silent mutation -	Female	Normal	neg	Gottlieb et al; Hum Mutat. 14: 527-539, 1999			
0423	PAIS	Substitut	1 Nterm	211 995	Glu⇒Glu GAG⇒GAA	23	24	v low		Silent mutation -	Male	Ambiguous		Gottlieb et al; Hum Mutat. 14: 527-539, 1999			
0424	PAIS	Substitut	1 Nterm	211 995	Glu⇒Glu GAG⇒GAA	19	24	normal	high	Silent mutation -	Male	Ambiguous	pos	Gottlieb et al; Hum Mutat. 14: 527-539, 1999			
0425	MAIS	Substitut	1 Nterm	211 995	Glu⇒Glu GAG⇒GAA	20	16	normal	high	Silent mutation -	Male	Normal		Gottlieb et al; Hum Mutat. 14: 527-539, 1999			
0705	MAIS	Substitut	1 Nterm	211 995	Glu⇒Glu GAG⇒GAA				normal		Male	Ambiguous		Deeb et al; Clinical Endocrinol 63:56-62, 2005			
0701	Normal	Substitut	1 Nterm	211 995	Glu⇒Glu GAG⇒GAA					Silent mut.polymorph 65% Ivory Coast, 28% N African freqs.	Male	Normal		Estaban et al; Am J Hum Biol 17: 690-695, 2005			
0756	Prostate cancer	Substitut	1 Nterm	211 995	Glu⇒Glu GAG⇒GAA					patient lower Gleason score than patient -wt AR- som mutation	Male	Normal		Sanchez et al. BJU Int 98:1320-1325, 2006			
0757	Prostate cancer	Substitut	1 Nterm	211 995	Glu⇒Glu GAG⇒GAA					patient lower Gleason score than patient -wt AR- som mutation	Male	Normal		Sanchez et al. BJU Int 98:1320-1325, 2006			
0758	Prostate cancer	Substitut	1 Nterm	211 995	Glu⇒Glu GAG⇒GAA					patient lower Gleason score than patient -wt AR- som mutation	Male	Normal		Sanchez et al. BJU Int 98:1320-1325, 2006			
0914	Prostate cancer	Substitut	1 Nterm	211 995	Glu⇒Glu GAG⇒GAA					Both treated and untreated Occurred in 2 cases	Male	Normal		Steinkamp et al; Cancer Res 69:4434-4442, 2009			
1019	Premature ovarian failure	Substitut	1 Nterm	211 995	Glu⇒Glu GAG⇒GAA					Present in 17.85% of patients & 15% of controls	Female	Normal		Panda et al. Gyncol Endocrinol 2010			

Accession #	Mutation type	Proven Phenotype	Pathogenicity	CpG hot spot	Exon Domain	Position	Amino acid Base	Change Amino acid Base	Exon 1 tracts				Androgen Binding			Comments	Sex of rearing	External Genitalia	Family history	Reference
									Poly Gln #	Poly Gly #	Bmax	Kd	Thermolabile k							
0379	MAIS	Substitution	1 Nterm	*	214	Gly⇒ Arg	<u>GGG</u> ⇒ <u>AGG</u>	27	23	normal	normal	norm	severe oligospermia-20% lower transactivation	Male	Normal		Wang et al; Clinical Genetics 54: 185-192, 1998			
0707	PAIS	Substitution	1 Nterm		214	Gly⇒ Arg	<u>GGG</u> ⇒ <u>AGG</u>			normal					Female	Ambiguous		Deeb et al; Clinical Endocrinology 63: 56-62, 2005		
0708	PAIS	Substitution	1 Nterm		214	Gly⇒ Arg	<u>GGG</u> ⇒ <u>AGG</u>			normal					Male	Ambiguous		Deeb et al; Clinical Endocrinology 63: 56-62, 2005		
0709	PAIS	Substitution	1 Nterm		214	Gly⇒ Arg	<u>GGG</u> ⇒ <u>AGG</u>			high					Female	Ambiguous		Deeb et al; Clinical Endocrinology 63: 56-62, 2005		
0380	Normal	Substitution	1 Nterm		214	Gly⇒ Arg	<u>GGG</u> ⇒ <u>AGG</u>								Male	Normal		Wang et al; Clinical Genetics 54: 185-192, 1998		
0016	CAIS	Insertion	1 Nterm		215	Ala⇒ Gly	GCT⇒ GGCT								Female	Normal	neg	Hiort et al; Hum Mol Genet 3: 1163-1166 1994		
0966	CAIS	Deletion	1 Nterm		219	Ser⇒	18	17	zero	zero				I nt deletion causing frameshift & stop in Codon 232	Female	Normal	neg	Audi et al. J Clin Endocrinol Metab 95:1876-1888, 2010		
0695	Prostate cancer	Substitution	1 Nterm	*	221	Asp⇒ His	<u>GAC</u> ⇒ <u>CAC</u>	16		normal	normal		Increased response to DHT	Male	Normal	neg	Chen et al; The Prostate 63:395-406, 2005			
0548	Prostate cancer	Substitution	1 Nterm		222	Asn⇒ Asp	<u>AAT</u> ⇒ <u>GAT</u>						Treated with flutamide also Thr877Ala - somatic	Male	Normal		Taplin et al; 37th meeting ASCO 20: Abstr, 1738 2001			
0650	CAIS	Substitution	1 Nterm		223	Tyr⇒ Stop	<u>TAC</u> ⇒ <u>TAG</u>						Woolfian remnants	Female	Normal		Hannema et al. J Clin Endocrinol & Metab 89: 5815-5822, 2004			
0917	Prostate cancer	Substitution	1 Nterm		227	Thr⇒ Ala	<u>ACT</u> ⇒ <u>GCT</u>						Both treated and untreated	Male	Normal		Steinkamp et al; Cancer Res 69:4434-4442, 2009			
0915	Prostate cancer	Substitution	1 Nterm		227	Thr⇒ Cys	<u>ACT</u> ⇒ <u>TGC</u>						Untreated - Occurred in two cases	Male	Normal		Steinkamp et al; Cancer Res 69:4434-4442, 2009			
0916	Prostate cancer	Substitution	1 Nterm		227	Thr⇒ Cys	<u>ACT</u> ⇒ <u>TGT</u>						Both treated and untreated - Occurred in 2 cases	Male	Normal		Steinkamp et al; Cancer Res 69:4434-4442, 2009			
0885	Prostate cancer	Substitution	1 Nterm		229	Thr⇒ Cys	<u>ACT</u> ⇒ <u>TGT</u>						+Q58L, A251V, W433L, Flutamide treated	Male	Normal		Steinkamp et al; Cancer Res 69:4434-4442, 2009			
0706	PAIS	Substitution	1 Nterm	*	232	Ser⇒ Leu				high			*		Male	Normal		Giwercman et al. Clin Endocrinol 54: 827-834, 2001		
0531	MAIS	Substitution	1 Nterm	*	233	Asn⇒ Lys			normal				*	Azoospermia - transactivation 46% of wt	Male	Normal		Giwercman et al. Clin Endocrinol 54: 827-834, 2001		
0967	CAIS	Insertion	1 Nterm		239	Lys⇒ Stop	21	18							Female	Normal	neg	Audi et al. J Clin Endocrinol Metab 95:1876-1888, 2010		
0789	PAIS?	Substitution	1 Nterm		246	Gly⇒ Val	<u>GGC</u> ⇒ <u>GTC</u>											Mueller et al. Hum Genet 119:681, 2006		
0918	Prostate Cancer	Substitution	1 Nterm		251	Ala⇒ Val	<u>GCG</u> ⇒ <u>GTG</u>						Treated with anti-androgens Occurred in 2 cases	Male	Normal		Steinkamp et al; Cancer Res 69:4434-4442, 2009			
0883	Prostate Cancer	Substitution	1 Nterm		253	Glu⇒ Lys	<u>GAG</u> ⇒ <u>AAG</u>						+ L444S, R484C, K609E, R787X, L797P,L872P, +Flu	Male	Normal		Steinkamp et al; Cancer Res 69:4434-4442, 2009			
0350	CAIS	Substitution	1 Nterm	*	255	Leu⇒ Pro	<u>CTG</u> ⇒ <u>CCG</u>						*	Also Gly820Ala mut. Extra mutation causes greater thermolability	Female	Normal		Tanaka et al; Gynocol Endocrinol 12: 75-82, 1998		
0845	CAIS?	Insertion	1 Nterm		263	Gly⇒ O	<u>GGG</u> ⇒ <u>GgGG</u>											Mueller; Hum Genet 123:105, 2008		
0017	Prostate cancer	Substitution	1 Nterm		266	Met⇒ Thr							Also Leu574Pro (CTG to CCC) mut. Somatic mutation	Male	Normal		Tilley et al; Clinical Cancer Res. 2: 277-285, 1996			
0018	Prostate cancer	Substitution	1 Nterm		269	Pro⇒ Ser	<u>CCA</u> ⇒ <u>TCA</u>						Somatic mutation	Male	Normal		Tilley et al; Clinical Cancer Res. 2: 277-285, 1996			
0780	MAIS	Substitution	1 Nterm		270	Leu⇒ Phe	<u>CTT</u> ⇒ <u>TTT</u>						Male infertility	Male	Normal		Ferlin et al. Clin Endocrinol 65:606-610, 2006			

Accession #	Mutation type	Exon Domain	CpG hot spot	Position Base	Change Amino acid Base	Exon 1 tracts				Androgen Binding			Comments	Sex of rearing	External Genitalia	Family history	Reference
						Poly Gln #	Poly Gly #	Bmax	Kd	Thermolabile k							
0019	CAIS	Deletion	1 Nterm	272 1178	Gly⇒Gly GGAA⇒GGG			zero			1 nt deletion causing frameshift & stop in Codon 301	Female	Normal		Bruggenwirth et al; J Steroid Biochem Mol Biol 58: 569-575, 1996		
0606	CAIS	Substitution	1 Nterm	287 1221	Glu⇒Stop GAA⇒TAA			low	normal		low expression of WT AR - Somatic mosaicism	Female	Normal		Holterhaus et al; Genome Biology 4: R37		
0556	Prostate cancer	Substitution	1 Nterm	296 1250	Ser⇒Arg AGC⇒AGA						Poor differentiation of CaP. Germline mutation ?	Male	Normal		Yu et al; Sheng Wu Hua Xue 32: 459-462, 2000		
0874	Prostate cancer	Substitution	1 Nterm	296 1250	Ser⇒Arg AGC⇒AGA			normal			Transcrip activity activarted by estradiol and progesterone	Male	Normal		Li et al; Clin Exp Pharmacol Physiol 35: 1252-1257, 2008		
0816	Testicular cancer	Substitution	1 Nterm	297 1251	Ala⇒Thr GCA⇒ACA						Seminoma	Male	Normal		Garolla et al. Endocrine Related Cancer 12:645 -655, 2005		
0550	Prostate cancer	Substitution	1 Nterm	334 1359	Ser⇒Pro TCC⇒CCC						Treated with flutamide somatic mutation	Male	Normal		Taplin et al; 37th meeting ASCO 20: Abstr, 1738 2001		
0398	Prostate cancer	Substitution	1 Nterm	340 1381	Pro⇒Leu CCG⇒CTG						Somatic mutation Stage 3 tumor	Male	Normal		Castagnaro et al; Verh. Dtsch. Ges. Path. 77: 119-123, 1993		
0779	MAIS	Substitution	1 Nterm	340 1381	Pro⇒Leu CCG⇒CTG						Male infertility	Male	Normal		Ferlin et al. Clin Endocrinol 65:606-610, 2006		
0968	CAIS	Deletion	1 Nterm	346 1397	Tyr⇒Gln ATAAC⇒CAA	21	17				2 nt deletion causing fs & stop in Codon 499	Female	Normal	neg	Audi et al. J Clin Endocrinol Metab 95:1876-1888, 2010		
0903	CAIS	Deletion	1 Nterm	347 1401	Lys⇒Ile AAAG⇒ATC							Female	Normal	neg	Philibert et al; Fertility & Sterility 2009		
0903	CAIS	Deletion	1 Nterm	347 1407	Gly⇒ ⇒						22 bp deletion	Female	Normal	pos	Philibert et al; Fertility & Sterility 2009		
0020	CAIS	Substitution	1 Nterm	353 1419	Glu⇒Stop GAG⇒TAG	21	23	low			low specific binding with MB only-mRNA < 20%	Female	Normal	neg	Gottlieb et al; Hum Mutat. 14: 527-539, 1999		
0781	MAIS	Substitution	1 Nterm	353 1419	Glu⇒Gln GAG⇒CAG						Male infertility	Male	Normal		Ferlin et al. Clin Endocrinol 65:606-610, 2006		
0919	Prostate Cancer	Substitution	1 Nterm	357 1431	Ala⇒Thr GCT⇒ACT						Bicalutamide treated Occurred in 2 cases	Male	Normal		Steinkamp et al; Cancer Res 69:4434-4442, 2009		
0920	Prostate Cancer	Substitution	1 Nterm	357 1432	Ala⇒Val GCT⇒GTT						Bicalutamide treated Occurred in two cases	Male	Normal		Steinkamp et al; Cancer Res 69:4434-4442, 2009		
0921	Prostate cancer	Substitution	1 Nterm	360 1441	Arg⇒His CGC⇒CAC						Both treated and untreated Occurred in two cases	Male	Normal		Steinkamp et al; Cancer Res 69:4434-4442, 2009		
0021	CAIS	Substitution	1 Nterm	371 1474	Gly⇒Stop GGA⇒TGA						Somatic instability of polyglycine tract	Female	Normal	pos	Davies et al; Clinical Endocrinology 43: 69 -77, 1995		
1003	PAIS	Substitution	1 Nterm	378 1596	Pro⇒Arg CCT⇒CGT	17	18				Prenatal diagnosis	Male	Ambiguous	neg	Audi et al. J Clin Endocrinol Metab 95:1876-1888, 2010		
0899	CAIS	Insertion	1 Nterm	381 1505	Pro⇒ ⇒						201 bp insertion-dup (CCTCCGCCGCC)	Female	Normal	pos	Philibert et al; Fertility & Sterility 2009		
0908	CAIS	Substitution	1 Nterm	390 1530	Pro⇒Ser CCG⇒TCG			zero				Female	Normal		Appari et al; J Molecular Med: 87:623 -632., 2009		
0950	PAIS	Substitution	1 Nterm	390 1530	Pro⇒Ser CCG⇒TCG						Micropenis only	Male	Ambiguous		Bhangoo et al. Asian J Androl 12:561-566. 2010		
1004	PAIS	Substitution	1 Nterm	390 1530	Pro⇒Ser CCG⇒TCG	22	19	normal	normal			Male	Ambiguous	neg	Audi et al. J Clin Endocrinol Metab 95:1876-1888, 2010		
0338	MAIS	Substitution	1 Nterm	* 390 1530	Pro⇒Ser CCG⇒TCG						Oligospermia	Male	Normal		Hiort et al; J Clin Endocrinol & Metab 85: 2810-2815, 2000		
0504	MAIS	Substitution	1 Nterm	* 390 1530	Pro⇒Ser CCG⇒TCG						Oligospermia	Male	Normal		Hiort et al; J Clin Endocrinol & Metab 85: 2810-2815, 2000		
0767	MAIS	Substitution	1 Nterm	390 1530	Pro⇒Ser CCG⇒TCG						Male infertility	Male	Normal		Ferlin et al. Clin Endocrinol 65:606-610, 2006		

Accession #	Mutation type	Pathogenicity proven	Exon Domain	CpG hot spot	Position Amino acid Base	Change Amino acid Base	Exon 1 tracts				Androgen Binding Thermolabile				Comments	Sex of rearing	External Genitalia	Family history	Reference
							Poly Gln #	Poly Gly #	Bmax	Kd	k								
0817	Testicular cancer	Substitut	1 Nterm	390	Pro⇒ Ser <u>CCG</u> ⇒ <u>TCG</u>							Seminoma	Male	Normal		Garolla et al. Endocrine Related Cancer 12:645-655, 2005			
0608	Prostate cancer	Substitut	1 Nterm	390	Pro⇒ Leu <u>CCG</u> ⇒ <u>TCG</u>			zero					Female	Normal		Holterhaus et al; Genome Biology 4: R37			
0547	Prostate cancer	Substitut	1 Nterm	390	Pro⇒ Leu <u>CCG</u> ⇒ <u>CTG</u>							Treated with flutamide also Asn756Asp -	Male	Normal		Taplin et al; 37th meeting ASCO 20: Abstr, 1738, 2001			
0022	CAIS	Substitut	1 Nterm	390	Pro⇒ Arg <u>CCG</u> ⇒ <u>CGG</u>	20	24	zero				+ substs. Glu211Glu <u>GAG</u> to <u>GAA</u> &Gln443 Arg( <u>CA</u> Gto <u>CG</u> G)	Female	Normal	pos	Gottlieb et al; Hum Mutat. 14: 527-539, 1999			
0790	CAIS	Substitut	1 Nterm	393	Tyr⇒ Stop <u>TAC</u> ⇒ <u>TAG</u>								Female	Normal		Mueller et al. Hum Genet 119:680, 2006			
0896	CAIS	Substitut	1 Nterm	393	Tyr⇒ Stop <u>TAC</u> ⇒ <u>TAG</u>								Female	Normal	neg	Philibert et al; Fertility & Sterility 2009			
0426	CAIS	Substitut	1 Nterm	403	Gln⇒ Stop <u>CAG</u> ⇒ <u>TAG</u>	28	23	zero				mRNA < 20%	Female	Normal		Gottlieb et al; Hum Mutat. 14: 527-539, 1999			
0689	PAIS	Deletion	1 Nterm *	409	Leu⇒ 0 GTG⇒							Deletion of codons <u>409-411</u> . Normal twin has same deletion	Male	Ambiguous	pos	Holterhus et al; Exp Clin Endocrinol diabetes 113: 457-463,			
0690	PAIS	Substitut	1 Nterm *	411	Ser⇒ Asn <u>AGC</u> ⇒ <u>AAC</u>							Patient responded to testosterone treat at 12yrs.	Male	Ambiguous		Holterhus et al; Exp Clin Endocrinol diabetes 113: 457-463,			
0922	Prostate cancer	Substitut	1 Nterm	414	Gly⇒ Ser <u>GGC</u> ⇒ <u>AGC</u>							Bicalutamide treated Occurred in 2 cases	Male	Normal		Steinkamp et al; Cancer Res 69:4434-4442, 2009			
0923	Prostate cancer	Substitut	1 Nterm	414	Gly⇒ Asp <u>GAC</u> ⇒ <u>GAC</u>							Bicalutamide treated occurred in 2 cases	Male	Normal		Steinkamp et al; Cancer Res 69:4434-4442, 2009			
0691	PAIS	Substitut	1 Nterm *	432	Ser⇒ Phe <u>TCC</u> ⇒ <u>TTC</u>								Male	Ambiguous		Holterhus et al; Exp Clin Endocrinol diabetes 113: 457-463,			
0889	Prostate Cancer	Substitut	1 Nterm	433	Trp⇒ Leu <u>TGG</u> ⇒ <u>TTG</u>							+ΔQ86,T227C, T438P,T497I,V508L Q867X.Bical treated	Male	Normal		Steinkamp et al; Cancer Res 69:4434-4442, 2009			
0924	Prostate Cancer	Substitut	1 Nterm	433	Trp⇒ Leu <u>TGG</u> ⇒ <u>TTG</u>								Male	Normal		Steinkamp et al; Cancer Res 69:4434-4442, 2009			
0925	Prostate Cancer	Substitut	1 Nterm	433	Trp⇒ Cys <u>TGG</u> ⇒ <u>TGC</u>							Both treated and untreated	Male	Normal		Steinkamp et al; Cancer Res 69:4434-4442, 2009			
0926	Prostate Cancer	Substitut	1 Nterm	438	Thr⇒ Pro <u>ACA</u> ⇒ <u>CCA</u>							Treated with anti-androgens Occurred in 2 cases	Male	Normal		Steinkamp et al; Cancer Res 69:4434-4442, 2009			
0890	Prostate Cancer	Substitut	1 Nterm	438	Thr⇒ Ile <u>ACA</u> ⇒ <u>ATA</u>							+Q58L, ΔQ86, G457D	Male	Normal		Steinkamp et al; Cancer Res 69:4434-4442, 2009			
0759	Prostate cancer	Substitut	1 Nterm	449	Gly⇒ Asp <u>GGT</u> ⇒ <u>GAT</u>							patient lower Gleason score than patient -wt AR- som mutation	Male	Normal		Sanchez et al. BJU Int 98:1320-1325, 2006			
0760	Prostate cancer	Substitut	1 Nterm	451	Gly⇒ Asp <u>GGT</u> ⇒ <u>GAT</u>							patient lower Gleason score than patient -wt AR- som mutation	Male	Normal		Sanchez et al. BJU Int 98:1320-1325, 2006			
0969	CAIS	Substitut	1 Nterm	453	Gly⇒ Ser <u>GGT</u> ⇒ <u>AGT</u>	22	17					Also Y571C mutation 2 affected aunts	Female	Normal	pos	Audi et al. J Clin Endocrinol Metab 95:1876-1888, 2010			
0888	Prostate Cancer	Substitut	1 Nterm	454	Gly⇒ Ser <u>GGC</u> ⇒ <u>AGC</u>							+Q58L, ΔQ86, A251V, Bicalutamide treated	Male	Normal		Steinkamp et al; Cancer Res 69:4434-4442, 2009			
0927	Prostate Cancer	Substitut	1 Nterm	454	Gly⇒ Ser <u>GGC</u> ⇒ <u>AGC</u>							Treated with anti-androgens Occurred in more than 2 cases	Male	Normal		Steinkamp et al; Cancer Res 69:4434-4442, 2009			
0884	Prostate Cancer	Substitut	1 Nterm	455	Gly⇒ Asp <u>GGC</u> ⇒ <u>GAC</u>							+ΔQ86, V716M, Flutamide treated	Male	Normal		Steinkamp et al; Cancer Res 69:4434-4442, 2009			
0928	Prostate Cancer	Substitut	1 Nterm	455	Gly⇒ Asp <u>GGC</u> ⇒ <u>GAC</u>							Both treated and untreated Occurred in 2 cases	Male	Normal		Steinkamp et al; Cancer Res 69:4434-4442, 2009			
0438	CAIS	Deletion	1 Nterm	461	Gly⇒ Gly <u>GGAC</u> ⇒ <u>GGG</u>			zero				1 nt. deletion causing frameshift	Female	Normal		Ahmed et al; J Clin Endocrinol & Metab 85: 658-665, 2000			

Accession #	Mutation type	Proven Phenotype	Pathogenicity	CpG hot spot	Position Amino acid Base	Change Amino acid Base	Exon 1 tracts				Androgen Binding				Comments	Sex of rearing	External Genitalia	Family history	Reference
							Poly Gln #	Poly Gly #	Bmax	Kd	Thermolabile k								
0410	CAIS	Deletion	1 Nterm	472 <b>1776</b>	Glu⇒ <b>Gly</b>	GAAG⇒GGC	24	22				2nt. del causing frameshift & stop in cod <b>499</b> - mRNA 50%	Female	Normal		Thiele et al; J Clin Endocrinol & Metab 84: 1751-1753, 1999			
0693	CAIS	Deletion	1 Nterm	472 <b>1776</b>	Gly⇒ <b>Gly</b>	GAAG⇒GGC	21	28	zero			2nt. del causing frameshift & stop in cod <b>499</b> - mRNA 50%	Female	Normal		Holterhus et al; J Mol Med 2005			
0427	CAIS	Deletion	1 Nterm	473 <b>1779</b>	Glu⇒ <b>Gly</b>	GAAG⇒GGC	26	26	zero			2nt. del causing frameshift & stop in cod <b>499</b> - mRNA 50%	Female	Normal		Gottlieb et al; Hum Mutat. 14: 527-539, 1999			
0782	MAIS	Substitution	1 Nterm *	474 <b>1783</b>	Ala⇒ <b>Val</b>	<u>GCG</u> ⇒ <u>GTG</u>						male infertility	Male	Normal		Ferlin et al. Clin Endocrinol 65:606-610, 2006			
0821	MAIS	Substitution	1 Nterm *	474 <b>1783</b>	Ala⇒ <b>Val</b>	<u>GCG</u> ⇒ <u>GTG</u>	14	17				male infertility, low T severe hypospematogenesis	Male	Normal		Zuccarello et al. Clin Endocrinol 68:58-588, 2008			
0822	MAIS	Substitution	1 Nterm *	474 <b>1783</b>	Ala⇒ <b>Val</b>	<u>GCG</u> ⇒ <u>GTG</u>	24	17				male infertility, normal T	Male	Normal		Zuccarello et al. Clin Endocrinol 68:58-588, 2008			
0823	MAIS	Substitution	1 Nterm *	474 <b>1783</b>	Ala⇒ <b>Val</b>	<u>GCG</u> ⇒ <u>GTG</u>	19	17				male infertility, normal T, left cryptorchidism	Male	Normal		Zuccarello et al. Clin Endocrinol 68:58-588, 2008			
0804	Liver cancer	Substitution	1 Nterm	480 <b>1802</b>	Tyr⇒ <b>Tyr</b>	<u>TAC</u> ⇒ <u>TAT</u>						Somatic mutation	Female	Normal		Yeh et al. Int J Cancer 120:1610-1617, 2007			
0024	CAIS	Substitution	1 Nterm	480 <b>1802</b>	Tyr⇒ <b>Stop</b>	<u>TAC</u> ⇒ <u>TAA</u>	15	15	zero			Normal 110KD AR produced at 25% of normal level	Female	Normal		Gottlieb et al; Hum Mutat. 14: 527-539, 1999			
0651	CAIS	Substitution	1 Nterm	480 <b>1802</b>	Tyr⇒ <b>Stop</b>	<u>TAC</u> ⇒ <u>TAA</u>						Woolfian remnants present	Female	Normal		Hannema et al. J Clin Endocrinol & Metab 89: 5815-5822, 2004			
0929	Prostate cancer	Substitution	1 Nterm	484 <b>1811</b>	Arg⇒ <b>Cys</b>	CGG⇒						Both treated and untreated Occurred in 2 cases	Male	Normal		Steinkamp et al; Cancer Res 69:4434-4442, 2009			
0930	Prostate cancer	Substitution	1 Nterm	484 <b>1811</b>	Arg⇒ <b>Thr</b>	<u>CGG</u> ⇒ <u>AGG</u>						Both treated and untreated Occurred in 2 cases	Male	Normal		Steinkamp et al; Cancer Res 69:4434-4442, 2009			
0546	CAIS	Deletion	1 Nterm	487 <b>1821</b>	Gln⇒ <b>Stop</b>	<u>CAG</u> ⇒ <u>TAG</u>						3 affected siblings Variable phenotype	Female	Normal	pos	Boehmer et al; J Clin Endocrinol & Metab 86: 4151-4160, 2001			
0439	CAIS	Deletion	1 Nterm	488 <b>1824</b>	Gly⇒ <b>0</b>	⇒		low				5 nt. deletion causing frameshift	Female	Normal		Ahmed et al; J Clin Endocrinol & Metab 85: 658-665, 2000			
0440	CAIS	Substitution	1 Nterm	491 <b>1833</b>	Gly⇒ <b>Ser</b>	<u>GGC</u> ⇒ <u>AGC</u>		low	low				Female	Normal		Ahmed et al; J Clin Endocrinol & Metab 85: 658-665, 2000			
0891	Prostate Cancer	Substitution	1 Nterm	497 <b>1852</b>	Thr⇒ <b>Ile</b>	<u>ACC</u> ⇒ <u>ATC</u>						Also R484C Bicalutamide treated	Male	Normal		Steinkamp et al; Cancer Res 69:4434-4442, 2009			
0931	Prostate Cancer	Substitution	1 Nterm	497 <b>1852</b>	Thr⇒ <b>Ile</b>	<u>ACC</u> ⇒ <u>ATC</u>						Both treated and not treated Occurred in 2 cases	Male	Normal		Steinkamp et al; Cancer Res 69:4434-4442, 2009			
0932	Prostate Cancer	Substitution	1 Nterm	498 <b>1854</b>	Ala⇒ <b>Thr</b>	<u>GCA</u> ⇒ <u>ACA</u>						Flutamide treated Occurred in 2 cases	Male	Normal		Steinkamp et al; Cancer Res 69:4434-4442, 2009			
0933	Prostate Cancer	Substitution	1 Nterm	498 <b>1859</b>	Ala⇒ <b>Val</b>	<u>GCA</u> ⇒ <u>GTA</u>						Flutamide treated Occurred in 2 cases	Male	Normal		Steinkamp et al; Cancer Res 69:4434-4442, 2009			
0936	Prostate Cancer	Substitution	1 Nterm	499 <b>1859</b>	Pro⇒ <b>Pro</b>	CCT⇒						Treated with anti-androgens Occurred in more than 2 cases	Male	Normal		Steinkamp et al; Cancer Res 69:4434-4442, 2009			
0905	CAIS	Indel	1 Nterm	502 <b>1866</b>	Trp⇒	TGG⇒						Indel between c1866 -1871	Female	Normal	neg	Philibert et al; Fertility & Sterility 2009			
0025	CAIS	Substitution	1 Nterm	502 <b>1867</b>	Trp⇒ <b>Stop</b>	<u>TGG</u> ⇒ <u>TAG</u>							Female	Normal	pos	Bruggenwirth et al; J Steroid Biochem Mol Biol 58: 569-575, 1996			
0783	MAIS	Substitution	1 Nterm	506 <b>1879</b>	Gly⇒ <b>Asp</b>	<u>GGC</u> ⇒ <u>GAC</u>						Male infertility	Male	Normal		Ferlin et al. Clin Endocrinol 65:606-610, 2006			
0886	Prostate Cancer	Substitution	1 Nterm	508 <b>1884</b>	Val⇒ <b>Leu</b>	<u>GTG</u> ⇒ <u>CTG</u>						Bicalutamide treated	Male	Normal		Steinkamp et al; Cancer Res 69:4434-4442, 2009			
0934	Prostate Cancer	Substitution	1 Nterm	508 <b>1884</b>	Val⇒ <b>Leu</b>	<u>GTG</u> ⇒ <u>CTG</u>						Flutamide treated	Male	Normal		Steinkamp et al; Cancer Res 69:4434-4442, 2009			

Accession #	Mutation type	Exon Domain	CpG hot spot	Position Base	Change Amino acid	Pathogenicity proven	Exon 1 tracts				Androgen Binding				Comments	Sex of rearing	External Genitalia	Family history	Reference
							Poly Gln #	Poly Gly #	Bmax	Kd	Thermolabile k								
0935	Prostate Cancer	Substitut.	1 Nterm	508 1885	Val⇒Gly GTG⇒GGG						Treated with anti-androgens Occurred in 2 cases	Male	Normal		Steinkamp et al; Cancer Res 69:4434-4442, 2009				
0339	MAIS	Substitut.	1 Nterm *	511 1895	Val⇒Val GTG⇒GTA						Oligospermia caused by silent mutation	Male	Normal		Hiori et al; 80th US Endo Soc Meeting, Abstr P2-38, 1998				
0876	CAIS	Substitut.	1 Nterm	513 1902	Tyr⇒Stop TAT⇒TAA							Female	Normal	pos	Radpour et al; J of Andrology 30:230-232, 2009				
0567	Prostate cancer	Substitut.	1 Nterm	514 1903	Pro⇒Ser CCC⇒TCC						Somatic mut. Orchietomy + EMP Horm-refractory CaP	Male	Normal		Hyttinen et al; Lab Invest. 82: 1591-1598, 2002				
0686	Normal	Substitut.	1 Nterm	516 1907	Pro⇒Ser CCC⇒AGC						Patient suffered from phobia		Normal		Yan et al; Psychiatric Genet 14: 57-60, 2004				
0568	Prostate cancer	Substitut.	1 Nterm	524 1932	Gly⇒Ser GGC⇒AGC						Somatic mut. Orchi + EMP treat. Also Trp526stop mutation	Male	Normal		Hyttinen et al; Lab Invest. 82: 1591-1598, 2002				
0569	Prostate cancer	Substitut.	1 Nterm	524 1933	Gly⇒Asp GGC⇒GAC						Somatic mut. Orchietomy + EMP Horm-refractory CaP	Male	Normal		Hyttinen et al; Lab Invest. 82: 1591-1598, 2002				
0026	Prostate cancer	Substitut.	1 Nterm	528 1945	Asp⇒Gly GAT⇒GGT						Somatic mutation	Male	Normal		Tilley et al; Chemical Cancer Res. 2: 277-285, 1996				
900	CAIS	Insertion	1 Nterm	530 1951	Tyr⇒ ⇒						GCTA insertion	Female	Normal		Philibert et al; Fertility & Sterility 2009				
0570	Prostate cancer	Substitut.	1 Nterm	533 1959	Pro⇒Ser CCT⇒TCT						Somatic mut. Orchietomy + EMP horm-refractory CaP	Male	Normal		Hyttinen et al; Lab Invest. 82: 1591-1598, 2002				
0027	CAIS	Substitut.	1 Nterm	534 1964	Tyr⇒Stop TAC⇒TAG		zero					Female	Normal	neg	McPhaul et al; FASEB J 5:2910-15, 1991				
0028	CAIS and mental retardation	Deletion	1-8		⇒ ⇒		zero				Termini not yet defined	Female	Normal	neg	Trifiro et al; Mol Cell Endocrinol 75:37-47, 1991				
0029	CAIS	Deletion	1-8		⇒ ⇒		zero					Female	Normal	pos	Quigley et al; J Clin Endocrinol Metab 74:927, 1992				
0030	CAIS	Deletion	1-8		⇒ ⇒		zero					Female	Normal	pos	Hiori et al; Am J Med Genet. 63: 218-22, 1996				
0435	CAIS	Deletion	1-8		⇒ ⇒		zero					Female	Normal		Ahmed et al; J Clin Endocrinol & Metab 85: 658-665, 2000				
0031	CAIS	Deletion	2		⇒ ⇒							Female	Normal		Quigley et al; J Cell Biochem Suppl 16C; Abstr L323, 1992				
0579	CAIS	Deletion	2		⇒ ⇒						No immunoreactive AR	Female	Normal		Avila et al. J Clin Endocrinol Metab 87; 182-188, 2002				
0580	CAIS	Deletion	2		⇒ ⇒						No immunoreactive AR	Female	Normal		Avila et al. J Clin Endocrinol Metab 87; 182-188, 2002				
0441	CAIS	Duplicat.	2		⇒ ⇒						Duplication of exon 2	Female	Normal		Ahmed et al; J Clin Endocrinol & Metab 85: 658-665, 2000				
0652	CAIS	Duplicat.	2		⇒ ⇒						Duplication of exon 2 sister of 653	Female	Normal	pos	Hannema et al. J Clin Endocrinol & Metab 89: 5815-5822, 2004				
0653	CAIS	Duplicat.	2		⇒ ⇒						Duplication of exon 2 sister of 652	Female	Normal	pos	Hannema et al. J Clin Endocrinol & Metab 89: 5815-5822, 2004				
0970	CAIS	Deletion	2 DBD	545 1996	His⇒ CAT⇒	23	17				17bp del. at 2/3 splice site resulting in fs & stop in Codon 547?	Female	Normal	pos	Audi et al. J Clin Endocrinol Metab 95:1876-1888, 2010				
0032	PAIS	Substitut.	2	547 2003	Leu⇒Phe TTG⇒TTT			low	high		Also has Trp741Cys (TGG to TGT) mutation	Male	Ambiguous	pos	Karl et al; 76th US Endo Soc Meeting, Abstr 1735, 1994				
0673	PAIS	Substitut.	2	547 2003	Leu⇒Phe TTG⇒TTT								Ambiguous		Bouvattier et al; J Clin Endocrinol & Metab 87: 29-32, 2002				
0768	MAIS	Substitut.	2	547 2003	Leu⇒Phe TTG⇒TTT						Male infertility	Male	Normal		Ferlin et al. Clin Endocrinol 65:606-610, 2006				

Accession #	Mutation type	Exon Domain	CpG hot spot	Position Base	Change Amino acid	Pathogenicity proven	Exon 1 tracts				Androgen Binding				Comments	Sex of rearing	External Genitalia	Family history	Reference
							Poly Gln #	Poly Gly #	Bmax	Kd	Thermolabile k								
0357	Prostate cancer	Deletion	2	*	547 2003	Leu⇒Leu TTAG⇒TTC						Frameshift - somatic mutation	Male	Normal		Takahashi et al; Cancer Research 55: 1621-1624, 1995			
0824	MAIS	Substitution	2	*	547 2003	Leu⇒Phe TTG⇒TTT	19	17				Azoospermia, Normal T, Left varicocele, Sertoli Only syndrome	Male	Normal		Zuccarello et al. Clin Endocrinol 68:58-588, 2008			
0825	MAIS	Substitution	2	*	547 2003	Leu⇒Phe TTG⇒TTT	19	18				Male infertility, low T	Male	Normal		Zuccarello et al. Clin Endocrinol 68:58-588, 2008			
0033	MAIS	Substitution	2		548 2004	Pro⇒Ser CCC⇒TCC						Distal hypospadias, variable penetrance in family members	Male	Near-normal male	pos	Sutherland et al; J of Urology 156: 828-831, 1996			
0023	CAIS		2		2001	⇒ ⇒						Duplication of 8nt. # 2011-2018 frameshift & stop in Codon 563	Female	Normal		Lumbroso et al; 10th Int Cong of Endocrinol, Abstr P1-182, 1996			
0358	Prostate cancer	Deletion	2		554 2023	Pro⇒Pro CCAΔ⇒CCC						Frameshift - somatic mutation	Male	Normal		Takahashi et al; Cancer Research 55: 1621-1624, 1995			
0359	Prostate cancer	Deletion	2		554 2023	Pro⇒Pro CCAΔ⇒CCC						Frameshift - somatic mutation	Male	Normal		Takahashi et al; Cancer Research 55: 1621-1624, 1995			
0952	Prostate cancer	Substitution	2	DBD	558 2034	Thr⇒Ser ACC⇒TCC						Germline mutation early onset disease in African-American	Male	Normal	pos	Hu et al. Asian J Androl 12:336-343, 2010			
0034	CAIS	Substitution	2	DBD	*	559 2038	Cys⇒Tyr TGC⇒TAC		normal	normal				Female	Normal	neg	Zoppi et al; Mol Endocrinol 6:409, 1992		
0840	CAIS	Insertion	2	DBD	562 2045	Ile⇒ ATCins ⇒ CTG						Insertion of CTG	Female	Normal		Jeske et al; J Pediatr Endocrinol Metab 20:893-908, 2007			
0797	CAIS	Substitution	2	DBD	562 2047	Cys⇒Tyr TGT⇒TAT							Female	Normal		Jaaskelainen et al. Hum Mutat 27:291, 2006			
0035	PAIS	Substitution	2	DBD	568 2064	Gly⇒Trp GGG⇒TGG			normal	normal				Female	Normal		Lobaccaro et al; Clin Endocrinol, 40:297, 1994		
0674	PAIS	Substitution	2	DBD	568 2064	Gly⇒Trp GGG⇒TGG											Bouvattier et al; J Clin Endocrinol & Metab 87: 29-32, 2002		
0037	PAIS	Substitution	2	DBD	568 2065	Gly⇒Val GGG⇒GTG			normal	normal							Chang et al; 73rd US Endo Soc Meeting, Abstr 28, 1991		
0036	PAIS	Substitution	2	DBD	568 2065	Gly⇒Val GGG⇒GTG			normal		Severe hypospadias	Male	Ambiguous				Allera et al; J Clin Endocrinol & Metab 80: 2697-2699, 1995		
0971	CAIS	Substitution	2	DBD	568 2065	Gly⇒Glu GGG⇒GAG	26	18						Female	Normal	neg	Audi et al. J Clin Endocrinol Metab 95:1876-1888, 2010		
0545	PAIS	Substitution	2	DBD	571 2073	Tyr⇒His TAT⇒CAT					sibling of 0747	Male	Ambiguous	pos	Boehmer et al; J Clin Endocrinol & Metab 86: 4151-4160, 2001				
0558	PAIS	Substitution	2	DBD	571 2073	Tyr⇒His TAT⇒CAT					DHT therapy effective	Male	Ambiguous				Foresta et al; Am J Med Genet 107: 259-260, 2002		
0747	PAIS	Substitution	2	DBD	571 2073	Tyr⇒His TAT⇒CAT					sibling of 0545	Male	Ambiguous	pos	Boehmer et al; J Clin Endocrinol & Metab 86: 4151-4160, 2001				
0748	PAIS	Substitution	2	DBD	571 2073	Tyr⇒His TAT⇒CAT		normal	low		nephew of 0545 & 0747	Male	Ambiguous	pos	Boehmer et al; J Clin Endocrinol & Metab 86: 4151-4160, 2001				
0769	MAIS	Substitution	2	DBD	571 2073	Tyr⇒His TAT⇒CAT					male infertility	Male	Normal		Ferlin et al. Clin Endocrinol 65:606-610, 2006				
0826	PAIS?	Substitution	2	DBD	*	571 2073	Tyr⇒His TAT⇒CAT	19	19			male infertility	Male	Normal		Zuccarello et al. Clin Endocrinol 68:58-588, 2008			
0032	CAIS	Substitution	2	DBD	*	571 2974	Tyr⇒Cys TAT⇒TGT						Female	Normal		Komori et al; Arch Gynecol & Obstetrics 261: 95-100, 1998			
0972	CAIS	Substitution	2	DBD	573 2079	Ala⇒Asp GCT⇒ACT	24	18			1 affected sister	Female	Normal	pos	Audi et al. J Clin Endocrinol Metab 95:1876-1888, 2010				
0038	CAIS	Substitution	2	DBD	573 2080	Ala⇒Asp GCT⇒GAT			normal		Defective DNA binding & transactivation	Female	Normal	neg	Bruggenwirth et al; J Steroid Biochem Mol Biol 58: 569-575, 1996				

Accession #	Mutation type	Exon Domain	CpG hot spot	Position Base	Change Amino acid	Amino acid Base	Exon 1 tracts				Androgen Binding			Comments	Sex of rearing	External Genitalia	Family history	Reference
							Poly Gln #	Poly Gly #	Bmax	Kd	Thermolabile k							
0489	Prostate Cancer	Substitut	2 DBD	* 575 2085	Thr $\Rightarrow$ Ala <u>A</u> CA $\Rightarrow$ <u>G</u> CA						Somatic Mutation	Male	Normal		Marcelli et al; Cancer Research 60: 944-949, 2000			
0810	Prostate Cancer	Substitut	2 DBD	* 575 2085	Thr $\Rightarrow$ Ala <u>A</u> CA $\Rightarrow$ <u>G</u> CA						Som Mut. also T877A T575 bindisto AR- non-specific	Male	Normal		Monge et al. Cell Mol Life Sci 63:487-497, 2006			
0039	CAIS	Substitut	2 DBD	* 576 2088	Cys $\Rightarrow$ Arg <u>T</u> GT $\Rightarrow$ <u>C</u> GT			normal	normal			Female	Normal	pos	Zoppi et al; Mol Endocrinol 6:409, 1992			
0040	CAIS	Substitut	2 DBD	* 576 2089	Cys $\Rightarrow$ Phe <u>T</u> GT $\Rightarrow$ <u>T</u> TT			normal	normal			Female	Normal		Chang et al; 73rd US Endo Soc Meeting, Abstr 28, 1991			
0407	CAIS	Substitut	2 DBD	* 576 2089	Cys $\Rightarrow$ Phe <u>T</u> GT $\Rightarrow$ <u>T</u> TT					Lack of DNA binding -19 members of same family 3 testis tumors	Female	Normal	pos	Hooper et al; Clinical Genetics 65: 183-190, 2004				
0554	PAIS	Substitut	2 DBD	* 577 2091	Gly $\Rightarrow$ Arg <u>G</u> GA $\Rightarrow$ <u>A</u> GA			normal	normal	high	Alters affinity & selectivity of AR- ARE interactions				Nguyen et al; Mol Endocrinol 15:1790 -1802, 2001			
0509	PAIS	Substitut	2 DBD	* 578 2095	Ser $\Rightarrow$ Thr <u>A</u> GC $\Rightarrow$ <u>A</u> CC			normal			partial transactivation in COS cells	Male	Ambiguous		Giwercman et al; Hormone Research 53: 83-88, 2000			
0043	CAIS	Deletion	2 DBD	* 579 2099	Cys $\Rightarrow$ Cys TGAC $\Rightarrow$ TGA			zero			Single nt. deletion causing frameshift & stop in Codon 619	Female	Normal		Imai et al, Annals of Clin Biochem, 32: 482 -486, 1995			
0041	CAIS	Substitut	2 DBD	* 579 2098	Cys $\Rightarrow$ Tyr <u>T</u> GC $\Rightarrow$ <u>T</u> AC							Female	Normal		Sultan et al, J Steroid Biochem & Mol Biol:46			
0042	CAIS	Substitut	2 DBD	* 579 2098	Cys $\Rightarrow$ Phe <u>T</u> GC $\Rightarrow$ <u>T</u> TC			normal	normal		Reduced transcription & DNA binding	Female	Normal	pos	Imasaki et al; Mol & Cell Endocrinol 120: 15 -24, 1996			
0973	CAIS	Substitut	2 DBD	* 579 2099	Cys $\Rightarrow$ Trp <u>T</u> GC $\Rightarrow$ <u>T</u> GG	23	17	low	low		Mother & 1 aunt heterozygous carriers, 1 aunt affected	Female	Normal	pos	Audi et al. J Clin Endocrinol Metab 95:1876-1888, 2010			
0487	Prostate Cancer	Substitut	2 DBD	* 580 2101	Lys $\Rightarrow$ Arg <u>A</u> AG $\Rightarrow$ <u>A</u> GG						Somatic mutation	Male	Normal		Marcelli et al; Cancer Research 60: 944-949, 2000			
0843	PAIS	Substitut	2 DBD	* 580 2101	Lys $\Rightarrow$ Arg <u>A</u> AG $\Rightarrow$ <u>A</u> GG						Attempted sex reassignment at 31 did not succeed	Female	Ambiguous		Katsumata et al; Endocr J 55:225-228, 2008			
0044	CAIS	Substitut	2 DBD	* 581 2103	Val $\Rightarrow$ Phe <u>G</u> TC $\Rightarrow$ <u>T</u> TC			normal	normal			Female	Normal		Lumbroso et al; Fertil Steril, 60:814, 1993			
0675	CAIS	Substitut	2 DBD	* 581 2103	Val $\Rightarrow$ Phe <u>G</u> TC $\Rightarrow$ <u>T</u> TC						bilateral inguinal hernia	Female	Normal		Bouvattier et al: J Clin Endocrinol & Metab 87: 29-32, 2002			
0676	CAIS	Substitut	2 DBD	* 581 2103	Val $\Rightarrow$ Phe <u>G</u> TC $\Rightarrow$ <u>T</u> TC						bilateral inguinal hernia	Female	Normal		Bouvattier et al: J Clin Endocrinol & Metab 87: 29-32, 2002			
0719	PAIS	Substitut	2 DBD	* 581 2103	Val $\Rightarrow$ Leu <u>G</u> TC $\Rightarrow$ <u>C</u> TC						neice also affected	Female	Ambiguous	pos	Ledig et al: Horm Res 63:263-269, 2005			
0045	CAIS	Deletion	2 DBD	* 582 2104-6	Phe $\Rightarrow$ O <u>G</u> ATCTT $\Rightarrow$ GTC	22	23	low	normal		3 nt. del - Phe 582 del 2nt. from 581, 1nt. 582. 581 still Val	Female	Normal	neg	Beitel et al; Hum Mol Genet, 3:21, 1994			
0442	CAIS	Deletion	2 DBD	* 582 2106-8	Phe $\Rightarrow$ O TTC $\Rightarrow$			normal	normal		3 nt. del - of Phe	Female	Normal		Ahmed et al; J Clin Endocrinol & Metab 85: 658-665, 2000			
0597	CAIS	Deletion	2 DBD	* 582 2106-8	Phe $\Rightarrow$ O TTC $\Rightarrow$						3 nt. del - of Phe	Female	Normal		Scheiber et al; J Pediatric Endocrinol & Metab. 16: 367-373,			
0047	PAIS	Substitut	2 DBD	* 582 2107	Phe $\Rightarrow$ Ser <u>T</u> TC $\Rightarrow$ <u>T</u> CC			zero				Female	Ambiguous		Hiort et al; Hum Mol Genet 3: 1163-1166 1994			
0046	PAIS	Substitut	2 DBD	* 582 2107	Phe $\Rightarrow$ Tyr <u>T</u> TC $\Rightarrow$ <u>T</u> AC			normal	normal		Reduced transcription & DNA binding	Female	Ambiguous	pos	Imasaki et al; Mol & Cell Endocrinol 120: 15 -24, 1996			
0974	CAIS	Substitut	2 DBD	* 583 2110	Phe $\Rightarrow$ Leu <u>T</u> TC $\Rightarrow$ <u>T</u> TG	29	17				Mother & 2 sisters heterozygous carriers 1 sister & 1 aunt affct	Female	Normal	pos	Audi et al. J Clin Endocrinol Metab 95:1876-1888, 2010			
0048	CAIS	Substitut	2 DBD	* 585 2116	Arg $\Rightarrow$ Lys <u>A</u> GA $\Rightarrow$ <u>A</u> AA							Female	Normal		Sultan et al; J Steroid Biochem & Mol Biol:46			
0049	CAIS	Deletion	2-8		⇒						Similar 2-8 deletion in 2 different families	Female	Normal		Jakubiczka et al; Human Mutation 9: 57 -61, 1997			

Accession #	Mutation type	Exon Domain	Pathogenicity proven	CpG hot spot	Position Base	Change Amino acid Base	Exon 1 tracts				Androgen Binding				Comments	Sex of rearing	External Genitalia	Family history	Reference
							Poly Gln #	Poly Gly #	Bmax	Kd	Thermolabile k								
0050	CAIS	Deletion	3 DBD	*		⇒			high	normal		Produces internally deleted protein	Female	Normal	pos	Quigley et al; Mol Endocrinol 6:1103, 1992			
0051	CAIS	Deletion	3 DBD			⇒							Female	Normal	pos	Hiori et al; Am J Med Genet. 63: 218-22, 1996			
0443	CAIS	Deletion	3 DBD			⇒			zero				Female	Normal		Ahmed et al; J Clin Endocrinol & Metab 85: 658-665, 2000			
0444	CAIS	Deletion	3 DBD			⇒							Female	Normal		Ahmed et al; J Clin Endocrinol & Metab 85: 658-665, 2000			
0488	Prostate Cancer	Substitution	3 DBD	586 2119	Ala ⇒ Val GCC ⇒ GTC							Somatic mutation	Male	Normal		Marcelli et al; Cancer Research 60: 944-949, 2000			
0877	CAIS	Substitution	3 DBD	*	586 2119	Ala ⇒ Asp GCC ⇒ GAC			normal			Zero transactivation activity	Female	Normal	pos	Rajender et al; Fert Steril 91:933.e23-28, 2009			
0490	Prostate Cancer	Substitution	3 DBD	587 2121	Ala ⇒ Ser GCT ⇒ TCT							Somatic mutation	Male	Normal		Marcelli et al; Cancer Research 60: 944-949, 2000			
0052	CAIS	Substitution	3 DBD	*	590 2130	Lys ⇒ Stop AAA ⇒ TAA			zero				Female	Normal		Marcelli et al; Mol Endocrinol 4: 1105, 1990			
0975	CAIS	Substitution	3 DBD	593 2141	Tyr ⇒ Stop TAC ⇒ TAA	18	18						Female	Normal	neg	Audi et al. J Clin Endocrinol Metab 95:1876-1888, 2010			
0887	Prostate Cancer	Substitution	3 DBD	594 2142	Leu ⇒ Met CTG ⇒ ATG							Q58L,Q260X,ΔQ86, E665D. Bical treated	Male	Normal		Steinkamp et al; Cancer Res 69:4434-4442, 2009			
0053	PAIS	Substitution	3 DBD	*	596 2148	Ala ⇒ Thr GCC ⇒ ACC			normal	normal		Found in 2 unrelated fam. Abolishes dimerization	Male	Ambiguous	pos	Gast et al; Mol & Cell Endocrinol 111: 93-98, 1995			
0434	PAIS	Substitution	3 DBD	*	596 2148	Ala ⇒ Thr GCC ⇒ ACC			normal	normal		Somatic mosaicism	Male	Ambiguous		Holterhus et al; Pediatric Res 46: 684-690, 1999			
0510	PAIS	Substitution	3 DBD	*	596 2148	Ala ⇒ Thr GCC ⇒ ACC			normal			partial transactivation in COS cells	Male	Ambiguous		Giwercman et al; Hormone Research 53: 83-88, 2000			
0710	PAIS	Substitution	3 DBD	*	596 2148	Ala ⇒ Thr GCC ⇒ ACC			high				Male	Ambiguous		Deeb et al; Clinical Endocrinology 63: 56-62, 2005			
0959	E006AA Prost Can cell line	Substitution	3 DBD	597 2148	Ser ⇒ Gly AGC ⇒ GGC							Dominant-negative loss of function mut AR gene amplificat	Male	Normal		D'Antonio et al. PLOS One 5:e11475, 2010			
0054	PAIS	Substitution	3 DBD	*	597 2151	Ser ⇒ Gly AGC ⇒ GGC			normal	normal		High dissoc. rate. Also has Arg617Pro (CGG toCCG) mut.	Female	Ambiguous		Zoppi et al; Mol Endocrinol 6:409, 1992			
0390	PAIS	Substitution	3 DBD	597 2152	Ser ⇒ Thr AGC ⇒ ACC							Severe hypospadias and cryptorchidism	Male	Ambiguous		Nordenskjold et al Urological Res. 27: 49-55, 1999			
0609	PAIS	Substitution	3 DBD	597 2154	Ser ⇒ Arg AGC ⇒ AGA							Newborn treated with 1% DHT locally - normal penile size	Male	Ambiguous		Giwercmann et al; Horm Res 61: 58-62, 2004			
0610	Normal	Substitution	3 DBD	597 2154	Ser ⇒ Arg AGC ⇒ AGA							Adult had bilateral cryptorchadism in childhood	Male	Normal		Giwercmann et al; Horm Res 61: 58-62, 2004			
0720	CAIS	Deletion	3 DBD	599 2158	Asn ⇒ Met ΔΔAT ⇒ ATG							single nt deletion causing frameshift & stop at codon 624	Female	Normal	neg	Ledig et al; Horm Res 63:263-269, 2005			
0055	CAIS	Substitution	3 DBD	601 2164	Cys ⇒ Phe TGC ⇒ TTC								Female	Normal	pos	Baldazzi et al; Hum Mol Genet 3:1169-70 1994			
0946	PAIS	Substitution	3 DBD	*	601 2164	Cys ⇒ Ser TGC ⇒ TCC						40% loss of ligand-binding & 70% loss of transacription	Female	Ambiguous		Singh et al. J Steroid Biochem Mol Biol 2010			
0362	PAIS	Substitution	3 DBD	602 2166	Thr ⇒ Pro ACT ⇒ CCT	24						testis located in ingunal canal. Same family as 0831	Male	Ambiguous	pos	Melo et al; J Clin Endocrinol & Metab 88: 3241-3250, 2003			
0831	PAIS	Substitution	3 DBD	602 2166	Thr ⇒ Pro ACT ⇒ CCT							Same family as 0362	Male	Ambiguous	pos	Melo et al; Arq Bras Endocrinol Metab 49:87-97, 2005			
0942	PAIS	Substitution	3 DBD	603 2170	Ile ⇒ Asn ATT ⇒ AAT				zero			Somatic mosaicism - no transcriptional activity				Elffrich et al. Sexual Development 3:237-244, 2009			

Accession #	Mutation type	Exon Domain	CpG hot spot	Position Base	Change Amino acid Base	Exon 1 tracts				Androgen Binding			Comments	Sex of rearing	External Genitalia	Family history	Reference
						Poly Gln #	Poly Gly #	Bmax	Kd	Thermolabile k							
0056	PAIS	Substitut	3 DBD	604 2172	Asp⇒Tyr <u>GAT</u> ⇒ <u>TAT</u>									Male	Ambiguous		Hiort et al: Hum Mol Genet 3: 1163-1166 1994
0598	PAIS	Substitut	3 DBD	604 2172	Asp⇒Tyr <u>GAT</u> ⇒ <u>TAT</u>									Female	Ambiguous	pos	Scheiber et al; J Ped Endocrinol & Metab. 16: 367-373, 2003
0847	CAIS	Substitut	3 DBD	607 2181	Arg⇒Stop <u>CGA</u> ⇒ <u>TGA</u>								Diag at 1Mo Bilateral gonadectomy at 16y	Female	Normal	pos	Cheikhelard et al. J Urol 180:1496-1501, 2008
0848	CAIS	Substitut	3 DBD	* 607 2181	Arg⇒Stop <u>CGA</u> ⇒ <u>TGA</u>								Diag at 1 Mo-Woolfian derivatives on rt side only	Female	Normal	pos	Cheikhelard et al. J Urol 180:1496-1501, 2008
0057	CAIS	Substitut	3 DBD	* 607 2181	Arg⇒Stop <u>CGA</u> ⇒ <u>TGA</u>			zero						Female	Normal		Brown et al; Eur J Pediatr (Suppl 2) 152; S62, 1993
0511	CAIS	Substitut	3 DBD	* 607 2181	Arg⇒Stop <u>CGA</u> ⇒ <u>TGA</u>			zero						Female	Normal		Giwercman et al; Hormone Research 53: 83-88, 2000
0702	CAIS	Substitut	3 DBD	* 607 2181	Arg⇒Stop <u>CGA</u> ⇒ <u>TGA</u>				1 affected sibling					Female	Normal	pos	Boehmer et al; J Clin Endocrinol & Metab 86: 4151-4160, 2001
0770	MAIS	Substitut	3 DBD	* 607 2182	Arg⇒Gln <u>CGA</u> ⇒ <u>CAA</u>								Male infertility	Male	Normal		Ferlin et al. Clin Endocrinol 65:606-610, 2006
0677	PAIS	Substitut	3 DBD	* 607 2182	Arg⇒Gln <u>CGA</u> ⇒ <u>CAA</u>										Ambiguous		Bouvattier et al; J Clin Endocrinol & Metab 87: 29-32, 2002
0393	PAIS	Substitut	3 DBD	* 607 2182	Arg⇒Gln <u>CGA</u> ⇒ <u>CAA</u>								Germ cell tumour - in undescended testis	Female	Normal		Chen et al; Human Reproduction 14: 664-670, 1999
0347	PAIS	Substitut	3 DBD	* 607 2182	Arg⇒Gln <u>CGA</u> ⇒ <u>CAA</u>								Patient successfully treated with testosterone	Male	Ambiguous		Weidemann et al; J Clin Endocrinol & Metab 83: 1173-1176, 1998
0060	PAIS	Substitut	3 DBD	* 607 2182	Arg⇒Gln <u>CGA</u> ⇒ <u>CAA</u>									Female	Ambiguous		Hiort et al; Am J Med Genet. 63: 218-222, 1996
0059	PAIS	Substitut	3 DBD	* * 607 2182	Arg⇒Gln <u>CGA</u> ⇒ <u>CAA</u>			normal normal						Male	Ambiguous	pos	Weidemann et al; Clin Endocrinology 45: 733-739, 1996
0058	PAIS and breast cancer	Substitut	3 DBD	* 607 2182	Arg⇒Gln <u>CGA</u> ⇒ <u>CAA</u>									Male	Ambiguous	pos	Wooster et al; Nat Genet 2:132, 1992
0412	CAIS	Substitut	3 DBD	608 2184	⇒ ⇒								Mullerian ducts pres. 5nt. del frameshift & stop in codon 619	Female	Normal		Chen et al; Fertility & Sterility 72: 170-173, 1999
0061	PAIS	Substitut	3 DBD	608 2185	Arg⇒Lys <u>AGG</u> ⇒ <u>AAG</u>			normal normal						Male	Ambiguous		Saunders et al; Clin Endocrinol 37:214, 1992
0062	PAIS and breast cancer	Substitut	3 DBD	608 2185	Arg⇒Lys <u>AGG</u> ⇒ <u>AAG</u>			normal normal						Male	Ambiguous		Lobaccaro et al; Hum Mol Genet, 2:1799, 1993
0322	PAIS	Substitut	3 DBD	608 2185	Arg⇒Lys <u>AGG</u> ⇒ <u>AAG</u>			normal normal					Defective nuclear localization	Male	Ambiguous		Tincello et al; Clinical Endocrinology 46: 497-506, 1997
0352	PAIS	Substitut	3 DBD	608 2185	Arg⇒Lys <u>AGG</u> ⇒ <u>AAG</u>									Male	Ambiguous	pos	Hiort et al; J Pediatrics 132: 939- 943, 1998
0481	PAIS	Substitut	3 DBD	608 2185	Arg⇒Lys <u>AGG</u> ⇒ <u>AAG</u>			normal high									Ahmed et al; J Clin Endocrinol & Metab 85: 658-665, 2000
0956	PAIS	Substitut	3 DBD	608 2185	Arg⇒Lys <u>AGG</u> ⇒ <u>AAG</u>									Male	Ambiguous	neg	Wu et al. Fertility & Sterility 93:2076, e1-4, 2010
0063	PAIS	Substitut	3 DBD	* 610 2190	Asn⇒Thr AAT⇒ACT			normal low	*					Male	Ambiguous		Weidemann et al; Clin Endocrinology 45: 733-
0721	CAIS	Insertion	3 DBD	610 2190	Asn⇒Lys AAT⇒AAAT									Female	Normal	neg	Ledig et al; Horm Res 63:263-269, 2005
0496	CAIS	Substitut	3 DBD	611 2193	Cys⇒Tyr <u>TGT</u> ⇒ <u>TAT</u>									Female	Normal		Mockel et al; Geburtsh. und Frauen. 60: 232-234, 2000
0722	CAIS	Substitut	3 DBD	614 2203	Cys⇒Tyr <u>TGT</u> ⇒ <u>TAT</u>									Female	Normal	neg	Ledig et al; Horm Res 63:263-269, 2005

Accession #	Mutation type	Exon Domain	CpG hot spot	Position Base	Change Amino acid Base	Exon 1 tracts				Androgen Binding Thermolabile			Comments	Sex of rearing	External Genitalia	Family history	Reference
						Poly Gln #	Poly Gly #	Bmax	Kd	k							
0064	CAIS	Deletion	3 DBD	* 615 2204-6	Arg $\Rightarrow$ 0 <u>TGATCG</u> $\Rightarrow$ TGT	27	23	normal	normal		3 nt. del - Arg615 del, Int. from 614, 2nt. 615. 614 still Cys	Female	Normal		Beitel et al; Hum Mol Genet, 3:21, 1994		
0512	CAIS	Substitution	3 DBD	* 615 2205	Arg $\Rightarrow$ Gly <u>CGT</u> $\Rightarrow$ <u>GGT</u>						no transactivation in COS cells	Female	Normal		Giwerzman et al; Hormone Research 53: 83-88, 2000		
0065	CAIS	Substitution	3 DBD	* * 615 2206	Arg $\Rightarrow$ His <u>CGT</u> $\Rightarrow$ <u>CAT</u>	25	23	low	high			Female	Normal	pos	Beitel et al; Hum Mol Genet, 3:21, 1994		
0066	CAIS	Substitution	3 DBD	* * 615 2206	Arg $\Rightarrow$ His <u>CGT</u> $\Rightarrow$ <u>CAT</u>			normal	normal			Female	Normal	pos	Mowszowicz et al; Mol Endocrinol 7:861-869, 1993		
0067	CAIS	Substitution	3 DBD	* * 615 2206	Arg $\Rightarrow$ His <u>CGT</u> $\Rightarrow$ <u>CAT</u>							Female	Normal		Brown et al; Eur J Pediatr 152 (Suppl 2): S62, 1993		
0068	CAIS	Substitution	3 DBD	* * 615 2206	Arg $\Rightarrow$ His <u>CGT</u> $\Rightarrow$ CAT					2 affected siblings variable phenotype		Female	Normal	pos	Boehmer et al; J Clin Endocrinol & Metab 86:4151-4160, 2001		
0348	CAIS	Substitution	3 DBD	* 615 2206	Arg $\Rightarrow$ His <u>CGT</u> $\Rightarrow$ <u>CAT</u>							Female	Normal		Cabral et al; Brazilian J Mol & Biol Res. 31: 775-778, 1998		
0353	CAIS	Substitution	3 DBD	* 615 2206	Arg $\Rightarrow$ His <u>CGT</u> $\Rightarrow$ <u>CAT</u>							Female	Normal		Hiort et al; J Pediatrics 132: 939- 943, 1998		
0354	CAIS	Substitution	3 DBD	* 615 2206	Arg $\Rightarrow$ His <u>CGT</u> $\Rightarrow$ <u>CAT</u>							Female	Normal		Hiort et al; J Pediatrics 132: 939- 943, 1998		
0069	PAIS	Substitution	3 DBD	* 615 2206	Arg $\Rightarrow$ His <u>CGT</u> $\Rightarrow$ <u>CAT</u>							Male	Ambiguous		Hiort et al; Am J Med Genet. 63: 218-222, 1996		
0654	CAIS	Substitution	3 DBD	* 615 2206	Arg $\Rightarrow$ His <u>CGT</u> $\Rightarrow$ <u>CAT</u>					Woolfian remnants present - sister of 655		Female	Normal	pos	Hannema et al. J Clin Endocrinol & Metab 89: 5815-5822, 2004		
0655	CAIS	Substitution	3 DBD	* 615 2206	Arg $\Rightarrow$ His <u>CGT</u> $\Rightarrow$ <u>CAT</u>					Sister of 654		Female	Normal	pos	Hannema et al. J Clin Endocrinol & Metab 89: 5815-5822, 2004		
0069	MAIS	Substitution	3 DBD	* 615 2206	Arg $\Rightarrow$ His <u>CGT</u> $\Rightarrow$ <u>CAT</u>					Male infertility		Male	Normal		Ferlin et al. Clin Endocrinol 65:606-610, 2006		
0070	PAIS	Substitution	3 DBD	615 2206	Arg $\Rightarrow$ Pro <u>CGT</u> $\Rightarrow$ CCT							Male	Ambiguous		Hiort et al; Am J Med Genet. 63: 218-222, 1996		
0445	CAIS	Substitution	3 DBD	615 2206	Arg $\Rightarrow$ Pro <u>CGT</u> $\Rightarrow$ CCT			normal	high			Female	Normal		Ahmed et al; J Clin Endocrinol & Metab 85: 658-665, 2000		
0071	PAIS	Substitution	3 DBD	* 616 2209	Leu $\Rightarrow$ Arg <u>CTT</u> $\Rightarrow$ CGT			normal	normal			Female	Ambiguous	pos	De Bellis et al; J Clin Endocrinol Metab, 78:513, 1994		
0072	CAIS	Substitution	3 DBD	616 2209	Leu $\Rightarrow$ Pro <u>CTT</u> $\Rightarrow$ CCT							Female	Normal		Mebarki et al; 75th US Endo Soc Meeting, Abstr 602,1993		
0073	CAIS	Substitution	3 DBD	* 616 2209	Leu $\Rightarrow$ Pro <u>CTT</u> $\Rightarrow$ CCT			normal	normal			Female	Normal		Lobaccaro et al; Mol Cell Endocrinol, 5: 137 -147, 1996		
0074	PAIS	Substitution	3 DBD	* 617 2212	Arg $\Rightarrow$ Pro <u>CGG</u> $\Rightarrow$ CCG			normal	normal			Female	Ambiguous	pos	Marcelli et al; J Clin Invest. 87: 1123, 1991		
0075	PAIS	Substitution	3 DBD	* 617 2212	Arg $\Rightarrow$ Pro <u>CGG</u> $\Rightarrow$ CCG			normal	normal	high	Mutation also at 597	Female	Normal		Zoppi et al; Mol Endocrinol 6:409, 1992		
0431	Prostate cancer	Substitution	3 DBD	* 619 2218	Cys $\Rightarrow$ Tyr <u>TGT</u> $\Rightarrow$ TAT			low	high		Inactive transcription Does not bind DNA somatic mutation	Male	Normal		Nazereth et al; Mol Endocrinol 13: 2065 -2075, 1999		
0976	CAIS	Substitution	3 DBD	619 2217	Cys $\Rightarrow$ Arg <u>TGT</u> $\Rightarrow$ CGT	20	18				Mother heterozygous carrier, 1 affected sister	Female	Normal	pos	Audi et al. J Clin Endocrinol Metab 95:1876-1888, 2010		
0491	Prostate cancer	Substitution	3 DBD	619 2218	Cys $\Rightarrow$ Tyr <u>TGT</u> $\Rightarrow$ TAT						Somatic mutation	Male	Normal		Marcelli et al; Cancer Research 60: 944-949, 2000		
0076	CAIS	Deletion	3-8		⇒							Female	Normal		Brown et al, Eur J Pediatr (Suppl 2) 152: S62, 1993		
0077	MAIS	Deletion	4 LBD		⇒						Azoospermia	Male	Normal	neg	Aiken et al; Am J Obs & Gyn . 165:1891 -1894, 1991		

Accession #	Mutation type	Exon Domain	CpG hot spot	Position Base	Change Amino acid Base	Exon 1 tracts				Androgen Binding			Comments	Sex of rearing	External Genitalia	Family history	Reference
						Poly Gln #	Poly Gly #	Bmax	Kd	Thermolabile k							
0078	CAIS	Deletion	4 LBD	*		⇒					13 nt deletion causing frameshift and stop at codon 783	Female	Normal	pos	Lobaccaro et al; Mol & Cellular Endocrinology 111: 21-8, 1995		
0711	PAIS	Substitution	4	629 2247	Arg ⇒ Trp CGG ⇒ TGG				normal		40% higher transactivation than WT impaired N/C	Male	Ambiguous		Deeb et al; Clinical Endocrinology 63: 56-62, 2005		
0306	Prostate cancer	Substitution	4	629 2248	Arg ⇒ Gln CGG ⇒ CAG					1 of 6 of hormone-independent D2 patients- somatic mut	Male	Normal		Wang et al; Japanese J of Urology 88: 550-556, 1997			
0079	Prostate cancer	Substitution	4	630 2251	Lys ⇒ Thr AAG ⇒ ACG					Also Lys717Glu mut, (AAGtoGAG)+silent mut in 701. Som mut	Male	Normal		Tilley et al; Clinical Cancer Res. 2:277-285, 1996			
0400	CAIS	Substitution	4 LBD	640 2280	Gln ⇒ Stop CAG ⇒ TAG			zero				Female	Normal		Yaegashi et al; Tohoku J of Exp Med 187: 263-272, 1999		
0429	CAIS	Substitution	4 LBD	640 2280	Gln ⇒ Stop CAG ⇒ TAG			zero		also Trp751Stop mut, (TGGtoTGA) 47XXY,	Female	Normal		Uehara et al; Am J Med Genet. 86: 107-111, 1999			
0613	Prostate cancer	Substitution	4 LBD	*	640 2280	Gln ⇒ Stop CAG ⇒ TAG				also T877A. transactiv androgen-independent~275x	Male	Normal		Ceraline et al. Int. J. Cancer 108: 152-157, 2004			
0080	PAIS	Substitution	4 LBD	645 2296	Ala ⇒ Asp GCT ⇒ GAT						Male	Ambiguous		Hiori et al; Am J Med Genet. 63: 218-222, 1996			
0334	Normal	Substitution	4 LBD	645 2296	Ala ⇒ Asp GCT ⇒ GAT						Male	Normal		Nordenskjold et al; Human Mutation. 11: 339, 1998			
0617	CAIS	Substitution	4 LBD	645 2296	Ala ⇒ Asp GCT ⇒ GAT	27		low		Also Arg752Gln	Female	Normal		MacLean et al. Hum Mutat. 23:287, 2004			
0772	MAIS	Substitution	4 LBD	645 2296	Ala ⇒ Asp GCT ⇒ GAT					male infertility	Male	Normal		Ferlin et al. Clin Endocrinol 65:606-610, 2006			
0812	PAIS	Substitution	4 LBD	*	645 2296	Ala ⇒ Asp GCT ⇒ GAT	28			Long poly Q and short poly G contribute to PAIS	Male	Ambiguous		Werner et al. J Clin Endocrinol Metab 91:3515-3520, 2006			
0813	PAIS	Substitution	4 LBD	*	645 2296	Ala ⇒ Asp GCT ⇒ GAT	30			Long poly Q and short poly G contribute to PAIS	Male	Ambiguous		Werner et al. J Clin Endocrinol Metab 91:3515-3520, 2006			
0081	Prostate cancer	Substitution	4 LBD	647 2302	Ser ⇒ Asn AGC ⇒ AAC					+ Gly724Asp.Leu880 Gln & Ala896Thr. mut	Male	Normal		Taplin et al; New England J Med 332:1393-1398, 1995			
1020	Premature ovarian failure	Substitution	4 LBD	649 2307	Thr ⇒ Ala ACC ⇒ GCC					Patient had menopause at 28	Female	Normal		Panda et al. Gynecol Endocrinol 2010			
0576	Prostate cancer	Substitution	4 LBD	649 2309	Thr ⇒ Thr ACC ⇒ ACT					Somatic mut. -CaP Poorly diff, Stage B2 +Estramustine treat	Male	Normal		Segawa et al; Int J of Urology 9: 545-553, 2002			
0784	MAIS	Substitution	4 LBD	650 2310	Ser ⇒ Gly AGC ⇒ GGC					Male infertility	Male	Normal		Ferlin et al. Clin Endocrinol 65:606-610, 2006			
0827	MAIS	Substitution	4 LBD	*	650 2310	Ser ⇒ Gly AGC ⇒ GGC	23	18		Hypoandrogenism, scrotal hypoplasia hypospematogenesis	Male	Normal		Zuccarello et al. Clin Endocrinol 68:58-588, 2008			
0555	PAIS	Substitution	4 LBD	653 2319	Glu ⇒ Lys GAG ⇒ AAG					Also in family with CAH with no androgen insensitivity	Male	Ambiguous		Lundberg et al; J Clin Endocrinol & Metab 87: 2023-2028, 2002			
0517	CAIS	Substitution	4 LBD	657 2331	Gln ⇒ Stop CAG ⇒ TAG						Female	Normal		Chavez et al; Clin Genet 59:: 185-188, 2001			
1021	Premature ovarian failure	Substitution	4 LBD	657 2331	Gln ⇒ Lys CAG ⇒ AAG					Patient had menopause at 17	Female	Normal		Panda et al. Gynecol Endocrinol 2010			
0082	PAIS	Substitution	4 LBD	664 2353	Ile ⇒ Asn ATT ⇒ AAT	22	22	low	norm					Pinsky et al; Clin Inv Med 15: 456, 1992			
0937	Prostate cancer	Substitution	4 LBD	665 2357	Glu ⇒ Asp GAA ⇒					Treated with anti-androgens Occurred in 2 cases	Male	Normal		Steinkamp et al; Cancer Res 69:4434-4442, 2009			
0083	Prostate cancer	Substitution	4 LBD	670 2371	Gln ⇒ Arg CAG ⇒ CGG					Also Ser791Pro (TCT to CCT) mut. Somatic mutation	Male	Normal		Tilley et al; Clinical Cancer Res. 2: 277-285, 1996			
0943	CAIS	Substitution	4 LBD	*	671 2373	Pro ⇒ Ser CCC ⇒ TCC				Reduced transactivat no change in DNA or FxxLF binding	Female	Normal		Elfferich et al. Sexual Development 3:237-244, 2009			

Accession #	Mutation type	Exon Domain	CpG hot spot	Position Base	Change Amino acid	Pathogenicity proven	Exon 1 tracts				Androgen Binding			Comments	Sex of rearing	External Genitalia	Family history	Reference
							Poly Gln #	Poly Gly #	Bmax	Kd	Thermolabile k							
0084	PAIS	Substitut	4 LBD	671 2374	Pro⇒ His <u>CCC</u> ⇒ CAC									Male	Ambiguous		Hiort et al; Am J Med Genet. 63: 218-222, 1996	
0085	Prostate cancer	Substitut	4 LBD	672 2377	Ile⇒ Thr ATC⇒ ACC									Male	Normal		Tilley et al; Clinical Cancer Res. 2: 277-285, 1996	
0086	CAIS	Substitut	4 LBD	677 2392	Leu⇒ Pro CTG⇒ CCG		zero							Female	Normal	pos	Belsham et al; Human Mutation 5: 28-33, 1995	
0723	CAIS	Substitut	4 LBD	680 2401	Ile⇒ Thr ATT⇒ ACT								Affected twin sister	Female	Normal	pos	Ledig et al; Horm Res 63:263-269, 2005	
1005	PAIS	Substitut	4 LBD	680 2401	Ile⇒ Asn ATT⇒ AAT	21	4	normal high					sister , cousin and 2 great aunts affected	Female	Ambiguous	pos	Audi et al. J Clin Endocrinol Metab 95:1876-1888, 2010	
0087	CAIS	Substitut	4 LBD	681 2403	Glu⇒ Lys GAG⇒ AAG									Female	Normal		Hiort et al; J Clin Endocrinol Metab 77: 262-266, 1993	
0394	CAIS	Substitut	4 LBD	681 2403	Glu⇒ Lys GAG⇒ AAG								Germ cell tumour in undescended testis	Female	Normal		Chen et al; Human Reproduction 14: 664-670, 1999	
0618	CAIS	Substitut	4 LBD	681 2403	Glu⇒ Stop GAG⇒ TAG	21	v low							Female	Normal		MacLean et al. Hum Mutat. 23:287, 2004	
0619	CAIS	Substitut	4 LBD	681 2403	Glu⇒ Stop GAG⇒ TAG	21	low							Female	Normal		MacLean et al. Hum Mutat. 23:287, 2004	
947	CAIS	Substitut	4 LBD	681	Glu⇒ Asp GAG⇒ GAT								Mother a carrier- 3 affected siblings	Female	Normal	pos	Wu et al. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 26:606-609 2009	
0534	PAIS	Substitut	4 LBD	682 2406	Pro⇒ Thr CCA⇒ ACA		low							Female	Ambiguous		Chavez et al; J Hum Genet. 46: 560-565, 2001	
0724	CAIS	Substitut	4 LBD	682 2406	Pro⇒ Ala CCA⇒ GCA		low						aunt, 2 sisters and neice affected	Female	Normal	pos	Ledig et al; Horm Res 63:263-269, 2005	
0089	Prostate cancer	Substitut	4 LBD	683 2410	Gly⇒ Ala GGT⇒ GCT								Somatic mutation - transactivation normal	Male	Normal		Koivisto et al; Cancer Research 57: 314-319, 1997	
0090	CAIS	Substitut	4 LBD	684 2412	Val⇒ Ile GTA⇒ ATA		zero							Female	Normal		Mebarki et al; 75th US Endo Soc Meeting, Abstr 602, 1993	
0945	CAIS	Insertion	4 LBD	685	Val⇒ GTG⇒ GAGT								2 nt insert causing frameshift & stop in Codon 787	Female	Normal	pos	Rong et al; Eur J Obst & Gynecol & Reprod Biol 148:53-55, 2010	
0091	PAIS	Substitut	4 LBD	686 2418	Cys⇒ Arg TGT⇒ CGT									Male	Ambiguous		Hiort et al; Am J Med Genet. 63: 218-222, 1996	
0092	PAIS	Substitut	4 LBD	687 2422	Ala⇒ Val GCT⇒ GTT									Male	Ambiguous		Hiort et al; Am J Med Genet. 63: 218-222, 1996	
0093	CAIS	Substitut	4 LBD	688	Gly⇒ Glu GGA⇒								de novo mutation	Female	Normal	neg	Hiort et al; J Pediatrics 132: 939- 943, 1998	
0446	CAIS	Substitut	4 LBD	688 2424	Gly⇒ Stop GGA⇒ TGA		zero							Female	Normal		Ahmed et al; J Clin Endocrinol & Metab 85: 658-665, 2000	
0575	CAIS	Substitut	4 LBD	* 689 2428	His⇒ Pro CAC⇒ CCC		v low	low	high	*	v. low transactivation activity			Female	Normal		Rosa et al. J Clin Endocrinol & Metab 87; 4378-4382, 2002.	
0094	PAIS	Deletion	4 LBD	690 2430-2	Asp⇒ 0 GAC⇒ 0												Schwartz et al; Horm Res 41:117 Abstr 244, 1994	
0656	CAIS	Substitut	4 LBD	* 690 2431	Asp⇒ Val GAC⇒ GTC		high						Epididymis & Vas deferens present - v low transactivation	Female	Normal		Tadokoro et al; Clinical Endocrinology 71:253-260, 2009	
0095	CAIS	Deletion	4 LBD	692 2436-8	Asn⇒ 0 AAC⇒ 0			normal high		*	Three nucleotide deletion			Female	Normal		Batch et al; Hum Mol Genet 1:497, 1992	
0704	PAIS	Deletion	4 LBD	692 2436-8	Asn⇒ 0 AAC⇒ 0			normal high			3 nt. deletion. 3 affected siblings . variable phenotype			Female	Normal	pos	Boehmer et al; J Clin Endocrinol & Metab 86:4151-4160, 2001	
0849	CAIS	Substitut	4 LBD	693 2439	Gln⇒ Stop CAG⇒ TAG								Diag at 17y- Bilateral gonadectomy 17y	Female	Normal		Cheikhelard et al. J Urol 180:1496-1501, 2008	

Accession #	Mutation type	Exon Domain	Pathogenicity proven		CpG hot spot	Position Amino acid Base	Change Amino acid Base	Exon 1 tracts			Androgen Binding Thermolabile			Comments	Sex of rearing	External Genitalia	Family history	Reference
			Poly Gln #	Poly Gly #				Bmax	Kd	k								
0096	CAIS	Substitut	4 LBD	*	695 <i>2445</i>	Asp⇒ His GAC⇒ CAC			low						Female	Normal	neg	Ris-Stalpers et al; Mol Endocrinol 5:1562, 1991
0097	CAIS	Substitut	4 LBD	*	695 <i>2445</i>	Asp⇒ Asn GAC⇒ AAC			normal	normal	high			mutation found in two unrelated families	Female	Normal	pos	Ris-Stalpers et al; Mol Endocrinol 5:1562, 1991
0098	PAIS	Substitut	4 LBD	*	695 <i>2445</i>	Asp⇒ Asn GAC⇒ AAC								de novo mutation	Female	Ambiguous		Hiort et al; J Pediatrics 132: 939- 943, 1998
0657	CAIS	Substitut	4 LBD	*	695 <i>2445</i>	Asp⇒ Asn GAC⇒ AAC								Woolfian remnants present	Female	Normal		Hannema et al. J Clin Endocrinol & Metab 89: 5815-5822, 2004
0773	MAIS	Substitut	4 LBD	*	695 <i>2445</i>	Asp⇒ Asn GAC⇒ AAC								Male infertility	Male	Normal		Perlin et al. Clin Endocrinol 65:606-610, 2006
0977	CAIS	Substitut	4 LBD	*	695 <i>2445</i>	Asp⇒ Asn GAC⇒ AAC								Diag at 2 wk bilateral gonadectomy at 14yrs	Female	Normal	pos	Cheikhelard et al. J Urol 180:1496-1501, 2008
0978	CAIS	Substitut	4 LBD	*	695 <i>2445</i>	Asp⇒ Asn GAC⇒ AAC	22	17						Mother & 1 cousin heterozyg, 1 cousin & 1 aunt affect, sister wt	Female	Normal	pos	Audi et al. J Clin Endocrinol Metab 95:1876-1888, 2010
0977	CAIS	Substitut	4 LBD	695 <i>2445</i>	Asp⇒ Tyr GAC⇒ TAC	19	18							Mother heterozygous carrier	Female	Normal	pos	Audi et al. J Clin Endocrinol Metab 95:1876-1888, 2010
0335	CAIS	Substitut	4 LBD	695 <i>2446</i>	Asp⇒ Val GAC⇒ GTC	21								mtuation found in two siblings	Female	Normal	pos	Dork et al; Human Mutation 11: 337-339, 1998
0447	CAIS	Substitut	4 LBD	700 <i>2460</i>	Leu⇒ Met TTG⇒ ATG		zero							Epididymous and Vas deferns present	Female	Normal		Hannema et al. J Clin Endocrinol & Metab 89: 5815-5822, 2004
0725	CAIS	Deletion	4 LBD	700	Leu⇒ 0 TTG⇒									13 nt del framshift & stop at codon <i>783</i> sis & moth carr, neice aff	Female	Normal	pos	Ledig et al; Horm Res 63:263-269, 2005
0448	CAIS	Substitut	4 LBD	701 <i>2463</i>	Leu⇒ Phe CTC⇒ TTC										Female	Normal		Ahmed et al; J Clin Endocrinol & Metab 85: 658-665, 2000
0518	PAIS	Substitut	4 LBD	701 <i>2463</i>	Leu⇒ Ile CTC⇒ ATC													Chavez et al; Clin Genet 59:: 185-188, 2001
0099	Prostate cancer	Substitut	4 LBD	701 <i>2464</i>	Leu⇒ His CTC⇒ CAC									Somatic mutation	Male	Normal		Suzuki et al; J Steroid Biochem Molec Biol 46:759, 1993
0326	Prostate cancer	Substitut	4 LBD	701 <i>2464</i>	Leu⇒ His CTC⇒ CAC									Somatic mutation	Male	Normal		Watanabe et al; Jpn J Clin Oncol 27: 389 -393, 1997
0408	MDA PCa-Za	Substitut	4 LBD	701 <i>2464</i>	Leu⇒ His CTC⇒ CAC			normal	low					Som. mut. Prostate cancer cell line. Also has Thr877Ala	Male	Normal		Zao et al; J of Urology 162: 2192-2199, 1999
0100	CAIS	Substitut	4 LBD	702 <i>2466</i>	Ser⇒ Ala TCT⇒ GCT		zero											Pinsky et al; Clin Inv Med 15:456, 1992
0101	PAIS	Substitut	4 LBD	*	703 <i>2469</i>	Ser⇒ Gly AGC⇒ GGC		low	high									Radnayr et al; J of Urology 158: 1553 -1556, 1997
0449	CAIS	Substitut	4 LBD	*	703 <i>2469</i>	Ser⇒ Gly AGC⇒ GGC												Ahmed et al; J Clin Endocrinol & Metab 85: 658-665, 2000
0712	PAIS	Substitut	4 LBD	703 <i>2469</i>	Ser⇒ Gly AGC⇒ GGC				high									Deeb et al; Clinical Endocrinology 63: 56 -62, 2005
0713	PAIS	Substitut	4 LBD	703 <i>2469</i>	Ser⇒ Gly AGC⇒ GGC													Deeb et al; Clinical Endocrinology 63: 56 -62, 2005
0979	CAIS	Substitut	4 LBD	703 <i>2469</i>	Ser⇒ Cys AGC⇒ TGC	19	18	low	normal					Mother, sister, heterozygote carriers, I aunt wt	Female	Normal	pos	Audi et al. J Clin Endocrinol Metab 95:1876-1888, 2010
0559	CAIS	Substitut	4 LBD	705 <i>2475</i>	Asn⇒ Tyr AAT⇒ TAT									Sister a carrier	Female	Normal		Sills et al; Int J Mol Med 9: 45-48, 2002
0102	CAIS	Substitut	4 LBD	705 <i>2476</i>	Asn⇒ Ser AAT⇒ AGT		zero											Pinsky et al; Clin Inv Med 15:456, 1992
0103	CAIS	Substitut	4 LBD	705 <i>2476</i>	Asn⇒ Ser AAT⇒ AGT		zero											DeBellis et al; Mol Endocrinol 6:1909-20, 1992

Accession #	Mutation type	Exon Domain	CpG hot spot	Position Base	Change Amino acid Base	Exon 1 tracts				Androgen Binding Thermolabile			Comments	Sex of rearing	External Genitalia	Family history	Reference
						Poly Gln #	Poly Gly #	Bmax	Kd	k							
0104	CAIS	Substitut	4 LBD	705 2476	Asn⇒Ser AAT⇒AGT						Mutation found in two unrelated families	Female	Normal		Quigley et al; Endocrine Reviews 16: 271, 1995		
0482	PAIS	Substitut	4 LBD	705 2476	Asn⇒Ser AAT⇒AGT				normal high						Ahmed et al; J Clin Endocrinol & Metab 85: 658-665, 2000		
0633	CAIS	Substitut	4 LBD	705 2476	Asn⇒Ser AAT⇒AGT			zero			Testes located in abdomen	Female	Normal	neg	Melo et al; J Clin Endocrinol & Metab 88: 3241-3250, 2003		
0634	CAIS	Substitut	4 LBD	705 2476	Asn⇒Ser AAT⇒AGT	22		zero			Testes located in inguinal region	Female	Normal	pos	Melo et al; Arq Bras Endocrinol Metab 49:87-97, 2005		
0980	CAIS	Substitut	4 LBD	705 2476	Asn⇒Ser AAT⇒AGT	18	18	zero	zero			Female	Normal	neg	Audi et al. J Clin Endocrinol Metab 95:1876-1888, 2010		
0981	CAIS	Substitut	4 LBD	705 2476	Asn⇒Ser AAT⇒AGT	22	18				1 affected sister, 1 heterozygote sister, 2 wt sisters	Female	Normal	pos	Audi et al. J Clin Endocrinol Metab 95:1876-1888, 2010		
0581	CAIS	Substitut	4 LBD	705 2476	Asn⇒Ile AAT⇒ATT						Reduced immunoreactive AR	Female	Normal		Avila et al. J Clin Endocrinol Metab 87; 182-188, 2002		
0582	CAIS	Substitut	4 LBD	705 2476	Asn⇒Ile AAT⇒ATT						Low immunoreactive AR	Female	Normal		Avila et al. J Clin Endocrinol Metab 87; 182-188, 2002		
0105	CAIS	Substitut	4 LBD	* 2482	Leu⇒Arg CTG⇒CGG							Female	Normal		Lumbroso et al; J Clin Endo & Metab 81: 1984-1988, 1996		
0106	PAIS	Substitut	4 LBD	708 2485	Gly⇒Ala GGA⇒GCA							Male	Ambiguous		Hiort et al: Hum Mol Genet 3: 1163-1166 1994		
0314	PAIS	Substitut	4 LBD	708 2485	Gly⇒Ala GGA⇒GCA						Severe hypospadias	Male	Ambiguous		Albers et al; J of Pediatrics 131: 388-392, 1997		
0107	PAIS	Substitut	4 LBD	708 2485	Gly⇒Val GGA⇒GTA		zero				Mother had both mut. & wt. Ar genes.	Male	Ambiguous	pos	Auchus et al; 77th US Endo Soc Meeting, Abstr P1-508 1995		
1023	CAIS	Substitut	4 LBD	708 2485	Gly⇒Val GGA⇒GAA		low				Almost complete loss of transaction	Female	Normal		Rajender et al. J Androl 2010		
0819	PAIS	Substitut	4 LBD	* 2487	Glu⇒Lys GAG⇒AAG							Female	Ambiguous		Geoget et al. Mol Endocrinol 20:724-734, 2006		
0577	Prostate cancer	Substitut	4 LBD	709 2489	Glu⇒Glu GAG⇒GAA						Somatic mut. CaP Moder diff, Stage D1 + bicalutamide treat	Male	Normal		Segawa et al; Int J of Urology 9: 545-553, 2002		
0658	CAIS	Substitut	4 LBD	710 2491	Arg⇒Thr AGA⇒ACA		zero				Sister to 0450 - Epididymis & Vas deferens present	Female	Normal	pos	Hannema et al. J Clin Endocrinol & Metab 89: 5815-5822, 2004		
0450	CAIS	Substitut	4 LBD	710 2491	Arg⇒Thr AGA⇒ACA		zero				Sister to 0658- Epididymis & Vas deferens present	Female	Normal	pos	Hannema et al. J Clin Endocrinol & Metab 89: 5815-5822, 2004		
0525	PAIS	Substitut	4 LBD	* 2493	Gln⇒Glu CAG⇒GAG		v low				altered AR specificity 2x increased affinity for E2.	Female	Ambiguous	pos	Lumbroso et al. 83rd US Endo Soc Meeting, Abstr P2-29, 2001		
0535	PAIS	Substitut	4 LBD	* 2493	Gln⇒Glu CAG⇒GAG		normal					Female	Ambiguous	pos	Chavez et al; J Hum Genet. 46: 560-565, 2001		
0828	CAIS	Deletion	4 LBD	711 2494	Gln⇒ CAAG⇒CGC						Int del-frameshift & stop in codon 788- 3 affected aunts	Female	Normal	pos	Galani et al; Fertility & Sterility 2008		
0578	Prostate cancer	Substitut	4 LBD	711 2495	Gln⇒Gln CAG⇒CAA						Somatic mut. CaP Moder diff, Stage D2 + leuprolide treat	Male	Normal		Segawa et al; Int J of Urology 9: 545-553, 2002		
0108	PAIS	Substitut	4 LBD	* 2496	Leu⇒Phe CTT⇒GTT		normal high				Phenotypic diversity brother of 505& 506 Testost-induced	Male	Ambiguous	pos	Hiort et al; Am J Med Genet. 63: 218-222, 1996		
0505	PAIS	Substitut	4 LBD	* 2496	Leu⇒Phe CTT⇒GTT		normal high				Phenotypic diversity brother of 108& 506 Testost-induced	Male	Ambiguous	pos	Hiort et al; J Clin Endocrinol & Metab 85: 3245-3250, 2000		
0506	PAIS	Substitut	4 LBD	* 2496	Leu⇒Phe CTT⇒GTT		normal high				Phenotypic diversity brother of 505& 108 Testost-induced	Male	Ambiguous	pos	Hiort et al; J Clin Endocrinol & Metab 85: 3245-3250, 2000		
0507	PAIS	Substitut	4 LBD	* 2496	Leu⇒Phe CTT⇒GTT		normal high				Phenotypic diversity uncle of 108,505,506 Testost-induced	Male	Ambiguous	pos	Hiort et al; J Clin Endocrinol & Metab 85: 3245-3250, 2000		

Accession #	Mutation type	Exon Domain	CpG hot spot	Position Base	Change Amino acid Base	Exon 1 tracts				Androgen Binding			Comments	Sex of rearing	External Genitalia	Family history	Reference
						Poly Gln #	Poly Gly #	Bmax	Kd	Thermolabile k							
0109	Prostate cancer	Substitut	4 LBD	* 715 2507	Val⇒ Met <u>GTG</u> ⇒ <u>ATG</u>			normal			Somatic mutation. Receptor showed a gain in function	Male	Normal		Culig et al; Mol Endocrinol 7:1541-1550 1993		
0110	Prostate cancer	Substitut	4 LBD	* 715 2507	Val⇒ Met <u>GTG</u> ⇒ <u>ATG</u>			normal			Somatic mutation. Receptor showed a gain in function	Male	Normal		Bubley et al 87th Am Assoc Cancer Res Meet Abstr. 1680, 1996		
0678	CAIS	Substitut	4 LBD	* 715 2507	Val⇒ Stop GTG⇒						bilateral inguinal hernia	Female	Normal		Bouvattier et al: J Clin Endocrinol & Metab 87: 29-32, 2002		
0792	PAIS	Substitut	4 LBD	718 2514	Trp⇒ Arg <u>TGG</u> ⇒ <u>CGG</u>						Somatic mosaic 2/3 mutant to 1/3 wt				Mueller et al. Hum Genet 119:680, 2006		
0111	CAIS	Substitut	4 LBD	718 2516	Trp⇒ Stop <u>TGG</u> ⇒ <u>TGA</u>			zero				Female	Normal	pos	Sai et al; Am J Hum Genet 46:1095, 1990		
0112	Prostate cancer	Substitut	4 LBD	720 2520	Lys⇒ Glu <u>AAG</u> ⇒ <u>GAG</u>						Somatic mutation-Bone metastases of Prostate cancer	Male	Normal		Kleinerman et al; J of Urology 155: 624A, 1996		
0113	Prostate cancer	Substitut	4 LBD	721 2523	Ala⇒ Thr GCC⇒ ACC						Somatic mutation in 20% of isolates in initial cloning	Male	Normal		Taplin et al; New England J Med 332: 1393-1398, 1995		
0583	CAIS	Deletion	4 LBD	721 2523	Ala⇒ 0 GACC⇒ GTT						2nt.frameshift & stop in codon 766 - no immunoreactive AR	Female	Normal		Avila et al. J Clin Endocrinol Metab 87; 182-188, 2002		
0584	CAIS	Deletion	4 LBD	721 2523	Ala⇒ 0 GACCT⇒ TGC						3nt.frameshift - low immunoreactive AR	Female	Normal		Avila et al. J Clin Endocrinol Metab 87; 182-188, 2002		
0114	CAIS	Substitut	4 LBD	722 2526	Leu⇒ Phe <u>TTG</u> ⇒ <u>TTT</u>							Female	Normal		Hiort et al: Am J Med Genet. 63: 218-222, 1996		
0761	Prostate cancer	Substitut	4 LBD	722 2526	Leu⇒ Phe <u>TTG</u> ⇒ <u>TTT</u>						patient lower Gleason score than patient -wt AR- som mutation	Male	Normal		Sanchez et al. BJU Int 98:1320-1325, 2006		
0451	CAIS	Substitut	4 LBD	723 2529	Pro⇒ Ser <u>CCT</u> ⇒ <u>TCT</u>			normal high			-Epidimis present	Female	Normal		Hannema et al. J Clin Endocrinol & Metab 89: 5815-5822, 2004		
0791	PAIS ?	Substitut	4 LBD	723 2528	Pro⇒ Leu <u>CCT</u> ⇒ <u>CTT</u>										Mueller et al. Hum Genet 119:681, 2006		
0452	CAIS	Substitut	4 LBD	724 2532	Gly⇒ Ser <u>GGC</u> ⇒ <u>AGC</u>			zero				Female	Normal		Ahmed et al; J Clin Endocrinol & Metab 85: 658-665, 2000		
0453	CAIS	Substitut	4 LBD	724 2533	Gly⇒ Asp <u>GGC</u> ⇒ <u>GAT</u>			zero			Epidimis & Vas deferens present	Female	Normal		Hannema et al. J Clin Endocrinol & Metab 89: 5815-5822, 2004		
0620	CAIS	Substitut	4 LBD	724 2533	Gly⇒ Ala <u>GGC</u> ⇒ <u>GCC</u>	19		normal				Female	Normal		MacLean et al. Hum Mutat. 23:287, 2004		
0798	CAIS	Substitut	4 LBD	* 724 2533	Gly⇒ Val <u>GGC</u> ⇒ <u>GTC</u>			zero			Severely impaired AR transactivation	Female	Normal		Jaaskelainen et al. Hum Mutat 27:291, 2006		
0115	CAIS	Deletion	4-8 LBD		⇒			zero				Female	Normal		Brown et al; Proc Natl Acad Sci 85:8151, 1988		
0116	CAIS	Deletion	5 LBD		⇒			zero			Affected aunt deleted for exons 6 and 7 only.	Female	Normal	pos	Maclean et al; J Clin Invest, 91:1123, 1993		
0117	CAIS	Substitut	5 LBD		Tyr⇒ Arg ⇒			zero				Female	Normal		Marcelli et al; 74th US Endo Soc Meetings: Abstr. 224, 1992		
0118	PAIS	Substitut	5 LBD	* 725 2535	Phe⇒ Leu <u>TTC</u> ⇒ <u>CTC</u>			normal normal			Mutation disrupts N/C terminal interaction	Male	Ambiguous	pos	Quigley et al; Mech of Aging & Develop 125: 683-695, 2004		
0391	PAIS	Substitut	5 LBD	725 2535	Phe⇒ Leu <u>TTC</u> ⇒ <u>CTC</u>						Hypospadias and cryptorchidism	Male	Ambiguous	pos	Nordenskjold et al Urological Res, 27: 49-55, 1999		
0119	Prostate cancer	Substitut	5 LBD	* 726 2539	Arg⇒ Leu <u>CGC</u> ⇒ <u>CTC</u>			normal normal			Germ line mutation present in offspring	Male	Normal	pos	Elo et al ; J Clin Endocrinol Metab, 80: 3494-3500, 1995		
0508	Prostate cancer	Substitut	5 LBD	* 726 2539	Arg⇒ Leu <u>CGC</u> ⇒ <u>CTC</u>						Estimated that 2% of Finnish CAP patients have this mutation	Male	Normal	pos	Mononen et al; Cancer Res 60: 6479-6481, 2000		
0571	Prostate Cancer	Substitut	5 LBD	726 2539	Arg⇒ Leu <u>CGC</u> ⇒ <u>CTC</u>	20					Somatic mut polyGln 24 to 20 Orchietomy Horm-refractory CaP	Male	Normal		Hyttinen et al; Lab Invest. 82: 1591-1598, 2002		

Accession #	Mutation type	Exon Domain	CpG hot spot	Position Base	Change Amino acid	Amino acid Base	Exon 1 tracts				Androgen Binding				Comments	Sex of rearing	External Genitalia	Family history	Reference
							Poly Gln #	Poly Gly #	Bmax	Kd	Thermolabile k								
0687	Normal	Substitut	5 LBD	726 2539	Arg⇒Leu							Patient suffereing frm alcoholism			Normal		Yan et al; Psychiatric Genet 14: 57-60, 2004		
0120	MAIS	Substitut	5 LBD	727 2543	Asn⇒Lys							Oligospermia	Male	Normal			Yong et al; Lancet, 344: 826-827, 1994		
0121	PAIS	Substitut	5 LBD	728 2545	Leu⇒Ser				low			*					McPhaul et al; J Clin Inv, 90:2097, 1992		
0122	Prostate Cancer	Substitut	5 LBD	* 730 2550	Val⇒Met							Somatic mutation	Male	Normal			Newmark et al; Proc Natl AcadSci 89:6319, 1992		
0123	Prostate Cancer	Substitut	5 LBD	* 730 2550	Val⇒Met							Somatic mutation	Male	Normal			Petersiel et al; Int J Cancer 63: 544-550, 1995		
0762	Prostate Cancer	Substitut	5 LBD	* 730 2550	Val⇒Met							patient lower Gleason score than patient -wt AR- som mutation	Male	Normal			Sanchez et al. BJU Int 98:1320-1325, 2006		
0125	CAIS	Substitut	5 LBD	* 732 2556	Asp⇒Tyr				high				Female	Normal			Brown et al; 74th US Endo Soc Meeting, Abstr 1506, 1992		
0126	CAIS	Substitut	5 LBD	732 2556	Asp⇒Tyr				zero				Female	Normal			Pinsky et al; Clin Inv Med 15:456, 1992		
0127	CAIS	Substitut	5 LBD	732 2556	Asp⇒Tyr								Female	Normal			Ghirri and Brown; Pediatr Res 33: Abstr 95, 1993		
0801	CAIS	Substitut	5 LBD	732 2556	Asp⇒Tyr							6 affected family members	Female	Normal	pos		Scott et al. Endocr Pract 12:664-669, 2006		
0124	CAIS	Substitut	5 LBD	732 2556	Asp⇒Asn				high				Female	Normal			Brown et al; 74th US Endo Soc Meeting, Abstr 1506, 1992		
0659	CAIS	Substitut	5 LBD	732 2556	Asp⇒Asn							Epididymis & Vas deferens present	Female	Normal			Hannema et al. J Clin Endocrinol & Metab 89: 5815-5822, 2004		
0310	CAIS	Substitut	5 LBD	732 2556	Asp⇒Asn	19							Female	Normal			Ko et al; J Reprod. Med 42: 424- 427, 1997		
0955	CAIS	Substitut	5 LBD	732 2556	Asp⇒Asn								Female	Normal	neg		Wu et al. Fertility & Sterility 93:2076, e1-4, 2010		
0628	Prostate cancer	Substitut	5 LBD	732 2558	Asp⇒Asp							Orch + Bicalutamide +Iphosphamide treat Gleason 10. Somatic	Male	Normal			Haaplaa et al. Lab Invest. 81:1647-1651, 2001		
0752	CAIS	Substitut	5 LBD	733 2559	Gln⇒Stop							No WD development	Female	Normal	neg		Barbaro et al. Clin Endocrinol 66:822-826, 2007		
0128	PAIS	Substitut	5 LBD	733 2561	Gln⇒His							This patient was a mosaic for wt. & mut. alleles- de novo mut.	Female	Ambiguous	neg		Hiort et al; J Pediatrics 132: 939- 943, 1998		
0726	CAIS	Substitut	5 LBD	737 2571	Ile⇒Phe								Female	Normal	neg		Ledig et al; Horm Res 63:263-269, 2005		
0129	PAIS	Substitut	5 LBD	* 737 2572	Ile⇒Thr			low				Mutation disrupts N/C terminal interaction	Male	Ambiguous	pos		Quigley et al; Mech Aging & Develop 125:683-695		
0944	CAIS	Substitut	5 LBD	* 738 2575	Gln⇒Arg							V reduced transactiv reduced interaction with FxxLX	Female	Normal			Elfferich et al. Sexual Development 3:237 -244, 2009		
0530	CAIS	Substitut	5 LBD	* 739 2577	Tyr⇒Asp			zero				no transactivation in COS-1 cells	Female	Normal			Suzuki et al. Int. J Andrology 24: 183-188, 2001		
0616	PAIS	Substitut	5 LBD	* 740 2581	Ser⇒Cys			v low				Acute stress masked PAIS.	Male	Ambiguous	pos		Pitteloud et al. J Clin Endocrinol & Metab 89:1053-1058, 2004		
0982	CAIS	Substitut	5 LBD	741 2583	Trp⇒Arg	23	17						Female	Normal	neg		Audi et al. J Clin Endocrinol Metab 95:1876-1888, 2010		
0130	CAIS	Substitut	5 LBD	* 741 2583	Trp⇒Arg			low					Female	Normal	neg		Marcelli et al; J Clin Invest 94: 1642-1650, 1994		
0360	Prostate cancer	Substitut	5 LBD	741 2584	Trp⇒Stop							Somatic mutation	Male	Normal			Takahashi et al; Cancer Research 55: 1621 -1624, 1995		

Accession #	Mutation type	Exon Domain	CpG hot spot	Position Base	Change Amino acid	Pathogenicity proven	Exon 1 tracts				Androgen Binding				Comments	Sex of rearing	External Genitalia	Family history	Reference
							Poly Gln #	Poly Gly #	Bmax	Kd	Thermolabile k								
0595	CAIS	Substitut	5 LBD	*	741 2584	Trp⇒Leu TGG⇒TTG						Reduced immunoreactive AR	Female	Normal		Avila et al; J Clin Endocrinol Metab 87: 182-188, 2002			
0858	CAIS	Substitut	5 LBD		741 2584	Trp⇒Leu TGG⇒TTG						Diag at birth bilateral gonadectomy at 14yr	Female	Normal	pos	Cheikhelard et al; J Urol 180:1496-1501, 2008			
0859	CAIS	Substitut	5 LBD		741 2584	Trp⇒Leu TGG⇒TTG						Diag at birth bilateral gonadectomy at 12.5yr	Female	Normal	pos	Cheikhelard et al; J Urol 180:1496-1501, 2008			
0629	Prostate cancer	Substitut	5 LBD		741 2585	Trp⇒Cys TGG⇒TGT						Orch + bicalutamide Gleason 10- somatic mutation	Male	Normal		Haaplaa et al; Lab Invest. 81:1647-1651, 2001			
0635	PAIS	Substitut	5 LBD		741 2585	Trp⇒Cys TGG⇒TGT	27	low	high			Testes located in scrotum - Also has Leu547Phe mutation	Male	Ambiguous	pos	Melo et al; J Clin Endocrinol & Metab 88: 3241-3250, 2003			
0552	Prostate cancer	Substitut	5 LBD		741 2585	Trp⇒Cys TGG⇒TGT						Treated with bicalutamide - somatic mutation	Male	Normal		Taplin et al; J Clinical Oncology 21: 2673-2678, 2003			
0131	PAIS	Substitut	5 LBD		742 2586	Met⇒Val ATG⇒GTG			high							Ris-Stalpers et al; Pediatric Res. 36: 227-234, 1994			
0341	PAIS	Substitut	5 LBD		742 2586	Met⇒Val ATG⇒GTG	21	zero				Testis located in inguinal region	Female	Ambiguous	pos	Melo et al; J Clin Endocrinol & Metab 88: 3241-3250, 2003			
0744	PAIS	Substitut	5 LBD		742 2586	Met⇒Val ATG⇒GTG						affected neice of 0131	Female	Ambiguous		Boehmer et al; J Clin Endocrinol & Metab 86:4151-4160, 2001			
0132	PAIS	Substitut	5 LBD	*	742 2588	Met⇒Ile ATG⇒ATA		normal	high	*						Batch et al; Hum Mol Genet 1:497, 1992			
0948	PAIS	Substitut	5 LBD		742 2588	Met⇒Ile ATG⇒ATA										Nagaraja et al; J Pediatr Endocrinol Metab 22:1169-1173, 2009			
1006	PAIS	Substitut	5 LBD		742 2588	Met⇒Ile ATG⇒ATA	18	18	low	normal		Mother heterozygote carrier	Male	Ambiguous	pos	Audi et al; J Clin Endocrinol Metab 95:1876-1888, 2010			
0519	CAIS	Substitut	5 LBD		743 2589	Gly⇒Arg GGG⇒CGG										Chavez et al; Clin Genet 59:: 185-188, 2001			
0983	CAIS	Substitut	5 LBD		743 2590	Gly⇒Val GGG⇒GTG	24	17								Audi et al; J Clin Endocrinol Metab 95:1876-1888, 2010			
0133	PAIS	Substitut	5 LBD	*	743 2590	Gly⇒Val GGG⇒GTG		low	high			Transcription only at high conc of androgen	Female	Ambiguous		Georget et al; J Clin Endocrinol & Metab 83: 3597-3603, 1998			
0134	PAIS	Substitut	5 LBD		743 2590	Gly⇒Val GGG⇒GTG		normal	normal	*						Nakao et al; J Clin Endocrinol Metab 77:103-107, 1993			
0414	CAIS	Substitut	5 LBD		743 2590	Gly⇒Val GGG⇒GTG		zero				de novo mutation	Female	Normal		Lobaccaro et al; J Steroid Biochem & Mol Biol. 44: 211-216, 1993			
0536	CAIS	Substitut	5 LBD		743 2590	Gly⇒Glu GGG⇒GAG										Chavez et al; J Hum Genet. 46: 560-56, 2001			
0564	CAIS	Substitut	5 LBD	*	743 2590	Gly⇒Glu GGG⇒GAG		v low	high	high	*					Pujol et al; J Clin Endocrinol & Metab. 87: 5793-5800, 2002			
0572	Prostate cancer	Substitut	5 LBD		743 2591	Gly⇒Gly GGG⇒GGC						Somatic mutation + estrogen treatment Horm-refractory CaP	Male	Normal		Hyytinen et al; Lab Invest. 82: 1591-1598, 2002			
0361	Prostate cancer	Deletion	5 LBD		743 2591	Gly⇒Gly GGAG⇒GGC						Frameshift-somatic mut.- separate tumor in same indv. as 0362	Male	Normal		Takahashi et al; Cancer Research 55: 1621-1624, 1995			
0135	CAIS	Substitut	5 LBD		744 2592	Leu⇒Phe CTC⇒TTC						1 affected sibling			pos	Boehmer et al; J Clin Endocrinol & Metab 86:4151-4160, 2001			
0984	CAIS	Substitut	5 LBD		744 2592	Leu⇒Phe CTC⇒TTC	21	17				1 heterozygote sister & 1 wt sister	Female	Normal	pos	Audi et al; J Clin Endocrinol Metab 95:1876-1888, 2010			
0362	Prostate cancer	Substitut	5 LBD		744 2592	Leu⇒Phe CTC⇒TTC						Somatic mutation - separate tumor in same indv. as 0361	Male	Normal		Takahashi et al; Cancer Research 55: 1621-1624, 1995			
1007	PAIS	Substitut	5 LBD		745 2595	Met⇒Leu ATG⇒CTG	23	17				mother & grandmother heterozygote carriers	Male	Ambiguous	pos	Audi et al; J Clin Endocrinol Metab 95:1876-1888, 2010			

Accession #	Mutation type	Proven Pathogenicity	Exon Domain	CpG hot spot	Position Base	Change Amino acid	Exon 1 tracts				Androgen Binding			Comments	Sex of rearing	External Genitalia	Family history	Reference
							Poly Gln #	Poly Gly #	Bmax	Kd	Thermolabile k							
0136	PAIS	Substitut	5 LBD	745 2596	Met⇒Thr <u>ATG</u> ⇒ACG				zero							Ris-Stalpers et al; Pediatric Res 36: 227-234, 1994		
0727	CAIS	Substitut	5 LBD	745 2596	Met⇒Thr <u>ATG</u> ⇒ACG							Mother and sisters heterozygous	Female	Normal	pos	Ledig et al; Horm Res 63:263-269, 2005		
0755	CAIS	Substitut	5 LBD	* 745 2597	Met⇒Ile <u>ATG</u> ⇒ATC							Enhanced affinity for & increased transact for estradiol	Female	Normal		Bonagura et al. Mol Cell Endocrinol 263:79-89, 2007		
0138	PAIS	Substitut	5 LBD	746 2598	Val⇒Met <u>GTG</u> ⇒ATG								Male	Ambiguous		Hiort et al; Am J Med Genet. 63: 218-222, 1996		
0137	PAIS	Substitut	5 LBD	746 2598	Val⇒Met <u>GTG</u> ⇒ATG											Brown et al; 74th US Endo Soc Meeting, Abstr 1506, 1992		
0949	PAIS	Substitut	5 LBD	746 2598	Val⇒Met <u>GTG</u> ⇒ATG											Nagaraja et al. J Pediatr Endocrinol Metab 22:1169-1173, 2009		
0785	MAIS	Substitut	5 LBD	747 2601	Phe⇒Ile <u>TTT</u> ⇒ATT							Male Infertility	Male	Normal		Ferlin et al. Clin Endocrinol 65:606-610, 2006		
0985	CAIS	Substitut	5 LBD	747 2602	Phe⇒Cys <u>TTT</u> ⇒TGT	23	17					1 wt sister	Female	Normal	neg	Audi et al. J Clin Endocrinol Metab 95:1876-1888, 2010		
0763	Prostate cancer	Deletion	5 LBD	747 2603	Phe⇒Leu TTAT⇒TTG							patient lower Gleason score than patient -wt AR- som mutation	Male	Normal		Sanchez et al. BJU Int 98:1320-1325, 2006		
0492	Prostate cancer	Substitut	5 LBD	748 2604	Ala⇒Thr <u>GCC</u> ⇒ACC							Also Ser865Pro; Gln867Stop and Gln919Arg ;Som mut	Male	Normal		Marcelli et al; Cancer Research 60: 944-949, 2000		
0565	Prostate cancer	Substitut	5 LBD	* 748 2604	Ala⇒Thr <u>GCC</u> ⇒ACC			normal		high		Somatic mutation. weaker interaction with HSP	Male	Normal		James et al; Mol Endocrinol. 16: 2692-2705, 2002		
0139	PAIS	Substitut	5 LBD	* 748 2605	Ala⇒Asp <u>GCC</u> ⇒GAC			low		high		Abnormal dissociation				Marcelli et al; J Clin Invest 94: 1642-1650, 1994		
0363	Prostate cancer	Substitut	5 LBD	748 2605	Ala⇒Val <u>GCC</u> ⇒GTC							Somatic mutation	Male	Normal		Takahashi et al; Cancer Research 55: 1621-1624, 1995		
0140	CAIS	Substitut	5 LBD	749 2607	Met⇒Val <u>ATG</u> ⇒ <u>GTG</u>								Female	Normal	pos	DeBellis et al; Mol Endocrinol 6:1909-20, 1992		
0141	CAIS	Substitut	5 LBD	749 2607	Met⇒Val <u>ATG</u> ⇒ <u>GTG</u>								Female	Normal	pos	Jakubiczka et al; Hum Genet 90:311-2, 1992		
0483	PAIS	Substitut	5 LBD	749 2607	Met⇒Val <u>ATG</u> ⇒ <u>GTG</u>			normal	high							Ahmed et al; J Clin Endocrinol & Metab 85: 658-665, 2000		
0614	CAIS	Substitut	5 LBD	749 2607	Met⇒Val <u>ATG</u> ⇒ <u>GTG</u>							Fallopian tube present	Female	Normal		Van et al. Eur J. Pediatr. 162: 781-784, 2003		
0679	CAIS	Substitut	5 LBD	749 2607	Met⇒Val <u>ATG</u> ⇒ <u>GTG</u>							bilateral inguinal hernia	Female	Normal		Bouvattier et al: J Clin Endocrinol & Metab 87: 29-32, 2002		
0680	CAIS	Substitut	5 LBD	749 2607	Met⇒Val <u>ATG</u> ⇒ <u>GTG</u>							Diff between ext genital & chrom - in amniocentesis	Female	Normal		Bouvattier et al: J Clin Endocrinol & Metab 87: 29-32, 2002		
0364	Prostate cancer	Substitut	5 LBD	749 2609	Met⇒Ile <u>ATG</u> ⇒ATA							Somatic mutation	Male	Normal		Takahashi et al; Cancer Research 55: 1621-1624, 1995		
0630	Prostate cancer	Substitut	5 LBD	749 2609	Met⇒Ile <u>ATG</u> ⇒ATA							Orch + bicalutamide Gleason 10 +silent mut Gln867Gln	Male	Normal		Haaplaa et al. Lab Invest. 81:1647-1651, 2001		
0365	Prostate cancer	Substitut	5 LBD	750 2610	Gly⇒Ser <u>GGC</u> ⇒ <u>AGC</u>							Somatic mutation	Male	Normal		Takahashi et al; Cancer Research 55: 1621-1624, 1995		
0142	CAIS	Substitut	5 LBD	* 750 2611	Gly⇒Asp <u>GGC</u> ⇒ <u>GAC</u>			v low				Mutation found in two unrelated patients	Female	Normal		Bevan et al; J Steroid Biochem Molec. Biol 61: 19-26, 1997		
0143	CAIS	Substitut	5 LBD	750 2611	Gly⇒Asp <u>GGC</u> ⇒ <u>GAC</u>								Female	Normal		Brown et al; 74th US Endo Soc Meeting, Abstr 1506, 1992		
0703	CAIS	Substitut	5 LBD	751 2613	Trp⇒Arg <u>TGG</u> ⇒ <u>AGG</u>			normal	high			Sibling of 0144	Female	Normal		Boehmer et al; J Clin Endocrinol & Metab 86:4151-4160, 2001		

Accession #	Mutation type	Exon Domain	CpG hot spot	Position Base	Change Amino acid	Pathogenicity proven	Exon 1 tracts				Androgen Binding				Comments	Sex of rearing	External Genitalia	Family history	Reference
							Poly Gln #	Poly Gly #	Bmax	Kd	Thermolabile k								
0144	CAIS	Substitut	5 LBD	751 2613	Trp⇒ Arg <u>TGG</u> ⇒ <u>AGG</u>				low	high		Sibling of 0703	Female	Normal	pos	Brinkmann et al; J Steroid Biochem Mol Biol 53: 443, 1995			
0366	Prostate cancer	Substitut	5 LBD	751 2614	Trp⇒ Stop <u>TGG</u> ⇒ <u>TAG</u>							Somatic mutation	Male	Normal		Takahashi et al; Cancer Research 55: 1621 -1624, 1995			
0367	Prostate cancer	Substitut	5 LBD	751 2614	Trp⇒ Stop <u>TGG</u> ⇒ <u>TAG</u>							Somatic mutation	Male	Normal		Takahashi et al; Cancer Research 55: 1621 -1624, 1995			
0368	Prostate cancer	Substitut	5 LBD	751 2615	Trp⇒ Stop <u>TGG</u> ⇒ <u>TGA</u>							Somatic mutation	Male	Normal		Takahashi et al; Cancer Research 55: 1621 -1624, 1995			
0401	CAIS	Substitut	5 LBD	751 2615	Trp⇒ Stop <u>TGG</u> ⇒ <u>TGA</u>			zero					Female	Normal		Yaegashi et al; Tohoku J of Exp Med 187: 263 -272, 1999			
0664	PAIS	Substitut	5 LBD	751 2615	Trp⇒ Stop <u>TGG</u> ⇒ <u>TGA</u>							Somatic mosaicism - male changed to female at 18mths	Female	Ambiguous		Kohler et al; J Clin Endocrinol & Metab 90: 106-111, 2005			
0145	CAIS	Substitut	5 LBD	* 752 2616	Arg⇒ Stop <u>CGA</u> ⇒ <u>TGA</u>			zero					Female	Normal		Pinsky et al; Clin Inv Med 15:456, 1992			
0146	CAIS	Substitut	5 LBD	* 752 2616	Arg⇒ Stop <u>CGA</u> ⇒ <u>TGA</u>								Female	Normal		Brinkmann et al; J Steroid Biochem Mol Biol 53: 443, 1995			
0342	CAIS	Substitut	5 LBD	* 752 2616	Arg⇒ Stop <u>CGA</u> ⇒ <u>TGA</u>	16		zero				Testes located in abdomen	Female	Normal	pos	Melo et al; J Clin Endocrinol & Metab 88: 3241-3250, 2003			
0402	CAIS	Substitut	5 LBD	* 752 2616	Arg⇒ Stop <u>CGA</u> ⇒ <u>TGA</u>			zero					Female	Normal		Yaegashi et al; Tohoku J of Exp Med 187: 263 -272, 1999			
0728	CAIS	Substitut	5 LBD	* 752 2616	Arg⇒ Stop <u>CGA</u> ⇒ <u>TGA</u>								Female	Normal	neg	Ledig et al; Horm Res 63:263-269, 2005			
0754	CAIS	Substitut	5 LBD	* 752 2617	Arg⇒ Gln <u>CGA</u> ⇒ <u>CAA</u>							Inherited from maternal grandmother present in two sisters	Female	Normal	pos	Olafsson et al. Laeknabladid 86:263 -166, 2000			
0147	CAIS	Substitut	5 LBD	* 752 2617	Arg⇒ Gln <u>CGA</u> ⇒ <u>CAA</u>			zero				Mutation found in two unrel. families. Equivalent to tfm rat	Female	Normal		Brown et al; 74th US Endo Soc Meeting, Abstr 1506, 1992			
0333	CAIS	Substitut	5 LBD	* 752 2617	Arg⇒ Gln <u>CGA</u> ⇒ <u>CAA</u>								Female	Normal	pos	Komori et al; Arch Gynecol & Obstetrics 261: 95-100, 1998			
0349	CAIS	Substitut	5 LBD	* 752 2617	Arg⇒ Gln <u>CGA</u> ⇒ <u>CAA</u>								Female	Normal		Cabral et al; Brazilian J Med & Biol Res. 31: 775-758, 1998			
0148	CAIS	Substitut	5 LBD	* 752 2617	Arg⇒ Gln <u>CGA</u> ⇒ <u>CAA</u>			zero				Equivalent to tfm rat	Female	Normal		Evans; J Endocrinol 135 Suppl, Abstr P26, 1992			
0497	CAIS	Substitut	5 LBD	* 752 2617	Arg⇒ Gln <u>CGA</u> ⇒ <u>CAA</u>							Bilateral testicular tumors	Female	Normal		Sakai et al; IntJ of Urology 7: 390-392, 2000			
0860	CAIS	Substitut	5 LBD	* 752 2617	Arg⇒ Gln <u>CGA</u> ⇒ <u>CAA</u>							Prenatal Diagnosis	Female	Normal		Cheikhelard et al. J Urol 180:1496-1501, 2008			
0879	CAIS	Substitut	5 LBD	* 754 2622	Phe⇒ Val <u>TTC</u> ⇒ <u>GTC</u>			high				Greatly reduced transactivation 5%	Female	Normal		Tadokoro et al; Clinical Endocrinology 71:253 -260, 2009			
0150	CAIS	Substitut	5 LBD	754 2622	Phe⇒ Val <u>TTC</u> ⇒ <u>GTC</u>								Female	Normal		Hiori et al; Am J Med Genet. 63: 218-222, 1996			
0149	CAIS	Substitut	5 LBD	754 2622	Phe⇒ Val <u>TTC</u> ⇒ <u>GTC</u>			zero					Female	Normal		Lobaccaro et al; Hum Mol Genet 2:1041 -1043, 1993			
0880	PAIS	Substitut	5 LBD	* 754 2623	Phe⇒ Ser <u>TTC</u> ⇒ <u>TCC</u>			normal				Microphallus no hypospadias	Male	Ambiguous		Tadokoro et al; Clinical Endocrinology 71:253 -260, 2009			
0369	Prostate cancer	Substitut	5 LBD	754 2622	Phe⇒ Leu <u>TTC</u> ⇒ <u>CTC</u>							Somatic mutation	Male	Normal		Takahashi et al; Cancer Research 55: 1621 -1624, 1995			
0715	PAIS	Substitut	5 LBD	* 754 2623	Phe⇒ Leu <u>TTC</u> ⇒ <u>TTC</u>			high				Microphallus, hypospadias, cryptorchism	Male	Ambiguous		Deeb et al; Clinical Endocrinology 63: 56 -62, 2005			
0151	PAIS	Substitut	5 LBD	754 2624	Phe⇒ Leu <u>TTC</u> ⇒ <u>TTA</u>								Male	Ambiguous		Hiori et al; Hum Mol Genet 3: 1163-1166 1994			

Accession #	Mutation type	Exon Domain	Pathogenicity proven	CpG hot spot	Position Base	Change Amino acid Base	Exon 1 tracts				Androgen Binding			Comments	Sex of rearing	External Genitalia	Family history	Reference
							Poly Gln #	Poly Gly #	Bmax	Kd	Thermolabile k							
0152	PAIS	Substitut	5 LBD	*	754 <b>2624</b>	Phe⇒ <b>Leu</b> TTC⇒TTA			normal	high	*			Male	Ambiguous	Weidemann et al; Clin Endocrinology 45: 733-739, 1996		
0714	PAIS	Substitut	5 LBD		754 <b>2624</b>	Phe⇒ <b>Leu</b> TTC⇒TTA			high		*			Male	Ambiguous	Deeb et al; Clinical Endocrinology 63: 56-62, 2005		
0370	Prostate cancer	Substitut	5 LBD		755 <b>2625</b>	Thr⇒ <b>Ala</b> <u>ACC</u> ⇒GCC						Somatic mutation		Male	Normal	Takahashi et al; Cancer Research 55: 1621-1624, 1995		
0602	Prostate cancer	Substitut	5 LBD		756 <b>2628</b>	Asn⇒ <b>Asp</b> <u>AAT</u> ⇒GAT						Flutamide treated - somatic mutation		Male	Normal	Taplin et al; J Clinical Oncology 21: 2673-2678, 2003		
0153	PAIS	Substitut	5 LBD		756 <b>2629</b>	Asn⇒ <b>Ser</b> <u>AAT</u> ⇒AGT								Male	Ambiguous	Hiort et al; Am J Med Genet. 63: 218-222, 1996		
0532	MAIS	Substitut	5 LBD	*	756 <b>2629</b>	Asn⇒ <b>Ser</b> <u>AAT</u> ⇒AGT			high			Severe oligospermia-transactivation 38% of wt.		Male	Normal	Giwercman et al. Clin Endocrinol 54: 827-834, 2001		
0573	Prostate cancer	Substitut	5 LBD		757 <b>2631</b>	Val⇒ <b>Ile</b> <u>GTC</u> ⇒ATC						Somatic mutation + Orchietomy Horm-refractory CaP		Male	Normal	Hyytinen et al; Lab Invest. 82: 1591-1598, 2002		
0300	Prostate cancer	Substitut	5 LBD	*	757 <b>2632</b>	Val⇒ <b>Ala</b> <u>GTC</u> ⇒GCC						Binds R1881 norm.-transcriptionally inactive- Som mut		Male	Normal	James et al; 79th US Endo Soc Meeting, Abstr P2-484, 1997		
0493	Prostate cancer	Substitut	5 LBD		757 <b>2632</b>	Val⇒ <b>Ala</b> <u>GTC</u> ⇒GCC						Somatic mutation		Male	Normal	Marcelli et al; Cancer Research 60: 944-949, 2000		
0346	PAIS	Substitut	5 LBD	*	758 <b>2635</b>	Asn⇒ <b>Thr</b> <u>AAC</u> ⇒ACC		normal		high	*	50% reduction in transactivation in COS-7				Yong et al; Mol & Cell Endocrinol. 137: 41-50, 1998		
0371	Prostate cancer	Substitut	5 LBD		759 <b>2637</b>	Ser⇒ <b>Pro</b> <u>TCC</u> ⇒CCC						Somatic mutation		Male	Normal	Takahashi et al; Cancer Research 55: 1621-1624, 1995		
0154	CAIS	Substitut	5 LBD		759 <b>2638</b>	Ser⇒ <b>Phe</b> <u>TCC</u> ⇒TTC		zero						Female	Normal	DeBellis et al; Mol Endocrinol. 6:1909-20, 1992		
0605	CAIS	Deletion/insertion	5 LBD		760 <b>2640</b>	Arg⇒ <b>O</b> ⇒		zero				7bp del (2640-2646) 11bp ins (2652-2662) stop 9 codon downstr.		Female	Normal	Viachlis et al. J Hum Genet 48:346-351, 2003		
0841	PAIS	Substitut	5 LBD		760	Arg⇒ <b>Ser</b> AGG⇒										Jeske et al; J Pediatr Endocrinol Metab 20:893-908, 2007		
0938	Prostate cancer	Substitut	5 LBD		760 <b>2642</b>	Arg⇒ <b>Arg</b> AGG⇒						Treated with anti-androgens. Occurred in 2 cases		Male	Normal	Steinkamp et al; Cancer Res 69:4434-4442, 2009		
0729	PAIS	Substitut	5 LBD		761 <b>2644</b>	Met⇒ <b>Thr</b> <u>ATG</u> ⇒ACG						mother heterozygous		Male	Ambiguous	Ledig et al; Horm Res 63:263-269, 2005		
0155	CAIS	Substitut	5 LBD		762 <b>2646</b>	Leu⇒ <b>Phe</b> <u>CTC</u> ⇒TTC		zero						Female	Normal	Brown et al; 74th US Endo Soc Meeting, Abstr 1506, 1992		
0156	CAIS	Substitut	5 LBD	*	762 <b>2646</b>	Leu⇒ <b>Phe</b> <u>CTC</u> ⇒TTC		zero						Female	Normal	Bevan et al; J Steroid Biochem Molec. Biol 61: 19-26, 1997		
0861	CAIS	Substitut	5 LBD		762 <b>2646</b>	Leu⇒ <b>Phe</b> <u>CTC</u> ⇒TTC						Diag at 7yr bilateral gonadectomy at 8yrs		Female	Normal	Cheikhelard et al. J Urol 180:1496-1501, 2008		
0862	CAIS	Substitut	5 LBD		762 <b>2646</b>	Leu⇒ <b>Phe</b> <u>CTC</u> ⇒TTC						Diagnosed at 1 wk		Female	Normal	Cheikhelard et al. J Urol 180:1496-1501, 2008		
0157	CAIS	Substitut	5 LBD		763 <b>2649</b>	Tyr⇒ <b>His</b> <u>TAC</u> ⇒CAC								Female	Normal	Quigley et al; Endocrin. Reviews, 16:271, 1995		
0159	PAIS	Substitut	5 LBD		763 <b>2650</b>	Tyr⇒ <b>Cys</b> <u>TAC</u> ⇒TGC		low						Male	Ambiguous	Morono et al; Human Mutation 6: 152-162, 1995		
0405	PAIS	Substitut	5 LBD		763 <b>2650</b>	Tyr⇒ <b>Cys</b> <u>TAC</u> ⇒TGC								Male	Ambiguous	Batch et al; Arch Disease Child 68: 453, 1993		
0484	PAIS	Substitut	5 LBD		763 <b>2650</b>	Tyr⇒ <b>Cys</b> <u>TAC</u> ⇒TGC			normal	high						Ahmed et al; J Clin Endocrinol & Metab 85: 658-665, 2000		
0485	PAIS	Substitut	5 LBD		763 <b>2650</b>	Tyr⇒ <b>Cys</b> <u>TAC</u> ⇒TGC			normal	high						Ahmed et al; J Clin Endocrinol & Metab 85: 658-665, 2000		

Accession #	Mutation type	Exon Domain	Pathogenicity proven	CpG hot spot	Position Amino acid Base	Change Amino acid Base	Exon 1 tracts				Androgen Binding			Comments	Sex of rearing	External Genitalia	Family history	Reference
							Poly Gln #	Poly Gly #	Bmax	Kd	Thermolabile k							
0636	PAIS	Substitut	5 LBD	*	763 <b>2650</b>	Tyr⇒ <b>Cys</b> TAC⇒TGC	22		low			Gynecomastia -testis located in scrotum	Male	Ambiguous	neg	Melo et al; J Clin Endocrinol & Metab 88: 3241-3250, 2003		
0372	Prostate Cancer	Substitut	5 LBD	*	763 <b>2650</b>	Tyr⇒ <b>Cys</b> TAC⇒TGC						Somatic mutation	Male	Normal		Takahashi et al; Cancer Research 55: 1621 -1624, 1995		
0158	PAIS	Substitut	5 LBD	*	763 <b>2650</b>	Tyr⇒ <b>Cys</b> TAC⇒TGC	12		normal high			* PolyGln tract short ( only 12 repeats)	Male	Ambiguous	pos	McPhaul et al; J Clin Inv 87:1413,1991;Batch&al		
0850	CAIS	Substitut	5 LBD	*	763 <b>2651</b>	Tyr⇒ <b>Stop</b> TAC⇒						Diag at 1 wk-Bilateral gonadectomy at 3wks	Female	Normal		Cheikhelard et al. J Urol 180:1496-1501, 2008		
0160	CAIS	Substitut	5 LBD	*	764 <b>2652</b>	Phe⇒ <b>Leu</b> TTC⇒			low	high			Female	Normal	neg	Marcelli et al; J clin Invest 94: 1642-1650, 1994		
0161	CAIS	Substitut	5 LBD	*	764 <b>2652</b>	Phe⇒ <b>Leu</b> TTC⇒CTC			zero				Female	Normal		Ris-Stalpers et al: Pediatric Res,36; 227 -234, 1994		
0162	CAIS	Substitut	5 LBD	*	764 <b>2654</b>	Phe⇒ <b>Leu</b> TTC⇒TTG			low	normal			Female	Normal		Pinsky et al; Clin Inv Med, 15:456, 1992		
0163	CAIS	Substitut	5 LBD	*	765 <b>2655</b>	Ala⇒ <b>Thr</b> GCC⇒ACC			zero				Female	Normal		Bevan et al; J Steroid Biochem Molec. Biol 61: 19-26, 1997		
0164	CAIS	Substitut	5 LBD	*	765 <b>2655</b>	Ala⇒ <b>Thr</b> GCC⇒ACC			zero				Female	Normal		Merkabi et al;75th US Endo Soc Meeting Abstr 602, 1993		
0165	CAIS	Substitut	5 LBD	*	765 <b>2655</b>	Ala⇒ <b>Thr</b> GCC⇒ACC							Female	Normal		Sweet et al; Fertil Sterility 58: 703, 1992		
0166	CAIS	Substitut	5 LBD	*	765 <b>2655</b>	Ala⇒ <b>Thr</b> GCC⇒ACC			zero				Female	Normal		Hiort et al; Am J Med Genet. 63: 218-222, 1996		
0311	CAIS	Substitut	5 LBD	*	765 <b>2655</b>	Ala⇒ <b>Thr</b> GCC⇒ACC	27						Female	Normal		Ko et al; J Reprod. Med 42: 424- 427, 1997		
0382	CAIS	Substitut	5 LBD	*	765 <b>2655</b>	Ala⇒ <b>Thr</b> GCC⇒ACC							Female	Normal		Giwercman et al; Human Genetics 103: 529-531, 1998		
0454	CAIS	Substitut	5 LBD	*	765 <b>2655</b>	Ala⇒ <b>Thr</b> GCC⇒ACC							Female	Normal		Ahmed et al; J Clin Endocrinol & Metab 85: 658-665, 2000		
0455	CAIS	Substitut	5 LBD	*	765 <b>2655</b>	Ala⇒ <b>Thr</b> GCC⇒ACC							Female	Normal		Ahmed et al; J Clin Endocrinol & Metab 85: 658-665, 2000		
0456	CAIS	Substitut	5 LBD	*	765 <b>2655</b>	Ala⇒ <b>Thr</b> GCC⇒ACC						Woolfian remnants present	Female	Normal		Hannema et al. J Clin Endocrinol & Metab 89: 5815-5822, 2004		
0585	CAIS	Substitut	5 LBD	*	765 <b>2655</b>	Ala⇒ <b>Thr</b> GCC⇒ACC						Reduced immunoreactive AR	Female	Normal		Avila et al. J Clin Endocrinol Metab 87; 182-188, 2002		
0586	PAIS	Substitut	5 LBD	*	765 <b>2655</b>	Ala⇒ <b>Thr</b> GCC⇒ACC						Reduced immunoreactive AR	Female	Ambiguous		Avila et al. J Clin Endocrinol Metab 87; 182-188, 2002		
0730	CAIS	Substitut	5 LBD	*	765 <b>2655</b>	Ala⇒ <b>Thr</b> GCC⇒ACC							Female	Normal	neg	Ledig et al: Horm Res 63:263-269, 2005		
0520	PAIS	Substitut	5 LBD	*	765 <b>2655</b>	Ala⇒ <b>Ser</b> GCC⇒TCC										Chavez et al; Clin Genet 59:: 185-188, 2001		
0167	CAIS	Substitut	5 LBD	*	765 <b>2656</b>	Ala⇒ <b>Val</b> GCC⇒GTC	20		zero				Female	Normal		Pinsky et al, Clin Inv Med, 15:456, 1992		
0665	PAIS	Substitut	5 LBD	*	766 <b>2658</b>	Pro⇒ <b>Ser</b> CCT⇒TCT						Somatic mosaicism	Female	Ambiguous		Kohler et al; J Clin endocrinol & Metab 90: 106-111, 2005		
0168	CAIS	Substitut	5 LBD	*	766 <b>2658</b>	Pro⇒ <b>Ser</b> CCT⇒TCT			low	high	high		Female	Normal	pos	Marcelli et al; J Clin Invest 94: 1642-1650, 1994		
0457	CAIS	Substitut	5 LBD	*	766 <b>2658</b>	Pro⇒ <b>Ser</b> CCT⇒TCT							Female	Normal		Ahmed et al; J Clin Endocrinol & Metab 85: 658-665, 2000		
0681	CAIS	Substitut	5 LBD	*	766 <b>2658</b>	Pro⇒ <b>Ala</b> CCT⇒GCT						bilateral inguinal hernia	Female	Normal		Bouvattier et al; J Clin Endocrinol & Metab 87: 29-32, 2002		

Accession #	Mutation type	Proven Phenotype	Pathogenicity proven	Exon Domain	CpG hot spot	Position Base	Amino acid Change	Amino acid Base	Exon 1 tracts			Androgen Binding			Comments	Sex of rearing	External Genitalia	Family history	Reference
									Poly Gln #	Poly Gly #	Bmax	Kd	Thermolabile k						
0543	CAIS	Substitution	5 LBD		766 2658	Pro $\Rightarrow$ Ala <u>CCT</u> $\Rightarrow$ <u>GCT</u>			normal	high				2 affected siblings variable phenotype	Female	Normal	pos	Boehmer et al; J Clin Endocrinol & Metab 86: 4151-4160, 2001	
0611	CAIS	Substitution	5 LBD		766 2658	Pro $\Rightarrow$ Ala <u>CCT</u> $\Rightarrow$ <u>GCT</u>								Twin sisters	Female	Normal	pos	Correa et al; 16th Meet. Latin Amer.Soc Ped Endo. Abstr: 26, 2003	
0587	CAIS	Deletion	5 LBD		766 2659	Pro $\Rightarrow$ Leu CACT $\Rightarrow$ CTG								1 nt. del.-frameshift & stop in codon 787 low immunoreact AR	Female	Normal		Avila et al. J Clin Endocrinol Metab 87; 182-188, 2002	
0169	CAIS	Deletion	5 LBD		766 2660	Pro $\Rightarrow$ Pro CCAT $\Rightarrow$ CCG								Single nt. deletion causing frameshift & stop in Codon 807	Female	Normal	pos	Baldazzi et al; Hum Mol Genet 3:1169-1170, 1994	
0388	CAIS	Deletion	5 LBD		766 2660	Pro $\Rightarrow$ Pro CCAT $\Rightarrow$ CCG								Single nt. deletion causing frameshift & stop in Codon 807	Female	Normal		Chung et al; Molecules & Cells 8: 741-745, 1998	
0458	CAIS	Deletion	5 LBD		766 2660	Pro $\Rightarrow$ Pro CCAT $\Rightarrow$ CCG								1nt. del-frameshit & stop in Codon 807 Woolfian remnants	Female	Normal		Hannema et al. J Clin Endocrinol & Metab 89: 5815-5822, 2004	
0459	CAIS	Deletion	5 LBD		766 2660	Pro $\Rightarrow$ Pro CCAT $\Rightarrow$ CCG								1nt. del-frameshit & stop in Codon 807 Woolfian remnants	Female	Normal		Hannema et al. J Clin Endocrinol & Metab 89: 5815-5822, 2004	
0561	CAIS	Deletion	5 LBD		766 2660	Pro $\Rightarrow$ Pro CCAT $\Rightarrow$ CCG								1nt. del frame shift & stop in Codon 807 in 2 unrelat individs	Female	Normal		Guillen et al; An Esp Pediatr 56: 341-352, 2002	
0588	CAIS	Deletion	5 LBD		766 2660	Pro $\Rightarrow$ Pro CCAT $\Rightarrow$ CCG								1 nt. del framshift & stop Codon 807 no immunoreact AR	Female	Normal		Avila et al. J Clin Endocrinol Metab 87; 182-188, 2002	
0853	CAIS	Deletion	5 LBD		766 2660	Pro $\Rightarrow$ Pro CCAT $\Rightarrow$ CCG								1nt. del. framshift & stop in Codon 807 Diag - 7yr Woolf rem	Female	Normal		Cheikhelard et al. J Urol 180:1496-1501, 2008	
0953	CAIS	Deletion	5 LBD		766 2660	Pro $\Rightarrow$ Pro CCAT $\Rightarrow$ CCG								1nt. del. framshift & stop in Codon 807 Male gender identity	Female	Normal		T'Sjoen et al. Arch Sex Behav 2010	
0893	CAIS	Substitution	5 LBD		767 2661	Asp $\Rightarrow$ Tyr <u>GAT</u> $\Rightarrow$ <u>TAT</u>								Bone size intermediate between male and female	Female	Normal		Taes et al. Bone 45: 392-397, 2009	
0170	CAIS	Substitution	5 LBD		767 2663	Asp $\Rightarrow$ Glu <u>GAT</u> $\Rightarrow$ <u>GAG</u>			v low						Female	Normal		Lobaccaro et al; Pediatr Res. 33.Abstr 115, 1993	
0343	CAIS	Substitution	5 LBD		767 2663	Asp $\Rightarrow$ Glu <u>GAT</u> $\Rightarrow$ <u>GAG</u>									Female	Normal		Melo et al; 80th US Endo Soc Meeting Abstr P2-44, 1998	
0544	PAIS	Substitution	5 LBD		768 2664	Leu $\Rightarrow$ Met <u>CTG</u> $\Rightarrow$ <u>ATG</u>			normal	high				2 affected siblings with variable phenotype	Female	Ambiguous	pos	Boehmer et al; J Clin Endocrinol & Metab 86: 4151-4160, 2001	
0637	CAIS	Substitution	5 LBD		768 2664	Leu $\Rightarrow$ Val <u>CTG</u> $\Rightarrow$ <u>GTG</u>	20							Testis located in labia majora	Female	Normal		Melo et al; J Clin Endocrinol & Metab 88: 3241-3250, 2003	
0460	CAIS	Substitution	5 LBD		768 2665	Leu $\Rightarrow$ Pro <u>CTG</u> $\Rightarrow$ <u>CCG</u>									Female	Normal		Ahmed et al; J Clin Endocrinol & Metab 85: 658-665, 2000	
0666	CAIS	Substitution	5 LBD		770 2671	Phe $\Rightarrow$ Stop <u>TTC</u> $\Rightarrow$ <u>TAA</u>								Somatic mosaicism sister heterozygous mother som mosaic ?	Female	Normal	pos	Kohler et al; J Clin endocrinol & Metab 90: 106-111, 2005	
0171	PAIS	Substitution	5 LBD		771 2673	Asn $\Rightarrow$ His <u>AAT</u> $\Rightarrow$ <u>CAT</u>									Female	Ambiguous		Hiort et al; Hum Mol Genet 3: 1163-1166 1994	
0526	PAIS	Substitution	5 LBD	*	771 2673	Asn $\Rightarrow$ His <u>AAT</u> $\Rightarrow$ <u>CAT</u>			high					Size & level of expression of AR normal	Female	Ambiguous		Zhu et al, 83rd US Endo Soc Meeting, Abstr P2-34, 2001	
0172	CAIS	Substitution	5 LBD		772 2676	Glu $\Rightarrow$ Stop <u>GAG</u> $\Rightarrow$ <u>TAG</u>			zero						Female	Normal		Imasaki et al; Endocrine Journal 42: 643-648 1995	
0839	CAIS	Deletion	5 LBD		772 2676	Glu $\Rightarrow$ O <u>AGACT</u> $\Rightarrow$								4 nt deletion leading to stop in codon 787	Female	Normal		Jeske et al; J Pediatr Endocrinol Metab 20:893-908, 2007	
0173	PAIS	Substitution	5 LBD	*	772 2677	Glu $\Rightarrow$ Gly <u>GAG</u> $\Rightarrow$ <u>GGG</u>			low	high								Tincello et al; Clinical Endocrinology 46: 497-506, 1997	
0174	PAIS	Substitution	5 LBD	*	772 2677	Glu $\Rightarrow$ Ala <u>GAG</u> $\Rightarrow$ <u>GCG</u>	25	23	normal	normal	high				Male	Ambiguous		Shkolny et al; J Clin Endocrinol & Metab 84: 805-810, 1999	
0863	CAIS	Substitution	5 LBD	*	774 2682	Arg $\Rightarrow$ Cys <u>CGC</u> $\Rightarrow$ <u>TCC</u>								Prenat Diagnosis bilateral gonadectomy at 5yrs	Female	Normal		Cheikhelard et al. J Urol 180:1496-1501, 2008	

Accession #	Mutation type	Proven Pathogenicity	Exon Domain	CpG hot spot	Position Base	Change Amino acid	Exon 1 tracts				Androgen Binding			Comments	Sex of rearing	External Genitalia	Family history	Reference
							Poly Gln #	Poly Gly #	Bmax	Kd	Thermolabile k							
0878	CAIS	Substitut	5 LBD	*	774 2682	Arg ⇒ Cys <u>CGC</u> ⇒ <u>TCC</u>									Female	Normal	pos	Qin et al; Zhonghua Fu Chan Ke Za Za 43:828-830, 2008
0986	CAIS	Substitut	5 LBD	*	774 2682	Arg ⇒ Cys <u>CGC</u> ⇒ <u>TCC</u>	27	17							Female	Normal	neg	Audi et al. J Clin Endocrinol Metab 95:1876-1888, 2010
0336	CAIS	Substitut	6 LBD	*	774 2682	Arg ⇒ Cys <u>CGC</u> ⇒ <u>TGC</u>	26	23	normal	normal					Female	Normal		Prior et al; Am J Hum Genet, 51:143, 1992
0176	CAIS	Substitut	6 LBD	*	774 2682	Arg ⇒ Cys <u>CGC</u> ⇒ <u>TGC</u>	27	19	zero						Female	Normal	pos	Prior et al; Am J Hum Genet, 51:143, 1992
0177	CAIS	Substitut	6 LBD	*	774 2682	Arg ⇒ Cys <u>CGC</u> ⇒ <u>TGC</u>			zero						Female	Normal		Mebarki et al; 72nd US Endo Soc Meeting, Abstr 791, 1990
0178	CAIS	Substitut	6 LBD	*	774 2682	Arg ⇒ Cys <u>CGC</u> ⇒ <u>TGC</u>									Female	Normal		Hiort et al; J Pediatrics 132: 939-943, 1998
0179	CAIS	Substitut	6 LBD	*	774 2682	Arg ⇒ Cys <u>CGC</u> ⇒ <u>TGC</u>			v low	high					Female	Normal	neg	Marcelli et al; J Clin Endocrinol & Metab 73: 318, 1991
0180	CAIS	Substitut	6 LBD	*	774 2682	Arg ⇒ Cys <u>CGC</u> ⇒ <u>TGC</u>									Female	Normal		Jakubiczka et al; Human Mutation 9: 57-61, 1997
0331	CAIS	Substitut	6 LBD	*	774 2682	Arg ⇒ Cys <u>CGC</u> ⇒ <u>TGC</u>									Female	Normal		Komori et al; Arch Gynecol & Obstetrics 261: 95-100, 1998
0175	CAIS	Substitut	6 LBD	*	774 2682	Arg ⇒ Cys <u>CGC</u> ⇒ <u>TGC</u>			v low						Female	Normal		Brown et al; Mol Endocrinol, 4:1759-72, 1990
0355	CAIS	Substitut	6 LBD	*	774 2682	Arg ⇒ Cys <u>CGC</u> ⇒ <u>TGC</u>					mosaic-de novo mutation				Female	Normal	neg	Hiort et al; J Pediatrics 132: 939-943, 1998
0589	CAIS	Substitut	6 LBD	*	774 2682	Arg ⇒ Cys <u>CGC</u> ⇒ <u>TGC</u>					Reduced immunoreactive AR				Female	Normal		Avila et al. J Clin Endocrinol Metab 87: 182-188, 2002
0599	CAIS	Substitut	6 LBD	*	774 2682	Arg ⇒ Cys <u>CGC</u> ⇒ <u>TGC</u>									Female	Normal		Scheiber et al; J Pediatric Endocrinol & Metab. 16: 367-373,
0731	CAIS	Substitut	6 LBD	*	774 2683	Arg ⇒ His <u>CGC</u> ⇒ <u>CAC</u>					sister affected				Female	Normal	pos	Ledig et al: Horm Res 63:263-269, 2005
0732	CAIS	Substitut	6 LBD	*	774 2683	Arg ⇒ His <u>CGC</u> ⇒ <u>CAC</u>					mother heterozygous				Female	Normal	pos	Ledig et al: Horm Res 63:263-269, 2005
0182	CAIS	Substitut	6 LBD	*	774 2683	Arg ⇒ His <u>CGC</u> ⇒ <u>CAC</u>			low	normal	*				Female	Normal		Batch et al; Hum Mol Genet, 1:497, 1992
0183	CAIS	Substitut	6 LBD	*	774 2683	Arg ⇒ His <u>CGC</u> ⇒ <u>CAC</u>			v low	high					Female	Normal		DeBellis et al; Mol Endocrinol, 6:1909-20, 1992
0184	CAIS	Substitut	6 LBD	*	774 2683	Arg ⇒ His <u>CGC</u> ⇒ <u>CAC</u>									Female	Normal		Hiort et al; Am J Med Genet. 63; 218-222, 1996
0461	CAIS	Substitut	6 LBD	*	774 2683	Arg ⇒ His <u>CGC</u> ⇒ <u>CAC</u>			zero						Female	Normal		Ahmed et al; J Clin Endocrinol & Metab 85: 658-665, 2000
0462	CAIS	Substitut	6 LBD	*	774 2683	Arg ⇒ His <u>CGC</u> ⇒ <u>CAC</u>									Female	Normal		Ahmed et al; J Clin Endocrinol & Metab 85: 658-665, 2000
0181	CAIS	Substitut	6 LBD	*	774 2683	Arg ⇒ His <u>CGC</u> ⇒ <u>CAC</u>			normal	high	high	*	mutation found in two unrelated families		Female	Normal	pos	Prior et al; Am J Hum Genet, 51:143, 1992
0987	CAIS	Substitut	6 LBD	*	774 2683	Arg ⇒ His <u>CGC</u> ⇒ <u>CAC</u>	20	17							Female	Normal	neg	Audi et al. J Clin Endocrinol Metab 95:1876-1888, 2010
0185	PAIS	Substitut	6 LBD	*	774 2683	Arg ⇒ His <u>CGC</u> ⇒ <u>CAC</u>												Quigley et al; Endocrin Rev 16: 271, 1995
0186	CAIS	Substitut	6 LBD	*	779 2697	Arg ⇒ Trp <u>CGG</u> ⇒ <u>TGG</u>									Female	Normal		Hiort et al; Hum Mol Genet 3: 1163-1166 1994
0187	CAIS	Substitut	6 LBD	*	779 2697	Arg ⇒ Trp <u>CGG</u> ⇒ <u>TGG</u>									Female	Normal		Morono et al; Human Mutation 6: 152-162, 1995

Accession #	Mutation type	Proven Pathogenicity	Exon Domain	CpG hot spot	Position Base	Change Amino acid	Exon 1 tracts				Androgen Binding				Comments	Sex of rearing	External Genitalia	Family history	Reference
							Poly Gln #	Poly Gly #	Bmax	Kd	Thermolabile k								
0188	CAIS	Substitut	6 LBD	*	779 2697	Arg⇒Trp <u>CGG</u> ⇒ <u>TGG</u>										Female	Normal		Sinnecker et al; Eur J. Pediatr. 156: 7-14, 1997
0463	CAIS	Substitut	6 LBD	*	779 2697	Arg⇒Trp <u>CGG</u> ⇒ <u>TGG</u>										Female	Normal		Ahmed et al; J Clin Endocrinol & Metab 85: 658-665, 2000
0621	CAIS	Substitut	6 LBD	*	779 2697	Arg⇒Trp <u>CGG</u> ⇒ <u>TGG</u>	21		low						AR partially purified appears truncated (43 kD)	Female	Normal		MacLean et al. Hum Mutat. 23:287, 2004
0638	CAIS	Substitut	6 LBD	*	779 2697	Arg⇒Trp <u>CGG</u> ⇒ <u>TGG</u>	24								Testis located in inguinal region	Female	Normal	neg	Melo et al; J Clin Endocrinol & Metab 88: 3241-3250, 2003
0733	CAIS	Substitut	6 LBD	*	779 2697	Arg⇒Trp <u>CGG</u> ⇒ <u>TGG</u>										Female	Normal	neg	Ledig et al; Horm Res 63:263-269, 2005
0189	PAIS	Substitut	6 LBD	*	780 2702	Met⇒Ile <u>ATG</u> ⇒ <u>ATA</u>			normal high		*					Female	Ambiguous		Bevan et al; Hum Mol Genet, 5: 265-273, 1996
0190	PAIS	Substitut	6 LBD		780 2702	Met⇒Ile <u>ATG</u> ⇒ <u>ATA</u>	20	23	normal high	high		1 family member - male. Rest of family - females				Female / Male	Ambiguous	pos	Pinsky et al; Clin Inv Med, 15:456, 1992
0191	PAIS	Substitut	6 LBD		780 2702	Met⇒Ile <u>ATG</u> ⇒ <u>ATA</u>													Brinkmann et al; J Steroid Biochem & Mol Biol 53: 443, 1995
0192	PAIS	Substitut	6 LBD		780 2702	Met⇒Ile <u>ATG</u> ⇒ <u>ATA</u>													Rodien et al; J Clin Endo & Metab 81: 2904-2908, 1996
0305	CAIS	Substitut	6 LBD		780 2702	Met⇒Ile <u>ATG</u> ⇒ <u>ATA</u>										Female	Normal	pos	Rodien et al; J Clin Endo & Metab 81: 2904-2908, 1996
0193	CAIS	Substitut	6 LBD		780 2702	Met⇒Ile <u>ATG</u> ⇒ <u>ATA</u>										Female	Normal		Jakubiczka et al; Human Mutation 9: 57-61, 1997
0464	CAIS	Substitut	6 LBD		780 2702	Met⇒Ile <u>ATG</u> ⇒ <u>ATA</u>			low	high						Female	Normal	pos	Hannema et al. J Clin Endocrinol & Metab 89: 5815-5822, 2004
0660	CAIS	Substitut	6 LBD		780 2702	Met⇒Ile <u>ATG</u> ⇒ <u>ATA</u>										Female	Normal	pos	Hannema et al. J Clin Endocrinol & Metab 89: 5815-5822, 2004
0682	PAIS	Substitut	6 LBD		780 2702	Met⇒Ile <u>ATG</u> ⇒ <u>ATA</u>											Ambiguous		Bouvattier et al; J Clin Endocrinol & Metab 87: 29-32, 2002
0743	PAIS	Substitut	6 LBD		780 2702	Met⇒Ile <u>ATG</u> ⇒ <u>ATA</u>										Female	Ambiguous	pos	Boehmer et al; J Clin Endocrinol & Metab 86:4151-4160, 2001
0774	MAIS	Substitut	6 LBD		780 2702	Met⇒Ile <u>ATG</u> ⇒ <u>ATA</u>										Male	Normal		Farlin et al. Clin Endocrinol 65:606-610, 2006
0988	CAIS	Substitut	6 LBD		781 2701	Tyr⇒Asp <u>TAC</u> ⇒ <u>GAC</u>	20	18	low	high						Female	Normal	pos	Audi et al. J Clin Endocrinol Metab 95:1876-1888, 2010
0194	Prostate cancer	Substitut	6 LBD		782 2707	Ser⇒Asn <u>AGC</u> ⇒ <u>AAC</u>										Male	Normal		Tilley et al; 2: Clinical Cancer Res. 2: 277-285, 1996
0383	CAIS	Substitut	6 LBD	*	784 2713	Cys⇒Tyr <u>TGT</u> ⇒ <u>TAT</u>			zero							Female	Normal		Giwercman et al; Human Genetics 103: 529-531, 1998
0864	CAIS	Substitut	6 LBD		784 2713	Cys⇒Tyr <u>TGT</u> ⇒ <u>TAT</u>										Female	Normal		Cheikhelard et al. J Urol 180:1496-1501, 2008
0667	CAIS	Deletion	6 LBD		785 2715	Val⇒Pro <u>ΔGTC</u> ⇒CCG										Female	Normal		Kohler et al; J Clin endocrinol & Metab 90: 106-111, 2005
0989	CAIS	Deletion	6 LBD		785 2715	Val⇒Pro <u>ΔGTC</u> ⇒CCG	19	18	zero	zero						Female	Normal	neg	Audi et al. J Clin Endocrinol Metab 95:1876-1888, 2010
0195	CAIS	Substitut	6 LBD	*	786 2718	Arg⇒Stop <u>CGA</u> ⇒ <u>TGA</u>										Female	Normal		Pinsky et al; Clin Inv Med, 15:456, 1992
0557	CAIS	Substitut	6 LBD	*	786 2718	Arg⇒Stop <u>CGA</u> ⇒ <u>TGA</u>										Female	Normal		Ignaccack et al; J Appl Genet 43: 109-114, 2002
0600	CAIS	Substitut	6 LBD	*	786 2718	Arg⇒Stop <u>CGA</u> ⇒ <u>TGA</u>										Female	Normal		Scheiber et al; J Pediatric Endocr Metab 16:367-373, 2003

Accession #	Mutation type	Exon Domain	CpG hot spot	Position Base	Change Amino acid	Exon 1 tracts				Androgen Binding			Comments	Sex of rearing	External Genitalia	Family history	Reference
						Poly Gln #	Poly Gly #	Bmax	Kd	Thermolabile k							
0892	Prostate Cancer	Substitut	6 LBD	* 786 2718	Arg $\Rightarrow$ Stop <u>CGA</u> $\Rightarrow$ <u>TGA</u>					+ΔQ86, Q867X Bicalutamide treated	Male	Normal			Steinkamp et al; Cancer Res 69:4434-4442, 2009		
0939	Prostate Cancer	Substitut	6 LBD	* 786 2718	Arg $\Rightarrow$ Stop <u>CGA</u> $\Rightarrow$ <u>TGA</u>					Untreated with anti-androgens	Male	Normal			Steinkamp et al; Cancer Res 69:4434-4442, 2009		
0196	CAIS	Substitut	6 LBD	* 787 2721	Met $\Rightarrow$ Val <u>ATG</u> $\Rightarrow$ <u>G</u> <u>TG</u>		zero				Female	Normal	pos		Nakao et al; J Clin Endocrinol Metab, 74:1152, 1992		
0615	CAIS	Substitut	6 LBD	787 2721	Met $\Rightarrow$ Val <u>ATG</u> $\Rightarrow$ <u>G</u> <u>TG</u>					Uterus present	Female	Normal			Van et al. Eur J. Pediatr. 162: 781-784, 2003		
0990	CAIS	Substitut	6 LBD	787 2723	Met $\Rightarrow$ Ile <u>ATG</u> $\Rightarrow$ <u>ATA</u>	23	18				Female	Normal	neg		Audi et al. J Clin Endocrinol Metab 95:1876-1888, 2010		
0991	CAIS	Substitut	6 LBD	787 2723	Met $\Rightarrow$ Ile <u>ATG</u> $\Rightarrow$ <u>ATA</u>	23	17			1 sister affected	Female	Normal	pos		Audi et al. J Clin Endocrinol Metab 95:1876-1888, 2010		
0992	CAIS	Substitut	6 LBD	787 2723	Met $\Rightarrow$ Ile <u>ATG</u> $\Rightarrow$ <u>ATT</u>	26	17				Female	Normal	neg		Audi et al. J Clin Endocrinol Metab 95:1876-1888, 2010		
0406	MAIS	Substitut	6 LBD	788 2726	Arg $\Rightarrow$ Ser <u>AGG</u> $\Rightarrow$ <u>AGT</u>	24	23	normal	normal	high	Male	Normal	pos		Lumbroso et al 81st. US Endo Soc Meetings Abstr. P.3-288, 1999		
0716	PAIS	Substitut	6 LBD	788 2726	Arg $\Rightarrow$ Ser <u>AGG</u> $\Rightarrow$ <u>AGT</u>			high			Male	Ambiguous			Deeb et al; Clinical Endocrinology 63: 56-62, 2005		
0735	CAIS	Duplicat	6 LBD	788 2726	Arg $\Rightarrow$ AGG $\Rightarrow$					Arg (AGG) duplicated	Male	Normal	neg		Ledig et al; Horm Res 63:263-269, 2005		
0197	MAIS	Substitut	6 LBD	* 790 2730	Leu $\Rightarrow$ Phe <u>CTC</u> $\Rightarrow$ <u>TTC</u>		normal	low		*	Male	Near-normal male			Tsukada et al: J Clin Endocrinol Metab, 79:1202, 1994		
0842	CAIS	Substitut	6 LBD	790 2731	Leu $\Rightarrow$ Pro <u>CTC</u> $\Rightarrow$ <u>CCC</u>						Female	Normal			Raicu et al; Asian J Androl 10:687-91, 2008		
0993	CAIS	Deletion	6 LBD	792 2737	Gln $\Rightarrow$ Arg <u>ΔCAA</u> $\Rightarrow$ CGA	20	17			Heterozygous sister 2nt del causing fs & stop in Codon 827	Female	Normal	pos		Audi et al. J Clin Endocrinol Metab 95:1876-1888, 2010		
0198	MAIS	Substitut	6 LBD	793 2741	Glu $\Rightarrow$ Asp <u>GAG</u> $\Rightarrow$ <u>GAC</u>		normal	normal		Inconsistent increases in gynecomastia & infertility	Male	Normal			Pinsky et al; Clin Inv Med, 15:456, 1992		
0397	Normal	Substitut	6 LBD	793 2741	Glu $\Rightarrow$ Asp <u>GAG</u> $\Rightarrow$ <u>GAC</u>					Homosexual individual	Male	Normal			Macke et al; Am J Human Genetics 53: 844-852, 1993		
0199	CAIS	Substitut	6 LBD	794 2743	Phe $\Rightarrow$ Ser <u>TTT</u> $\Rightarrow$ <u>TCT</u>		zero				Female	Normal			Hiort et al; Am J Med Genet. 63: 218-222, 1996		
0200	CAIS	Substitut	6 LBD	794 2743	Phe $\Rightarrow$ Ser <u>TTT</u> $\Rightarrow$ <u>TCT</u>						Female	Normal			Jakubiczka et al Human Mutation 9: 57-61, 1997		
0907	PAIS	Substitut	6 LBD	795 2747	Gly $\Rightarrow$ Gly <u>GGA</u> $\Rightarrow$ <u>GGG</u>	low	high			Silent mutation	Male	Ambiguous			Appari et al; J Mol Med 87: 623-632, 2009		
0201	CAIS	Substitut	6 LBD	* 796 2750	Trp $\Rightarrow$ Stop <u>TGG</u> $\Rightarrow$ <u>TGA</u>		v low				Female	Normal			Marcelli et al; J Clin Invest 85: 1522, 1990		
0954	PAIS	Substitut	6 LBD	* 798 2754	Gln $\Rightarrow$ Glu <u>CAA</u> $\Rightarrow$ <u>GAA</u>					Virilization post-gonadectomy heteroz P450OR p.Y601C	Female	Ambiguous			Idkowiak et al. J Clin Endocrinol Metab 95:3418-3527, 2010		
0202	PAIS	Substitut	6 LBD	* 798 2754	Gln $\Rightarrow$ Glu <u>CAA</u> $\Rightarrow$ <u>GAA</u>		normal	normal	*		Female	Ambiguous			Bevan et al; Hum Mol Genet, 5: 265-273, 1996		
0203	PAIS	Substitut	6 LBD	798 2754	Gln $\Rightarrow$ Glu <u>CAA</u> $\Rightarrow$ <u>GAA</u>		normal	normal							Quigley et al; Endocrine Reviews 16: 271, 1995		
0204	PAIS	Substitut	6 LBD	798 2754	Gln $\Rightarrow$ Glu <u>CAA</u> $\Rightarrow$ <u>GAA</u>						Female	Ambiguous			Hiort et al; Am J Med Genet. 63: 218-222, 1996		
0205	Prostate cancer	Substitut	6 LBD	798 2754	Gln $\Rightarrow$ Glu <u>CAA</u> $\Rightarrow$ <u>GAA</u>					Also present in genomic DNA	Male	Normal			Evans et al; Prostate 28: 162-171, 1996		
0399	Prostate cancer	Substitut	6 LBD	798 2754	Gln $\Rightarrow$ Glu <u>CAA</u> $\Rightarrow$ <u>GAA</u>					Somatic mutation Stage 4 tumor	Male	Normal			Castagnaro et al; Verh. Dtsch. Ges. Path. 77; 119-123, 1993		

Accession #	Mutation type	Exon Domain	CpG hot spot	Position Base	Change Amino acid Base	Exon 1 tracts				Androgen Binding			Comments	Sex of rearing	External Genitalia	Family history	Reference
						Poly Gln #	Poly Gly #	Bmax	Kd	Thermolabile k							
0340	MAIS	Substitut	6 LBD	*	798 <b>2754</b>	Gln⇒ <b>Glu</b> <u>CAA</u> ⇒ <b>GAA</b>			normal	Azoospermia	Male	Normal		Hiori et al; J Clin Endocrinol & Metab 85: 2810-2815, 2000			
0381	MAIS	Substitut	6 LBD	*	798 <b>2754</b>	Gln⇒ <b>Glu</b> <u>CAA</u> ⇒ <b>GAA</b>			normal	Azoospermia - defective transactivation	Male	Normal		Wang et al; J Clin Endocrinol & Metab 83:			
0775	MAIS	Substitut	6 LBD		798 <b>2754</b>	Gln⇒ <b>Glu</b> <u>CAA</u> ⇒ <b>GAA</b>				Male infertility	Male	Normal		Farlin et al. Clin Endocrinol 65:606-610, 2006			
0648	CAIS	Substitut	6 LBD		798 <b>2754</b>	Gln⇒ <b>Stop</b> <u>CAA</u> ⇒ <b>TAA</b>				Abdominal tumor - Sertoli cell adenoma	Female	Normal		Ignacek et al: Gynecol Endocrinol 19: 178-181, 2004			
0764	Prostate cancer	Substitut	6 LBD		799 <b>2758</b>	Ile⇒ <b>Thr</b> <u>ATC</u> ⇒ <b>ACC</b>				patient lower Gleason score than patient -wt AR- som mutation	Male	Normal		Sanchez et al. BJU Int 98:1320-1325, 2006			
0596	PAIS	Substitut	6 LBD		800 <b>2761</b>	Thr⇒ <b>Ile</b> <u>ACC</u> ⇒ <b>ATC</b>				Variable expressivity- four additional males with MAIS	Male	Ambiguous	pos	Galli-Tsinopoulou et al. J Pediatr Endocrinol Metab 16:149-154, 2003			
0542	CAIS	Deletion	6 LBD		800 <b>2762</b>	Thr⇒ <b>Thr</b> <u>ACAC</u> ⇒ <b>ACC</b>				Single nt. del causing frameshift & stop in codon 807 1 affect sib	Female	Normal	pos	Boehmer et al; J Clin Endocrinol & Metab 86: 4151-4160, 2001			
0521	PAIS	Substitut	6 LBD		802 <b>2767</b>	Gln⇒ <b>Arg</b> <u>CAG</u> ⇒ <b>CGG</b>								Chavez et al; Clin Genet 59:: 185-188, 2001			
0498	CAIS	Substitut	6 LBD		803 <b>2769</b>	Glu⇒ <b>Lys</b> <u>GAA</u> ⇒ <b>AAA</b>	zero	zero			Female	Normal	pos	Sawai et al. J Hum Genet 45: 342-345, 2000			
0563	CAIS	Substitut	6 LBD		804 <b>2772</b>	Phe⇒ <b>Leu</b> <u>TTC</u> ⇒ <b>CTC</b>				<i>de novo</i> mutation. + glaucoma & hypertrophic pyloric stenos	Female	Normal	neg	Gad et al. Clin Genet. 63: 59-63, 2003			
0865	CAIS	Substitut	6 LBD		804 <b>2772</b>	Phe⇒ <b>Ile</b> <u>TTC</u> ⇒ <b>ATC</b>				Diagnosis at 1mo	Female	Normal		Cheikhelard et al. J Urol 180:1496-1501, 2008			
0206	PAIS	Substitut	6 LBD		806 <b>2779</b>	Cys⇒ <b>Tyr</b> <u>TGC</u> ⇒ <b>TAC</b>								Brown et al; Eur J Pediatr 152: (Suppl 2) S62, 1993			
0207	CAIS	Substitut	6 LBD	*	807 <b>2781</b>	Met⇒ <b>Val</b> <u>ATG</u> ⇒ <b>GTG</b>	30	low			Female	Normal		Morono et al; Human Mutation 6: 152-162, 1995			
0639	CAIS	Substitut	6 LBD		807 <b>2781</b>	Met⇒ <b>Val</b> <u>ATG</u> ⇒ <b>GTG</b>	30	low		Testis located in inguinal region	Female	Normal	neg	Melo et al; J Clin Endocrinol & Metab 88: 3241-3250, 2003			
0428	PAIS	Substitut	6 LBD	*	807 <b>2782</b>	Met⇒ <b>Thr</b> <u>ATG</u> ⇒ <b>ACG</b>		low		Treatment with topical DHT restored male genital	Female	Ambiguous		Ong et al; Lancet 354: 1444-1445, 1999			
0208	CAIS	Substitut	6 LBD		807 <b>2782</b>	Met⇒ <b>Arg</b> <u>ATG</u> ⇒ <b>AGG</b>		zero			Female	Normal		Adeyemo et al; Hum Mol Genet, 2:1809, 1993			
0403	PAIS	Substitut	6 LBD		812 <b>2796</b>	Leu⇒ <b>Phe</b> <u>CTC</u> ⇒ <b>TTC</b>					Female	Normal		Yaegashi et al; Tohoku J of Exp Med 187: 263-272, 1999			
0799	CAIS	Substitut	6 LBD	*	812 <b>2797</b>	Leu⇒ <b>Pro</b> <u>CTC</u> ⇒ <b>CCC</b>		zero		Severely impaired AR transactivation	Female	Normal		Jaaskelainen et al. Hum Mutat 27:291, 2006			
0209	PAIS	Substitut	6 LBD		814 <b>2803</b>	Ser⇒ <b>Asn</b> <u>AGC</u> ⇒ <b>AAC</b>	20	normal		Hormone binding specificity altered.	Female	Ambiguous		Pinsky et al; Clin Inv Med, 15:456, 1992			
0210	MAIS	Substitut	6 LBD		814 <b>2803</b>	Ser⇒ <b>Asn</b> <u>AGC</u> ⇒ <b>AAC</b>	20	normal		Hormone binding specificity altered	Male	Normal	pos	Pinsky et al; Clin Inv Med, 15:456, 1992			
0685	PAIS	Substitut	7 LBD		817 <b>2811</b>	Pro⇒ <b>Ala</b> <u>CCA</u> ⇒ <b>GCA</b>		normal high		Mother a carrier	Male	Ambiguous	pos	Lombrosos et al; J Mol Endocrinol 32: 679-687, 2004			
0811	CAIS	Substitut	7 LBD		817 <b>2812</b>	Pro⇒ <b>Leu</b> <u>CCA</u> ⇒ <b>CTA</b>				Two sisters with CAIS mother a carrier	Female	Normal	pos	Turek-Plewa et al. Hum Genet 119:361, 2006			
0501	CAIS	Substitut	7 LBD		819 <b>2818</b>	Asp⇒ <b>Gln</b> <u>GAT</u> ⇒ <b>GGT</b>				Also del of G (aa2702) caussing frameshift &	Female	Normal		Choi et al; Arch Gynecol Obstet 263: 201-205, 2000			
0211	CAIS	Substitut	7 LBD	*	820 <b>2821</b>	Gly⇒ <b>Ala</b> <u>GGG</u> ⇒ <b>GCG</b>		normal high		* Also Leu 257 Pro, enhances thermolability	Female	Ambiguous	neg	Tanaka et al; Gynecological Endo. 12: 75-82, 1998			
0212	PAIS	Substitut	7 LBD		821 <b>2823</b>	Leu⇒ <b>Val</b> <u>CTG</u> ⇒ <b>GTG</b>	24	23	normal normal					Pinsky et al; Clin Inv Med, 15:456, 1992			

Accession #	Mutation type	Exon Domain	CpG hot spot	Position Base	Change Amino acid	Amino acid Base	Exon 1 tracts				Androgen Binding				Comments	Sex of rearing	External Genitalia	Family history	Reference	
							Poly Gln #	Poly Gly #	Bmax	Kd	Thermolabile k									
0776	MAIS	Substitut	7 LBD	*	821 2823	Leu⇒ Val <u>CTG</u> ⇒ <u>GTG</u>									Male infertility	Male	Normal		Fein et al; Clin Endocrinol 65:606-610, 2006	
0513	MAIS	Substitut	7 LBD	*	824 2832	Gln⇒ Lys <u>CAA</u> ⇒ <u>AAA</u>									Gynecomastia-normal fertility - related to 514	Male	Normal	pos	Giwercman et al; J Clin Endocrinol & Metab 85: 2253-2259, 2000	
0514	MAIS	Substitut	7 LBD	*	824 2832	Gln⇒ Lys <u>CAA</u> ⇒ <u>AAA</u>									Gynecomastia-normal fertility - related to 513	Male	Normal	pos	Giwercman et al; J Clin Endocrinol & Metab 85: 2253-2259, 2000	
0875	PAIS	Substitut	7 LBD	*	826 2840	Phe⇒ Leu <u>TTC</u> ⇒ <u>TTA</u>	22	17	normal						Increased N/C terminal interaction & TIF2 co-activation	Male	Ambiguous	pos	Wong et al; Mol Cell Endocrinol 292:69-78, 2008	
0537	CAIS	Substitut	7 LBD		827 2841	Phe⇒ Val <u>TTT</u> ⇒ <u>GTT</u>										Female	Normal			Chavez et al; J Hum Genet. 46: 560-565, 2001
0622	CAIS	Insertion	7 LBD		829 2847	Glu⇒ 0 GAA⇒ +CA	18								2nt insertion causing frameshift and stop in Codon 833	Female	Normal	pos	MacLean et al; Hum Mutat. 23:287, 2004	
0522	CAIS	Substitut	7 LBD		830 2850	Leu⇒ Val <u>CTT</u> ⇒ <u>GTT</u>										Female	Normal			Chavez et al; Clin Genet 59:: 185-188, 2001
0995	CAIS	Substitut	7 LBD	*	831 2853	Arg⇒ Stop CGA⇒ TGA	19	18								Female	Normal	neg		Audi et al; J Clin Endocrinol Metab 95:1876-1888, 2010
0213	CAIS	Substitut	7 LBD	*	831 2853	Arg⇒ Stop <u>CGA</u> ⇒ <u>TGA</u>			zero							Female	Normal	pos		DeBellis et al; Mol Endocrinol, 6:1909-20, 1992
0214	CAIS	Substitut	7 LBD	*	831 2853	Arg⇒ Stop <u>CGA</u> ⇒ <u>TGA</u>			zero							Female	Normal			Tincello et al; J Endocrinol, 132 Suppl, Abstr 87, 1992
0215	CAIS	Substitut	7 LBD	*	831 2853	Arg⇒ Stop <u>CGA</u> ⇒ <u>TGA</u>			zero							Female	Normal			Ris-Stalpers et al; 74th Endo Soc Meeting, 1992
0384	CAIS	Substitut	7 LBD	*	831 2853	Arg⇒ Stop <u>CGA</u> ⇒ <u>TGA</u>										Female	Normal			Giwercman et al; Human Genetics 103: 529-531, 1998
0465	CAIS	Substitut	7 LBD	*	831 2853	Arg⇒ Stop <u>CGA</u> ⇒ <u>TGA</u>									Woolfian remnants present	Female	Normal			Hannema et al; J Clin Endocrinol & Metab 89: 5815-5822, 2004
0500	CAIS	Substitut	7 LBD	*	831 2853	Arg⇒ Stop <u>CGA</u> ⇒ <u>TGA</u>										Female	Normal			Choi et al; Arch Gynecol Obstet 263: 201-205, 2000
0515	CAIS	Substitut	7 LBD	*	831 2853	Arg⇒ Stop <u>CGA</u> ⇒ <u>TGA</u>									Harmatoma found in pubertal patient	Female	Normal			Chen et al; Fertility & Sterility 74: 182-183, 2000
0466	CAIS	Substitut	7 LBD	*	831 2854	Arg⇒ Gln <u>CGA</u> ⇒ <u>CAA</u>										Female	Normal			Ahmed et al; J Clin Endocrinol & Metab 85: 658-665, 2000
0499	CAIS	Substitut	7 LBD	*	831 2854	Arg⇒ Gln <u>CGA</u> ⇒ <u>CAA</u>										Female	Normal			Choi et al; Arch Gynecol Obstet 263: 201-205, 2000
0814	CAIS	Substitut	7 LBD	*	831 2854	Arg⇒ Gln <u>CGA</u> ⇒ <u>CAA</u>								"hamatomatous testes" present	Female	Normal			Goulis et al; Hirmenes (Athens) 5: 200-204, 2006	
0216	CAIS	Substitut	7 LBD	*	831 2854	Arg⇒ Gln <u>CGA</u> ⇒ <u>CAA</u>			v low							Female	Normal	pos		Brown et al; Mol Endocrinol, 4:1759-72, 1990
0217	CAIS	Substitut	7 LBD	*	831 2854	Arg⇒ Gln <u>CGA</u> ⇒ <u>CAA</u>			zero						Found in two unrelated families	Female	Normal			McPhaul et al; J Clin Inv, 90: 2097, 1992
0404	CAIS	Substitut	7 LBD		831 2854	Arg⇒ Gln <u>CGA</u> ⇒ <u>CAA</u>			zero							Female	Normal			Yaegashi et al; Tohoku J of Exp Med 187: 263-272, 1999
0524	CAIS	Substitut	7 LBD		831 2854	Arg⇒ Gln <u>CGA</u> ⇒ <u>CAA</u>			zero						Sertoli cell carcinoma	Female	Normal			Ko et al; Int. J. Gynecol. Pathol. 20: 196-199, 2001
0994	CAIS	Substitut	7 LBD		831 2854	Arg⇒ Gln <u>CGA</u> ⇒ <u>CAA</u>	23	17							Mother heterozygous carrier	Female	Normal			Audi et al; J Clin Endocrinol Metab 95:1876-1888, 2010
0218	CAIS	Substitut	7 LBD	*	831 2854	Arg⇒ Leu <u>CGA</u> ⇒ <u>CTA</u>	21	19	zero							Female	Normal			Shkolny et al; Human Mol Genetics 4: 515-521, 1995
0307	CAIS	Substitut	7 LBD	*	831 2854	Arg⇒ Leu <u>CGA</u> ⇒ <u>CTA</u>	26	16	zero							Female	Normal			Shkolny et al; Human Mol Genetics 4: 515-521, 1995

Accession #	Mutation type	Proven Phenotype	Pathogenicity proven	Exon Domain	CpG hot spot	Position Base	Amino acid Change	Amino acid Base	Exon 1 tracts				Androgen Binding			Comments	Sex of rearing	External Genitalia	Family history	Reference
									Poly Gln #	Poly Gly #	Bmax	Kd	Thermolabile k							
0590	CAIS	Substitution	7 LBD	*	831 2854	Arg⇒Leu CGA⇒CTA								Reduced immunoreactive AR	Female	Normal		Avila et al; J Clin Endocrinol Metab 87; 182-188, 2002		
0996	CAIS	Deletion			833 2859-61	Asn⇒0 ΔAAC⇒0	19	18							Female	Normal	neg	Audi et al; J Clin Endocrinol Metab 95:1876-1888, 2010		
0219	CAIS	Substitution	7 LBD		834 2863	Tyr⇒Cys TAC⇒TGC			zero						Female	Normal		Wilson et al; J Clin Endocrinol Metab, 75:1474-8, 1992		
0997	CAIS	Substitution	7 LBD		838 2874	Leu⇒Val CTC⇒GTC	8	17							Female	Normal	neg	Audi et al; J Clin Endocrinol Metab 95:1876-1888, 2010		
0392	PAIS	Substitution	7 LBD		838 2876	Leu⇒Leu CTC⇒CTT							Hypospadia and cryptorchidism - silent mutation	Male	Ambiguous		Nordenskjold et al Urological Res, 27: 49-55, 1999			
0765	Prostate cancer	Substitution	7 LBD		838 2876	Leu⇒Leu CTC⇒CTT							patient lower Gleason score than patient -wt AR- som mutation	Male	Normal		Sanchez et al; BJU Int 98:1320-1325, 2006			
0415	PAIS	Substitution	7 LBD		840 2880	Arg⇒Ser CGT⇒AGT	25						Testis located in inguinal region. same family as 0832	Male	Ambiguous		Melo et al; J Clin Endocrinol & Metab 88: 3241-3250, 2003			
0626	PAIS	Substitution	7 LBD		840 2880	Arg⇒Ser CGT⇒AGT							Diagnosis at 6.5 yr. Reassigned as male after testosterone	Female	Ambiguous		Mazen et al; J Endocrinol Invest. 27:57-60, 2004			
0832	PAIS	Substitution	7 LBD		840 2880	Arg⇒Ser CGT⇒AGT							Testis located in inguinal region. same family as 0415	Male	Ambiguous		Melo et al; Arq Bras Endocrinol Metab 49:87-97, 2005			
0220	PAIS	Substitution	7 LBD	*	840 2880	Arg⇒Cys CGT⇒TGT	20	16	normal high	norm	*			Male	Ambiguous	pos	Beitel et al; J Clin Inv, 94: 546-554 1994			
0221	PAIS	Substitution	7 LBD	*	840 2880	Arg⇒Cys CGT⇒TGT			low	high	*		Found in two unrelated individuals.	Female			McPhaul et al; J Clin Inv, 90: 2097, 1992			
0222	PAIS	Substitution	7 LBD	*	840 2880	Arg⇒Cys CGT⇒TGT							Sibling of 0308	Female	Ambiguous	pos	Bevan et al; Hum Mol Genet, 5: 265-273, 1996			
0308	PAIS	Substitution	7 LBD	*	840 2880	Arg⇒Cys CGT⇒TGT							Sibling of 0222	Male	Ambiguous	pos	Bevan et al; Hum Mol Genet, 5: 265-273, 1996			
0387	PAIS	Substitution	7 LBD	*	840 2880	Arg⇒Cys CGT⇒TGT							Transcriptional activity only at high conc of androgen				Georget et al; J Clin Endocrinol & Metab 83: 3597-3603, 1998			
0698	PAIS	Substitution	7 LBD	*	840 2880	Arg⇒Cys CGT⇒TGT							Family member of 0699 & 0700 with phenotypic varaiation	Male	Ambiguous	pos	Wang et al; Biochem Biophys Res Comm 335: 335-342, 2005			
0699	PAIS	Substitution	7 LBD	*	840 2880	Arg⇒Cys CGT⇒TGT							Family member of 0698 & 0700 with phenotypic varaiation	Male	Ambiguous	pos	Wang et al; Biochem Biophys Res Comm 335: 335-342, 2005			
0700	PAIS	Substitution	7 LBD	*	840 2880	Arg⇒Cys CGT⇒TGT							Family member of 0698 & 0699 with , phenotypic varaiation	Male	Ambiguous	pos	Wang et al; Biochem Biophys Res Comm 335: 335-342, 2005			
0734	PAIS	Substitution	7 LBD	*	840 2880	Arg⇒Cys CGT⇒TGT							brother affected, sister heterozygous	Male	Ambiguous	pos	Ledig et al; Horm Res 63:263-269, 2005			
0385	PAIS	Substitution	7 LBD	*	840 2880	Arg⇒Gly CGT⇒GGT			low				Reduced transactivation				Giwercman et al; Human Genetics 103: 529-531, 1998			
0818	PAIS	Substitution	7 LBD	*	840 2881	Arg⇒His CGT⇒CAT								Male	Ambiguous		Yen et al; Acta Paediatr Taiwan 46: 101-105, 2005			
0683	CAIS	Substitution	7 LBD	*	840 2881	Arg⇒His CGT⇒CAT							bilateral inguinal hernia	Female	Normal		Bouvattier et al; J Clin Endocrinol & Metab 87: 29-32, 2002			
0820	CAIS	Substitution	7 LBD	*	840 2881	Arg⇒His CGT⇒CAT								Female	Normal		Wang et al; Yi Chuan Xue Bao 33:19-25, 2006			
0337	PAIS	Substitution	7 LBD	*	840 2881	Arg⇒His CGT⇒CAT	19		normal high	high	*			Female	Ambiguous	pos	Beitel et al; J Clin Inv, 94: 546-554 1994			
0224	PAIS	Substitution	7 LBD	*	840 2881	Arg⇒His CGT⇒CAT	18	24	normal high	high	*			Female	Ambiguous	pos	Beitel et al; J Clin Inv, 94: 546-554 1994			
0225	PAIS	Substitution	7 LBD	*	840 2881	Arg⇒His CGT⇒CAT				high			Found in two unrelated families	Female	Ambiguous	pos in 1 fam	Hiort et al; J Clin Endocrinol Metab, 77:262-266, 1993			

Accession #	Mutation type	Proven Pathogenicity	Exon Domain	CpG hot spot	Position Base	Change Amino acid	Exon 1 tracts				Androgen Binding			Comments	Sex of rearing	External Genitalia	Family history	Reference
							Poly Gln #	Poly Gly #	Bmax	Kd	Thermolabile k							
0226	PAIS	Substitution	7 LBD	*	840 2881	Arg ⇒ His CGT ⇒ CAT			zero								McPhaul et al; J Clin Inv, 90:2097, 1992	
0227	PAIS	Substitution	7 LBD	*	840 2881	Arg ⇒ His CGT ⇒ CAT			normal	normal				* In same fam. persons raised as males with ambiguous genitalia	Female	Ambiguous	pos	Imasaki et al; Eur J Endocrinol, 130: 569-574, 1994
0228	PAIS	Substitution	7 LBD	*	840 2881	Arg ⇒ His CGT ⇒ CAT			low								Lumbroso et al; Eur J Endocrinol 130: 327, 1994	
0229	PAIS	Substitution	7 LBD	*	840 2881	Arg ⇒ His CGT ⇒ CAT			low								Imai et al; Annals of Clinical Biochem, 32: 482-486, 1995	
0230	PAIS	Substitution	7 LBD	*	840 2881	Arg ⇒ His CGT ⇒ CAT											Ghirri & Brown; Pediatr Res 33: Abstr.95, 1993	
0231	PAIS	Substitution	7 LBD	*	840 2881	Arg ⇒ His CGT ⇒ CAT			low	high	high						Marcelli et al; J Clin Invest 94: 1642-1650, 1994	
0232	PAIS	Substitution	7 LBD	*	840 2881	Arg ⇒ His CGT ⇒ CAT			normal	high			*		Female	Ambiguous	pos	Weidemann et al; Clin Endocrinology 45: 733 -
0223	PAIS	Substitution	7 LBD	*	840 2881	Arg ⇒ His CGT ⇒ CAT			low	high					Female	Ambiguous		De Bellis et al; J Clin Endocrinol Metab, 78:513, 1994
0668	PAIS	Substitution	7 LBD	*	840 2881	Arg ⇒ His CGT ⇒ CAT								Somatic mosaicism	Male	Ambiguous		Kohler et al; J Clin endocrinol & Metab 90: 106-111, 2005
1008	PAIS	Substitution	7 LBD	*	840 2881	Arg ⇒ His CGT ⇒ CAT	23	11						1 affected niece	Female	Ambiguous	pos	Audi et al. J Clin Endocrinol Metab 95:1876-1888, 2010
0233	PAIS	Substitution	7 LBD	841 2884	Ile ⇒ Ser ATC ⇒ AGC				low	high					Female	Ambiguous		Hiori et al; Am J Med Genet. 63: 218-222, 1996
0234	CAIS	Substitution	7 LBD	842 2887	Ile ⇒ Thr ATT ⇒ ACT				normal	high					Female	Normal	pos	Hiori et al; J Clin Endocrinol Metab, 77:262-266, 1993
0235	PAIS	Substitution	7 LBD	*	842 2887	Ile ⇒ Thr ATT ⇒ ACT			low	high		*			Male	Ambiguous	pos	Weidemann et al Clin Endocrinology 45: 733 - 739, 1996
0591	CAIS	Substitution	7 LBD	842 2887	Ile ⇒ Asn ATT ⇒ AAT									Normal immunoreactive AR	Female	Normal		Avila et al. J Clin Endocrinol Metab 87; 182-188, 2002
0736	PAIS	Substitution	7 LBD	843 2890	Ala ⇒ Glu GCA ⇒ GAA									de novo mutation	Male	Ambiguous	neg	Ledig et al; Horm Res 63:263-269, 2005
0494	Prostate cancer	Substitution	7 LBD	846 2898	Arg ⇒ Gly AGA ⇒ GGA									Somatic mutation	Male	Normal		Marcelli et al; Cancer Research 60: 944-949, 2000
0957	CAIS	Insertion	7 LBD	848 2906	Asn ⇒ Lys AAT ⇒ AAAT									1nt insert - frameshift & stop in Codon 879	Female	Normal	neg	Wu et al. Fertility & Sterility 93:2076, e1-4, 2010
0236	CAIS	Insertion	7 LBD	848 2906	Asn ⇒ Lys AAT ⇒ AAAT				zero					1nt insert frameshift& stop in Codon 879& loss of 44 AA's	Female	Normal		Brinkmann et al; J Steroid Biochem Mol Biol 53: 443, 1995
0467	CAIS	Insertion	7 LBD	848 2906	Asn ⇒ Lys AAT ⇒ AAAT				zero					1nt insert causes frame-shift.	Female	Normal		Ahmed et al; J Clin Endocrinol & Metab 85: 658-665, 2000
0854	CAIS		7 LBD	848	Asn ⇒ AAT ⇒									Frameshit & stop in Codon 875 Diag & bilat gonadect at 7y	Female	Normal		Cheikhelard et al. J Urol 180:1496-1501, 2008
0237	CAIS	Substitution	7 LBD	853 2920	Ser ⇒ Stop TCA ⇒ TGA				zero						Female	Normal		Wilson et al; J Clin Endocrinol Metab, 75:1474-8, 1992
0238	CAIS	Substitution	7 LBD	853 2920	Ser ⇒ Stop TCA ⇒ TGA				zero						Female	Normal		Jakubiczka et al; Human Mutation 9: 57-61, 1997
0793	CAIS	Deletion	7 LBD	853 2922	Ser ⇒ TCAA ⇒									2 nt deletion	Female	Normal		Mueller et al. Hum Genet 119:673, 2006
0239	PAIS	Substitution	7 LBD	854 2923	Arg ⇒ Lys AGA ⇒ AAA				low			*						McPhaul et al; J Clin Inv, 90:2097, 1992
0833	CAIS	Substitution	7 LBD	*	855 2925	Arg ⇒ Cys CGC ⇒ TGC								gonads located in abdomen. Same family as 0604	Female	Normal		Melo et al; Arq Bras Endocrinol Metab 49:87-97, 2005

Accession #	Mutation type	Exon Domain	CpG hot spot	Position Base	Change Amino acid	Exon 1 tracts				Androgen Binding			Comments	Sex of rearing	External Genitalia	Family history	Reference
						Poly Gln #	Poly Gly #	Bmax	Kd	Thermolabile k							
0866	CAIS	Substitut	7 LBD	* 855 2925	Arg ⇒ Cys <u>CGC</u> ⇒ <u>TGC</u>								Diagnosis at 3 wks	Female	Normal		Cheikhelard et al; J Urol 180:1496-1501, 2008
0240	CAIS	Substitut	7 LBD	* 855 2925	Arg ⇒ Cys <u>CGC</u> ⇒ <u>TGC</u>			zero						Female	Normal		DeBellis et al; Mol Endocrinol 6:1909-20, 1992
0241	CAIS	Substitut	7 LBD	* 855 2925	Arg ⇒ Cys <u>CGC</u> ⇒ <u>TGC</u>									Female	Normal		Tincello et al; J Endocrinol 132 Suppl, Abstr 87, 1992
0242	CAIS	Substitut	7 LBD	* 855 2925	Arg ⇒ Cys <u>CGC</u> ⇒ <u>TGC</u>			zero						Female	Normal		McPhaul et al; J Clin Inv, 90:2097, 1992
0243	CAIS	Substitut	7 LBD	* 855 2925	Arg ⇒ Cys <u>CGC</u> ⇒ <u>TGC</u>									Female	Normal		Loboccaro et al; Pediat Res 33: Abstr 115, 1993
0244	CAIS	Substitut	7 LBD	* * 855 2925	Arg ⇒ Cys <u>CGC</u> ⇒ <u>TGC</u>			low						Female	Normal	pos	Morono et al; Human Mutation 6: 152-162, 1995
0245	CAIS	Substitut	7 LBD	* 855 2925	Arg ⇒ Cys <u>CGC</u> ⇒ <u>TGC</u>			zero						Female	Normal		Sultan et al; J Steroid Biochem & Mol Biol:40
0246	CAIS	Substitut	7 LBD	* 855 2925	Arg ⇒ Cys <u>CGC</u> ⇒ <u>TGC</u>									Female	Normal		Brinkmann et al; J Steroid Biochem & Mol Biol 53: 443, 1995
0247	CAIS	Substitut	7 LBD	* 855 2925	Arg ⇒ Cys <u>CGC</u> ⇒ <u>TGC</u>			zero						Female	Normal		Hiort et al; Am J Med Genet. 63: 218-222, 1996
0248	CAIS	Substitut	7 LBD	* 855 2925	Arg ⇒ Cys <u>CGC</u> ⇒ <u>TGC</u>			v low	high					Female	Normal	pos	Malmgren et al; Clin Genet. 50:202-205, 1996
0320	CAIS	Substitut	7 LBD	* 855 2925	Arg ⇒ Cys <u>CGC</u> ⇒ <u>TGC</u>									Female	Normal		Komori et al; J Obstetrics & Gynocol. Res. 23: 277-81, 1997
0468	CAIS	Substitut	7 LBD	* 855 2925	Arg ⇒ Cys <u>CGC</u> ⇒ <u>TGC</u>			zero						Female	Normal		Ahmed et al; J Clin Endocrinol & Metab 85: 658-665, 2000
0469	CAIS	Substitut	7 LBD	* 855 2925	Arg ⇒ Cys <u>CGC</u> ⇒ <u>TGC</u>			normal	high					Female	Normal		Ahmed et al; J Clin Endocrinol & Metab 85: 658-665, 2000
0527	CAIS	Substitut	7 LBD	* * 855 2925	Arg ⇒ Cys <u>CGC</u> ⇒ <u>TGC</u>			v low	high					Female	Normal		Elhaji et al; 83rd US Endo Soc Meeting, Abstr P2-37, 2001
0592	CAIS	Substitut	7 LBD	* * 855 2925	Arg ⇒ Cys <u>CGC</u> ⇒ <u>TGC</u>					v low	immunoreactive AR			Female	Normal		Avila et al; J Clin Endocrinol Metab 87; 182-188, 2002
0640	CAIS	Substitut	7 LBD	* * 855 2925	Arg ⇒ Cys <u>CGC</u> ⇒ <u>TGC</u>	19		zero		Testis located in abdomen Same family as 0833				Female	Normal	pos	Melo et al; J Clin Endocrinol & Metab 88: 3241-3250, 2003
0737	CAIS	Substitut	7 LBD	* 855 2925	Arg ⇒ Cys <u>CGC</u> ⇒ <u>TGC</u>					de novo mutation				Female	Normal	neg	Ledig et al; Horm Res 63:263-269, 2005
0661	CAIS	Substitut	7 LBD	* 855 2926	Arg ⇒ His <u>CGC</u> ⇒ <u>CAC</u>					Vas deferens present				Female	Normal		Hannema et al; J Clin Endocrinol & Metab 89: 5815-5822, 2004
0528	PAIS	Substitut	7 LBD	* * 855 2926	Arg ⇒ His <u>CGC</u> ⇒ <u>CAC</u>			normal	high	*				Male	Ambiguous		Elhaji et al; 83rd US Endo Soc Meeting, Abstr P2-37, 2001
0684	CAIS	Substitut	7 LBD	* 855 2926	Arg ⇒ His <u>CGC</u> ⇒ <u>CAC</u>					bilateral inguinal hernia				Female	Normal		Bouvattier et al; J Clin Endocrinol & Metab 87: 29-32, 2002
0688	CAIS	Substitut	7 LBD	* 855 2926	Arg ⇒ His <u>CGC</u> ⇒ <u>CAC</u>					Mother a heterozygote				Female	Normal		Skordis et al; j pediatr Endocrinol Metab 18: 309-313, 2005
0745	PAIS	Substitut	7 LBD	* 855 2926	Arg ⇒ His <u>CGC</u> ⇒ <u>CAC</u>					sibling of 0746				Male	Ambiguous	pos	Boehmer et al; J Clin Endocrinol & Metab 86:4151-4160, 2001
0746	PAIS	Substitut	7 LBD	* 855 2926	Arg ⇒ His <u>CGC</u> ⇒ <u>CAC</u>			normal	high	niece of 0745 also Pro398Ser				Female	Ambiguous	pos	Boehmer et al; J Clin Endocrinol & Metab 86:4151-4160, 2001
0777	MAIS	Substitut	7 LBD	* 855 2926	Arg ⇒ His <u>CGC</u> ⇒ <u>CAC</u>					Male infertility				Male	Normal		Ferlin et al; Clin Endocrinol 65:606-610, 2006
0251	PAIS	Substitut	7 LBD	* 855 2926	Arg ⇒ His <u>CGC</u> ⇒ <u>CAC</u>			normal	high								Chang et al; 73rd Endo Soc Meeting, Abstr 28, 1991

Accession #	Mutation type	Exon Domain	Pathogenicity proven	CpG hot spot	Position Amino acid Base	Change Amino acid Base	Exon 1 tracts				Androgen Binding Thermolabile				Comments	Sex of rearing	External Genitalia	Family history	Reference
							Poly Gln #	Poly Gly #	Bmax	Kd	k								
0252	PAIS	Substitut	7 LBD	*	855 2926	Arg⇒His CGC⇒CAC			normal	high	*	Servere hypospadi	Male	Ambiguous	pos	Batch et al; Hum Mol Genet, 1:497, 1992			
0253	PAIS	Substitut	7 LBD	*	855 2926	Arg⇒His CGC⇒CAC							Male	Ambiguous		Hiori et al; Am J Med Genet. 63: 218-222. 1996			
0254	PAIS	Substitut	7 LBD	*	855 2926	Arg⇒His CGC⇒CAC			zero				Female	Ambiguous	pos	Weidemann et al; Clin Endocrinology 45: 733 -			
0255	PAIS	Substitut	7 LBD	*	855 2926	Arg⇒His CGC⇒CAC			low	high	norm		Female	Ambiguous		Marcelli et al; J Clin Invest, 94:1642-1650, 1994			
0301	PAIS	Substitut	7 LBD	*	855 2926	Arg⇒His CGC⇒CAC	14					Brother of 0302 somatic & germ-line muts. in mother	Male	Ambiguous	pos	Boehmer et al; Am J Hum Genetics 60: 1003 -6, 1997			
0250	PAIS	Substitut	7 LBD	*	855 2926	Arg⇒His CGC⇒CAC			zero				Female	Ambiguous		Weidemann et al; Clin Endocrinology 45: 733 -739, 1996			
0302	PAIS	Substitut	7 LBD	*	855 2926	Arg⇒His CGC⇒CAC	14					Sister of 0301. somatic & germ-line muts. in mother	Female	Ambiguous	pos	Boehmer et al; Am J Hum Genetics 60: 1003 -6, 1997			
0249	CAIS	Substitut	7 LBD	*	855 2926	Arg⇒His CGC⇒CAC			low				Female	Normal		McPhaul et al; J Clin Invest. 90: 2097, 1992			
0344	PAIS	Substitut	7 LBD	*	855 2926	Arg⇒His CGC⇒CAC	28		zero to normal			Sex changed at 1yr Male to female - Same family as 0834	Female	Ambiguous	pos	Melo et al; J Clin Endocrinol & Metab 88: 3241-3250, 2003			
0834	PAIS	Substitut	7 LBD	*	855 2926	Arg⇒His CGC⇒CAC						Same family as 0344	Male	Ambiguous	pos	Melo et al; Arq Bras Endocrinol Metab 49:87-97, 2005			
0998	CAIS	Substitut	7 LBD	*	855 2926	Arg⇒His CGC⇒CAC	20	14				1 affected aunt; mother & 2 aunts heterozygotes	Female	Normal	pos	Audi et al. J Clin Endocrinol Metab 95:1876-1888, 2010			
1009	PAIS	Substitut	7 LBD	*	855 2926	Arg⇒His CGC⇒CAC	18	17				1 affected sister, mot & 2 aunts heterozygote carriers	Female	Ambiguous	pos	Audi et al. J Clin Endocrinol Metab 95:1876-1888, 2010			
0641	PAIS	Substitut	7 LBD	856 2930		Arg⇒His CGC⇒CAC	19		zero to normal			Testis located in inguinal region	Male	Ambiguous	neg	Melo et al; J Clin Endocrinol & Metab 88: 3241-3250, 2003			
0716	PAIS	Substitut	7 LBD	856 2930		Arg⇒His CGC⇒CAC			high				Male	Ambiguous		Deeb et al; Clinical Endocrinology 63: 56 -62, 2005			
0470	CAIS	Substitut	7 LBD	856 2930		Phe⇒Leu TTC⇒TTG							Female	Normal		Ahmed et al; J Clin Endocrinol & Metab 85: 658-665, 2000			
0662	CAIS	Substitut	7 LBD	856 2930		Phe⇒Leu TTC⇒TTG						Also Ser865Pro-twin of 0663	Female	Normal	pos	Hannema et al. J Clin Endocrinol & Metab 89: 5815-5822, 2004			
0663	CAIS	Substitut	7 LBD	856 2930		Phe⇒Leu TTC⇒TTG						Also Ser865Pro-twin of 0662	Female	Normal	pos	Hannema et al. J Clin Endocrinol & Metab 89: 5815-5822, 2004			
0356	CAIS	Substitut	7 LBD	857		Tyr⇒Stop TAC⇒						de novo mutation	Female	Normal	neg	Hiort et al; J Pediatrics 132: 939-943, 1998			
0941	CAIS	Insertion	7 LBD	857 2933		Tyr⇒Stop TAC⇒TAaC						1nt insertion resulted in stop codon Mother & sister carriers	Female	Normal	pos	Turek-Plewa et al. Hum Genet 125:34, 2009			
0753	CAIS	Substitut	7 LBD	*	859 2937	Leu⇒Phe CTC⇒TTC		v low				In silico analysis showed effect on ligand-binding pocket	Female	Normal		Rajender et al. J Andrology 28:772-6, 2007			
0867	CAIS	Substitut	7 LBD	860 2941		Thr⇒Asn ACC⇒AAC						Diagnosis at birth bilateral gonadectomy at 15yrs	Female	Normal		Cheikhelard et al. J Urol 180:1496-1501, 2008			
0256	CAIS	Substitut	7 LBD	863 2950		Leu⇒Arg CTG⇒CGG							Female	Normal		Brown et al; Eur J Pediatr 152: (Suppl 2) S62, 1993			
0257	CAIS	Substitut	7 LBD	*	864 2952	Asp⇒Asn GAC⇒AAC			low			Transactivation activity increases with horm.	Female	Normal		Bevan et al; J Steroid Biochem Molec. Biol 61: 19-26, 1997			
0471	CAIS	Substitut	7 LBD	864 2952		Asp⇒Asn GAC⇒AAC						Epididymis & vas deferens present	Female	Normal		Hannema et al. J Clin Endocrinol & Metab 89: 5815-5822, 2004			
0472	CAIS	Substitut	7 LBD	864 2953		Asp⇒Gly GAC⇒GGC			zero			Woolfian remnants present	Female	Normal		Hannema et al. J Clin Endocrinol & Metab 89: 5815-5822, 2004			

Accession #	Mutation type	Exon Domain	CpG hot spot	Position Base	Change Amino acid Base	Exon 1 tracts				Androgen Binding			Comments	Sex of rearing	External Genitalia	Family history	Reference
						Poly Gln #	Poly Gly #	Bmax	Kd	Thermolabile k							
0258	CAIS	Substitut	7 LBD	*	864 2953	Asp⇒ Gly GAC⇒ GGC			zero					Female	Normal		DeBellis et al; Mol Endocrinol, 6:1909-20, 1992
0486	CAIS	Substitut	7 LBD		865 2955	Ser⇒ Pro TCC⇒ CCC								Female	Normal		Ahmed et al; J Clin Endocrinol & Metab 85: 658-665, 2000
0560	CAIS	Substitut	7 LBD		865 2955	Ser⇒ Pro TCC⇒ CCC							de novo mut. also Phe868Leu mut -no effect horm binding	Female	Normal	pos	Mongan et al; J Clin endocrinol Metab 87: 1057-1061, 2002
0855	CAIS		7 LBD		866 2955	Val⇒ GTG⇒							Frameshit & stop in Codon 875 Diag 15yr Bilat gonadect at 16y	Female	Normal	pos	Cheikhelard et al. J Urol 180:1496-1501, 2008
0856	CAIS		7 LBD		866 2955	Val⇒ GTG⇒							Frameshit & stop in Codon 875 Diag & Bilat gonadect at 11yr	Female	Normal	pos	Cheikhelard et al. J Urol 180:1496-1501, 2008
0259	PAIS	Substitut	7 LBD		866 2958	Val⇒ Leu GTG⇒ TTG	21		normal high					Male	Ambiguous	pos	Saunders et al; Clin Endocrinol 37:214, 1992
0345	PAIS	Substitut	7 LBD		866 2958	Val⇒ Leu GTG⇒ TTG	25		normal high					Male	Ambiguous		Saunders et al; Clin Endocrinol, 37:214, 1992
0260	PAIS	Substitut	7 LBD	*	866 2958	Val⇒ Leu GTG⇒ TTG			normal high					Male	Ambiguous	pos	Kazemi-Esfarjani et al; Mol Endocrinol, 7:37 -46, 1993
0261	PAIS	Substitut	7 LBD		866 2958	Val⇒ Leu GTG⇒ TTG			high					Male	Ambiguous	pos	Hiort et al; J Clin Endocrinol Metab, 77:262-266, 1993
0262	PAIS	Substitut	7 LBD	*	866 2958	Val⇒ Leu GTG⇒			zero								Merkabi et al; 75th US Endo Soc Meeting Abstr 602, 1993
0263	CAIS	Substitut	7 LBD	*	866 2958	Val⇒ Met GTG⇒ ATG	20	16	normal high					Female	Normal		Kazemi-Esfarjani et al; Mol Endocrinol, 7:37 -46, 1993
0264	CAIS	Substitut	7 LBD	*	866 2958	Val⇒ Met GTG⇒ ATG			normal high					Female	Normal		Weidemann et al; Clin Endocrinology 45: 733 -
0265	CAIS	Substitut	7 LBD	*	866 2958	Val⇒ Met GTG⇒ ATG			normal high	*				Female	Normal		Lubahn et al; Proc Natl Acad Sci. 86: 9534, 1989
0266	PAIS	Substitut	7 LBD	*	866 2958	Val⇒ Met GTG⇒ ATG				*							McPhaul et al; J Clin Inv, 90:2097, 1992
0267	PAIS	Substitut	7 LBD	*	866 2958	Val⇒ Met GTG⇒ ATG			high	*	de novo mutation - mosaic 2 functionally diff AR's			Female	Ambiguous	neg	Hiort et al; J Pediatrics 132: 939- 943, 1998
0373	Prostate cancer	Substitut	7 LBD	*	866 2958	Val⇒ Met GTG⇒ ATG					Somatic mutation			Male	Normal		Takahashi et al; Cancer Research 55: 1621 -1624, 1995
0473	CAIS	Substitut	7 LBD	*	866 2958	Val⇒ Met GTG⇒ ATG					Vas deferens present			Female	Normal		Hannema et al. J Clin Endocrinol & Metab 89: 5815-5822, 2004
0474	CAIS	Substitut	7 LBD	*	866 2958	Val⇒ Met GTG⇒ ATG			zero		Woolfian remnants present			Female	Normal		Hannema et al. J Clin Endocrinol & Metab 89: 5815-5822, 2004
0475	CAIS	Substitut	7 LBD	*	866 2958	Val⇒ Met GTG⇒ ATG			zero		Epididymis present			Female	Normal		Hannema et al. J Clin Endocrinol & Metab 89: 5815-5822, 2004
0607	CAIS	Substitut	7 LBD	*	866 2958	Val⇒ Met GTG⇒ ATG			zero					Female	Normal		Holterhaus et al; Genome Biology 4: R37
0738	PAIS	Substitut	7 LBD	*	866 2958	Val⇒ Met GTG⇒ ATG								Female	Normal	neg	Ledig et al; Horm Res 63:263-269, 2005
0739	CAIS	Substitut	7 LBD	*	866 2958	Val⇒ Met GTG⇒ ATG								Female	Normal	neg	Ledig et al; Horm Res 63:263-269, 2005
0574	Prostate Cancer	Substitut	7 LBD	*	866 2958	Val⇒ Met GTG⇒ ATG					Somatic mutation. + orchietomy treatment Horm-			Male	Normal		Hytyinen et al; Lab Invest. 82: 1591-1598, 2002
0778	MAIS	Substitut	7 LBD	*	866 2958	Val⇒ Met GTG⇒ ATG					Male infertility			Male	Normal		Ferlin et al. Clin Endocrinol 65:606-610, 2006
0268	CAIS	Substitut	7 LBD		866 2959	Val⇒ Glu GTG⇒ GAG								Female	Normal		McPhaul et al; J Clin Inv, 90:2097, 1992

Accession #	Mutation type	Proven Phenotype	Pathogenicity proven	Exon Domain	CpG hot spot	Position Base	Amino acid Change	Exon 1 tracts				Androgen Binding				Comments	Sex of rearing	External Genitalia	Family history	Reference
								Poly Gln #	Poly Gly #	Bmax	Kd	Thermolabile k								
0851	CAIS	Substitut	7 LBD		867 2961	Gln $\Rightarrow$ Stop CAG $\Rightarrow$ TAG							Diag at 2.5 yr	Female	Normal	pos	Cheikhelard et al. J Urol 180:1496-1501, 2008			
0852	CAIS	Substitut	7 LBD		867 2961	Gln $\Rightarrow$ Stop CAG $\Rightarrow$ TAG							Diag at 2 wk	Female	Normal	pos	Cheikhelard et al. J Urol 180:1496-1501, 2008			
0940	Prostate Cancer	Substitut	7 LBD		867 2961	Gln $\Rightarrow$ Stop CAG $\Rightarrow$ TAG							Both treated and untreated Occurred in 2 cases	Male	Normal		Steinkamp et al; Cancer Res 69:4434-4442, 2009			
0601	CAIS	Insertion	8 LBD		868 2964	Pro $\Rightarrow$ Met CCT $\Rightarrow$ ATG							3 base insertion (ATG) at residue 868	Female	Normal		Scheiber et al; J Pediatric Endocrinol & Metab. 16: 367-373,			
0269	PAIS	Substitut	8 LBD *		869 2969	Ile $\Rightarrow$ Met ATT $\Rightarrow$ ATG							* Hypospadia	Male	Ambiguous	pos	Bevan et al; Hum Mol Genet 5: 265-273, 1996			
0718	PAIS	Substitut	8 LBD		869 2969	Ile $\Rightarrow$ Met ATT $\Rightarrow$ ATG							high	Male	Ambiguous	pos	Deeb et al; Clinical Endocrinology 63: 56-62, 2005			
0951	PAIS	Substitut	8 LBD *		870 2971	Ala $\Rightarrow$ Val GCG $\Rightarrow$ GTG							Micropenis only-Heterozygous for SRD5A2 V89L	Male	Ambiguous		Bhangoo et al. Asian J Androl 12:561-566. 2010q			
1010	PAIS	Substitut	8 LBD *		870 2971	Ala $\Rightarrow$ Val GCG $\Rightarrow$ GTG	25	11						Male	Ambiguous	neg	Audi et al. J Clin Endocrinol Metab 95:1876-1888, 2010			
0270	PAIS	Substitut	8 LBD *		870 2971	Ala $\Rightarrow$ Val GCG $\Rightarrow$ GTG							Found in two unrelated families	Male	Ambiguous		Hiort et al; Eur J Pediatr, 153:317, 1994			
0315	PAIS	Substitut	8 LBD		870 2971	Ala $\Rightarrow$ Gly GCG $\Rightarrow$ GGG							Severe hypospadias	Male	Ambiguous		Albers et al; J of Pediatrics 131: 388-392, 1997			
0271	PAIS	Substitut	8 LBD *		870 2971	Ala $\Rightarrow$ Gly GCG $\Rightarrow$ GGG							de novo mutation	Female	Ambiguous	neg	Hiort et al; J Pediatrics 132: 939- 943, 1998			
0562	MAIS	Substitut	8 LBD *		870 2971	Ala $\Rightarrow$ Gly GCG $\Rightarrow$ GGG							bilateral gynecomastia normal fertility	Male	Normal		Zenteno et al; Horm Res 57: 90-93, 2002			
0794	CAIS ?	Deletion	8 LBD		870 2972	Ala $\Rightarrow$ GCG $\Rightarrow$							1 nt. deletion				Mueller et al. Hum Genet 119:681, 2006			
0272	MAIS	Substitut	8 LBD *		871 2973	Arg $\Rightarrow$ Gly AGA $\Rightarrow$ GGA	26	24	normal	normal	norm		Gynocomastia & oligospermia	Male	Normal		Shkolny et al; J Clin Endocrinol & Metab 84: 805-810, 1999			
0696	Prostate cancer	Substitut	8 LBD *		872 2976	Glu $\Rightarrow$ Gln GAG $\Rightarrow$ CAG			normal	normal			Activated by estrodiol, progesterone & CPA	Male	Normal		Chen et al; The Prostate 63:395-406, 2005			
0273	Prostate cancer	Substitut	8 LBD		874 2982	His $\Rightarrow$ Tyr CAT $\Rightarrow$ TAT							Som mut- stimulated by progesterone & oestrogen	Male	Normal		Taplin et al; New England J Med 332: 1393-1398, 1995			
0274	Prostate cancer	Substitut	8 LBD		874 2982	His $\Rightarrow$ Tyr CAT $\Rightarrow$ TAT							Somatic mutation	Male	Normal		Tan et al; J of Urology 155: 340A, 1996			
0538	CAIS	Substitut	8 LBD		874 2983	His $\Rightarrow$ Arg CAT $\Rightarrow$ CGT			zero					Female	Normal		Chavez et al; J Hum Genet. 46: 560-565, 2001			
0868	CAIS	Substitut	8 LBD		874 2983	His $\Rightarrow$ Arg CAT $\Rightarrow$ CGT							Prenatal diagnosis	Female	Normal	pos	Cheikhelard et al. J Urol 180:1496-1501, 2008			
0869	CAIS	Substitut	8 LBD		874 2983	His $\Rightarrow$ Arg CAT $\Rightarrow$ CGT							Prenatal diagnosis	Female	Normal	pos	Cheikhelard et al. J Urol 180:1496-1501, 2008			
0870	CAIS	Substitut	8 LBD		874 2983	His $\Rightarrow$ Arg CAT $\Rightarrow$ CGT							Diagnosis at 2mo bilateral gnaadectomy at 16yrs	Female	Normal	pos	Cheikhelard et al. J Urol 180:1496-1501, 2008			
0871	CAIS	Substitut	8 LBD		874 2983	His $\Rightarrow$ Arg CAT $\Rightarrow$ CGT							Diagnosis at 1yr bilateral gonadectomy at 15yrs	Female	Normal	pos	Cheikhelard et al. J Urol 180:1496-1501, 2008			
0872	CAIS	Substitut	8 LBD		874 2983	His $\Rightarrow$ Arg CAT $\Rightarrow$ CGT							Diagnosis at 7 yrs bilateral gonadectomy at 14yrs	Female	Normal	pos	Cheikhelard et al. J Urol 180:1496-1501, 2008			
0873	CAIS	Substitut	8 LBD		874 2983	His $\Rightarrow$ Arg CAT $\Rightarrow$ CGT							Prenatal diagnosis & bilateral gonadectomy at 14yrs	Female	Normal	pos	Cheikhelard et al. J Urol 180:1496-1501, 2008			
0275	LNCaP cell line	Substitut	8 LBD		877 2991	Thr $\Rightarrow$ Ala ACT $\Rightarrow$ GCT							Altered binding specificity - somatic mutation	Male	Normal		Veldscholte et al; Biochem Biophys Res Comm, 172:534, 1990			

Accession #	Mutation type	Proven Phenotype	Pathogenicity proven	Exon Domain	CpG hot spot	Position Base	Amino acid Change	Exon 1 tracts				Androgen Binding			Comments	Sex of rearing	External Genitalia	Family history	Reference
								Poly Gln #	Poly Gly #	Bmax	Kd	Thermolabile k							
0276	Prostate cancer	Substitution	8 LBD		877 2991		Thr⇒ Ala ACT⇒ GCT						Somatic mutation 1/8 endocrine resistant therapy cases	Male	Normal		Suzuki et al; J Steroid Biochem Molec Biol 46:759, 1993		
0277	Prostate cancer	Substitution	8 LBD		877 2991		Thr⇒ Ala ACT⇒ GCT						6 out of 24 patients screened - somatic mutation	Male	Normal		Gaddipati et al; Cancer Res, 54: 2861-2864, 1994		
0278	Prostate cancer	Substitution	8 LBD		877 2991		Thr⇒ Ala ACT⇒ GCT						3 out of 22 cases in metastatic tissue - somatic mutation	Male	Normal		Suzuki et al; Prostate 29: 153-158, 1996		
0279	Prostate cancer	Substitution	8 LBD		877 2991		Thr⇒ Ala ACT⇒ GCT						Somatic mutation in bone metasteses of Prostate cancer	Male	Normal		Kleinerman et al; J of Urology 155: 624A, 1996		
0432	Prostate cancer	Substitution	8 LBD		877 2991		Thr⇒ Ala ACT⇒ GCT						Som mut found in 5 of 16 patients treated with flutamide	Male	Normal		Taplin et al; Cancer Research 59: 2511 -2515		
0603	Prostate cancer	Substitution	8 LBD		877 2991		Thr⇒ Ala ACT⇒ GCT						Somatic mutation - flutamide treated	Male	Normal		Taplin et al; J Clinical Oncology 21: 2673 -2678, 2003		
0604	Prostate cancer	Substitution	8 LBD		877 2991		Thr⇒ Ala ACT⇒ GCT						Somatic mutation - flutamide treated	Male	Normal		Taplin et al; J Clinical Oncology 21: 2673 -2678, 2003		
0647	Prostate cancer	Substitution	8 LBD	*	877 2991		Thr⇒ Ala ACT⇒ GCT						+Gln640Stop- late stage disease- som mut -transactivates	Male	Normal		Ceraline et al; Intl J Cancer 108:152-157, 2003		
0280	Prostate cancer	Substitution	8 LBD	*	877 2992		Thr⇒ Ser ACT⇒ AGT						Som mut. in 86% of isolates .Stimulated by estrogen &	Male	Normal		Taplin et al; New England J Med 332: 1393-1398, 1995		
0539	PAIS	Substitution	8 LBD		879 2997		Asp⇒ Tyr GAC⇒ TAC		normal					Male	Ambiguous		Chavez et al; J Hum Genet. 46: 560-565, 2001		
0553	Prostate cancer	Substitution	8 LBD		879 2998		Asp⇒ Gly GAC⇒ GCC						Treated with bicalumotide - somatic mutation	Male	Normal		Taplin et al; J Clinical Oncology 21: 2673 -2678, 2003		
0281	CAIS	Substitution	8 LBD		881 3003		Leu⇒ Val CTA⇒ GTA						Somatic instability in polyglutamine tract	Female	Normal	pos	Davies et al; Clinical Endocrinology 43: 69 -77, 1995		
0829	CAIS	Substitution	8 LBD		881 3004		Leu⇒ Pro CTA⇒ GCA							Female	Normal	neg	Galani et al; Fertility & Sterility 2008		
0282	CAIS	Substitution	8 LBD		883 3009		Lys⇒ Stop AAG⇒ TAG		zero					Female	Normal	pos	Trifiro et al; Am J Med Genet, 40:493, 1991		
0623	CAIS	Substitution	8 LBD		884 3013		Ser⇒ Stop TCA⇒ TGA	23	v low					Female	Normal		MacLean et al. Hum Mutat. 23:287, 2004		
0283	MAIS	Substitution	8 LBD	*	886 3018		Met⇒ Val ATG⇒ GTG	23	23	normal	normal	norm	Oligospermia-50% red. in transactivation	Male	Normal		Ghadessy et al. J. Clin. Endocrinol. 103:1517 -1525, 1999		
0309	MAIS	Substitution	8 LBD	*	886 3018		Met⇒ Val ATG⇒ GTG	21	24	normal	normal	norm	Oligospermia-50% red. in transactivation	Male	Normal		Ghadessy et al. J. Clin. Endocrinol. 103:1517 -1525, 1999		
0803	Liver cancer	Substitution	8 LBD	*	886 3018		Met⇒ Val ATG⇒ GTG	21	24				Som mut ? + T1034G in 5'UTR. found in tum & non-tumor	Male	Normal		Yeh et al. Int J Cancer 120:1610-1617, 2007		
0697	Prostate cancer	Substitution	8 LBD	*	886 3020		Met⇒ Ile ATG⇒ ATA	21		normal	normal		Increased response to TIF-2 & CBP w DHT w N-CoR > inhibition	Male	Normal		Chen et al; The Prostate 63:395-406, 2005		
0593	PAIS	Substitution	8 LBD	*	888 3026		Ser⇒ Lys AGC⇒ AAG						no immunoreactive AR	Female	Normal		Avila et al. J Clin Endocrinol Metab 87; 182-188. 2002		
0533	PAIS / Splice	Substitution	8 LBD	*	888 3026		Ser⇒ Ser AGC⇒ AGT	21	24	v low	normal		silent mut.-part exon 8+ part of 3' untransl also small amt. wt AR	Male	Ambiguous		Hellwinkel et al. J Clin Endocrinol & Metab 86: 2569-2575, 2001		
0540	PAIS	Substitution / Splice	8 LBD	*	888 3026		Ser⇒ Ser AGC⇒ AGT			normal			silent mutation	Male	Ambiguous		Chavez et al. J Hum Genet. 46: 560-565 2001		
1011	PAIS	Substitution	8 LBD	*	888 3026		Ser⇒ Ser AGC⇒ AGT	23	17	zero	zero		mother heterozygote carrier	Female	Ambiguous	pos	Audi et al. J Clin Endocrinol Metab 95:1876-1888, 2010		
1012	PAIS	Substitution	8 LBD	*	888 3026		Ser⇒ Ser AGC⇒ AGT	25	18					Female	Ambiguous	neg	Audi et al. J Clin Endocrinol Metab 95:1876-1888, 2010		
0284	CAIS	Substitution	8 LBD	*	889 3027		Val⇒ Met GTG⇒ ATG			zero				Female	Normal		Pinsky et al; Clin Inv Med, 15:456, 1992		

Accession #	Mutation type	Exon Domain	Pathogenicity proven	CpG hot spot	Position Base	Change Amino acid	Exon 1 tracts				Androgen Binding Thermolabile				Comments	Sex of rearing	External Genitalia	Family history	Reference
							Poly Gln #	Poly Gly #	Bmax	Kd	k								
0285	PAIS	Substitut	8 LBD	*	889 3027	Val⇒ Met GTG⇒ ATG			low	normal					Female	Ambiguous		De Bellis et al; J Clin Endocrinol Metab, 78:513, 1994	
0321	PAIS	Substitut	8 LBD	*	889 3027	Val⇒ Met GTG⇒ ATG									Female	Normal		Essawi et al; Disease Markers 13: 99-105, 1997	
0476	CAIS	Substitut	8 LBD	*	889 3027	Val⇒ Met GTG⇒ ATG			low	normal					Female	Normal		Ahmed et al; J Clin Endocrinol & Metab 85: 658-665, 2000	
0624	CAIS	Substitut	8 LBD	*	889 3027	Val⇒ Met GTG⇒ ATG	22		low						Female	Normal		MacLean et al. Hum Mutat. 23:287, 2004	
0740	CAIS	Substitut	8 LBD	*	889 3027	Val⇒ Met GTG⇒ ATG									Female	Normal	neg	Ledig et al; Horm Res 63:263-269, 2005	
0999	CAIS	Substitut	8 LBD	*	889 3027	Val⇒ Met GTG⇒ ATG	21	17							Female	Normal	pos	Audi et al. J Clin Endocrinol Metab 95:1876-1888, 2010	
1013	PAIS	Substitut	8 LBD	*	889 3027	Val⇒ Met GTG⇒ CTG	18	14							Male	Ambiguous	neg	Audi et al. J Clin Endocrinol Metab 95:1876-1888, 2010	
0433	Prostate cancer	Substitut	8 LBD	*	890 3030	Asp⇒ Asn GAC⇒ AAC						Mutation also found in peripheral blood			Male	Normal		Taplin et al; Cancer Research 59:2511-2515, 1999	
0389	CAIS	Substitut	8 LBD	*	892 3036	Pro⇒ Ser CCG⇒ TCG	26		low	high		Reduced transactivation			Female	Normal	neg	Peters et al; Mol & Cellular Endocrinol. 148: 47-53, 1999	
0375	CAIS	Substitut	8 LBD		892 3037	Pro⇒ Leu CCG⇒ CTG						Mutation found in two siblings			Female	Normal	pos	Knoke et al; Human Mutation 12: 220, 1998	
0413	CAIS	Substitut	8 LBD		892 3037	Pro⇒ Leu CCG⇒ CTG									Female	Normal		Kanayama et al; Int J Urology 6: 327-330, 1999	
0741	CAIS	Substitut	8 LBD		892 3037	Pro⇒ Leu CCG⇒ CTG									Female	Normal		Ledig et al; Horm Res 63:263-269, 2005	
0742	CAIS	Substitut	8 LBD		892 3037	Pro⇒ Leu CCG⇒ CTG									Female	Normal		Ledig et al; Horm Res 63:263-269, 2005	
0795	CAIS	Deletion	8 LBD		894 3042	Met⇒ 0 ΔATG⇒				3 nt. deletion					Female	Normal		Mueller et al. Hum Genet 119:681, 2006	
0766	Prostate cancer	Substitut	8 LBD		895 3045	Met⇒ Val ATG⇒ GTG						patient lower Gleason score than patient -wt AR- som mutation			Male	Normal		Sanchez et al. BJU Int 98:1320-1325, 2006	
0669	CAIS	Substitut	8 LBD		895 3046	Met⇒ Thr ATG⇒ ACG						Somatic mosaicism			Male	Ambiguous		Kohler et al; J Clin endocrinol & Metab 90: 106-111, 2005	
0386	CAIS	Substitut	8 LBD	*	895 3046	Met⇒ Thr ATG⇒ ACG			low			Reduced transactivation			Female	Normal		Giwercman et al; Human Genetics 103: 529-531, 1998	
1000	CAIS	Substitut	8 LBD		895 3046	Met⇒ Thr ATG⇒ ACG	26	17							Female	Normal	neg	Audi et al. J Clin Endocrinol Metab 95:1876-1888, 2010	
0642	PAIS	Substitut	8 LBD		898 3054	Ile⇒ Phe ATC⇒ TTC	19					Testis located in labia majora- Separated vaginal & urethra opn			Female	Ambiguous	pos	Melo et al; J Clin Endocrinol & Metab 88: 3241-3250, 2003	
0643	PAIS	Substitut	8 LBD		898 3054	Ile⇒ Phe ATC⇒ TTC	19					Testis located in inguinal -Separated vaginal & urethra opn			Female	Ambiguous	pos	Melo et al; J Clin Endocrinol & Metab 88: 3241-3250, 2003	
0644	PAIS	Substitut	8 LBD		898 3054	Ile⇒ Phe ATC⇒ TTC	19					Testis located in inguinal- Single vaginal & urethra opn			Female	Ambiguous	pos	Melo et al; J Clin Endocrinol & Metab 88: 3241-3250, 2003	
0645	PAIS	Substitut	8 LBD		898 3054	Ile⇒ Phe ATC⇒ TTC	19					Testis located in inguinal -Separated vaginal & urethra opn			Female	Ambiguous	pos	Melo et al; J Clin Endocrinol & Metab 88: 3241-3250, 2003	
0286	CAIS	Substitut	8 LBD		898 3055	Ile⇒ Thr ATC⇒ ACC						de novo mutation			Female	Normal	neg	Hiort et al; J Pediatrics 132: 939- 943, 1998	
0649	PAIS	Substitut	8 LBD	*	902 3065	Gln⇒ Lys CAA⇒ AAA			high	high		Involved in TIF2 N/C interaction			Male	Ambiguous	pos	Umar et al; J Clin Endocrinol & Metab 90:507-515, 2005	
1014	PAIS	Substitut	8 LBD		902 3065	Gln⇒ Lys CAA⇒ AAA	21	17				mother heterozygote carrier			Female	Ambiguous	pos	Audi et al. J Clin Endocrinol Metab 95:1876-1888, 2010	

Accession #	Mutation type	Exon Domain	CpG hot spot	Position Base	Change Amino acid Base	Exon 1 tracts				Androgen Binding			Comments	Sex of rearing	External Genitalia	Family history	Reference
						Poly Gln #	Poly Gly #	Bmax	Kd	Thermolabile k							
0287	Prostate cancer	Substitut	8 LBD	902 3066	Gln⇒ Arg CAA⇒ CGA					Somatic mutation in 37% of isolates in initial cloning	Male	Normal				Taplin et al; New England J Med 332: 1393-1398, 1995	
0288	PAIS	Substitut	8 LBD	903 3069	Val⇒ Met GTG⇒ ATG			low		Qualitative binding abnormality						McPhaul et al; J Clin Inv, 90:2097, 1992	
1001	CAIS	Substitut	8 LBD	903 3069	Val⇒ Leu GTG⇒ TTG	23	18			Mother heterozygote carrier	Female	Normal	pos			Audi et al; J Clin Endocrinol Metab 95:1876-1888, 2010	
0289	CAIS	Substitut	8 LBD	904 3072	Pro⇒ Ser CCC⇒ TCC	27	23	normal high			Female	Normal				Pinsky et al; Clin Inv Med, 15:456, 1992	
0290	CAIS	Substitut	8 LBD	904 3073	Pro⇒ His CCC⇒ CAC			zero			Female	Normal				McPhaul et al; J Clin Inv, 90:2097, 1992	
0646	CAIS	Substitut	8 LBD	904 3073	Pro⇒ Val CCC⇒ CGC	21				Testis located in inguinal region	Female	Normal	neg			Melo et al; J Clin Endocrinol & Metab 88: 3241-3250, 2003	
1002	CAIS	Deletion	8 LBD	905 3076	Lys⇒ Arg AAAG⇒ AGA	22	17			mother heterozygote carrier	Female	Normal	pos			Audi et al; J Clin Endocrinol Metab 95:1876-1888, 2010	
0291	CAIS	Substitut	8 LBD	* 3081	Leu⇒ Phe CTT⇒ TTT		low	normal		Decreased transactivat Epididymis & Vas	Female	Normal				Hannema et al; J Clin Endocrinol & Metab 89: 5815-5822, 2004	
0292	PAIS	Substitut	8 LBD	* 3087	Gly⇒ Arg GGG⇒ AGG		low	low		Also silent G to A mutation in codon 211	Female	Ambiguous	pos			Choong et al; J Clin Endocrinol Metab, 81: 236-243, 1996	
0374	Prostate cancer	Substitut	8 LBD	909 3088	Gly⇒ Glu GGG⇒ GAG					Somatic mutation	Male	Normal				Takahashi et al; Cancer Research 55: 1621 -1624, 1995	
0327	Prostate cancer	Substitut	8 LBD	910 3091	Lys⇒ Arg AAA⇒ AGA					Somatic mutation	Male	Normal				Watanabe et al; Jpn J Clin Oncol 27: 389 -393, 1997	
0430	PAIS	Substitut	8 LBD	911 3093	Val⇒ Leu GTC⇒ CTC	19				Severe oligozoospermia	Male	Ambiguous				Knoke et al; Andrologia 31: 199-201, 1999	
0293	PAIS	Substitut	8 LBD	913 3099	Pro⇒ Ser CCC⇒ TCC											Ghirri and Brown; Paed Res, 33(5) Suppl, Abstr 95, 1993	
1015	PAIS	Substitut	8 LBD	913 3099	Pro⇒ Ser CCC⇒ TCC		zero	zero			Female	Ambiguous	neg			Audi et al; J Clin Endocrinol Metab 95:1876-1888, 2010	
0958	CAIS	Substitut	8 LBD	913 3100	Pro⇒ Arg CCC⇒ CGC						Female	Normal	neg			Wu et al. Fertility & Sterility 93:2076, e1-4, 2010	
0844	CAIS	Deletion	8 LBD	* 3107	Tyr⇒ Stop TAAT⇒ TAG				12nt del.Stop in codon 915 affect sister & aunts.neg N/C inter	Female	Normal	pos			Werner et al; Sex Dev 2:73-83, 2008		
0318	CAIS	Substitut	8 LBD	* 3110	Phe⇒ Leu TTC⇒ TTG		low	high	*		Female	Normal				Radnayr et al; J of Urology 158: 1553 -1556, 1997	
0477	CAIS	Substitut	8 LBD	917 3112	His⇒ Arg CAC⇒ CGC						Female	Normal				Ahmed et al; J Clin Endocrinol & Metab 85: 658-665, 2000	
0303	Prostate cancer	Substitut	8 LBD	* 3118	Gln⇒ Arg CAG⇒ CGG					Somatic mutation	Male	Normal				Nazereth et al; 79th US Endo Soc Meetings Abstr. P2-489, 1997	
0294	CAIS	Splice	exon1/intron 1		⇒ gtt⇒ gttt	24	23			Insertion at +3 position of donor splice site	Female	Normal				Trifiro et al; Eur J Hum Genetics 5: 50-58, 1997	
0906	CAIS	Splice	exon1/intron 1		⇒ gttag⇒ gtaac					Substitution at +5 of donor splice site	Female	Normal	pos			Philibert et al; Fertility & Sterility 2009	
0304	CAIS	Splice	exon2/intron 2		⇒ ctg⇒ cta					Substitution at +1 pos of donor splice site - lacks exon 2	Female	Normal	neg			Hellwinkel et al; J Steroid Biochem & Mol Biol 68: 1-9, 1999	
0479	CAIS	Splice	exon2/intron 2		⇒ ⇒			zero			Female	Normal				Ahmed et al; J Clin Endocrinol & Metab 85: 658-665, 2000	
0480	CAIS	Splice	exon2/intron 2		⇒ ⇒						Female	Normal				Ahmed et al; J Clin Endocrinol & Metab 85: 658-665, 2000	
1016	CAIS	Splice	exon2/intron 2		⇒ cag⇒ ccg	13	18			Substit at -2 of acceptor site. Also Lys590Glu mut	Female	Normal	pos			Audi et al; J Clin Endocrinol Metab 95:1876-1888, 2010	

Accession #	Mutation type	Pathogenicity proven	Exon Domain	CpG hot spot	Position Amino acid Base	Change Amino acid Base	Exon 1 tracts				Androgen Binding Thermolabile				Comments	Sex of rearing	External Genitalia	Family history	Reference
							Poly Gln #	Poly Gly #	Bmax	Kd	k								
1017	CAIS	Splice	exon2/intron 2			⇒ <u>cag</u> ⇒ <u>gag</u>	26	18				Substit at -3 of acceptor site. Aborted fetus	Female	Normal	pos	Audi et al. J Clin Endocrinol Metab 95:1876-1888, 2010			
0295	CAIS	Splice	exon3/intron 3			⇒ <u>gtt</u> ⇒ <u>gat</u>						Substitution at +1 position of donor splice site	Female	Normal		Evans et al; J Endocrinol 129 Suppl, Abstr 65, 1991			
0478	CAIS	Splice	exon3/intron 3			⇒ <u>gtt</u> ⇒ <u>gat</u>			normal	normal		Substitution at +1 position of donor splice site	Female	Normal		Ahmed et al; J Clin Endocrinol & Metab 85: 658-665, 2000			
0296	CAIS	Splice	exon4/intron 4			⇒ <u>gtt</u> ⇒ <u>gtt</u>			zero			+1 pos of donor site. Splice site activated & del of aa's 683-723	Female	Normal		Ris-Stalpers et al; Proc Natl AcadSci 87:7866-70, 1990			
0297	CAIS	Splice	exon6/intron 6			⇒ <u>gta</u> ⇒ <u>tta</u>	21		zero			Substitution at +3 position of donor splice site	Female	Normal	pos	Pinsky et al; Eur J Hum Genetics 5: 50-58, 1997			
0503	PAIS	Splice	exon6/intron 6			⇒ <u>taa</u> ⇒ <u>tat</u>		low	normal			Substit. at +5 position of donor splice site, stop at + 79 bases	Female	Ambiguous		Sammarco et al; J Clin Endocrinol & Metab 85: 3256-3261, 2000			
0541	CAIS	Splice	exon6/intron 6			⇒ <u>aac</u> <u>aag</u> ⇒ <u>aac</u>			zero			Substit. at +6 position of donor splice site.	Female	Normal		Chavez et al; J Hum Genet 46: 560-565, 2001			
1018	CAIS	Splice	exon6/intron 6			⇒ <u>gta</u> ⇒ <u>ata</u>	28	17	low	normal		Substit. at -44 pos of donor acceptor site	Female	Normal	neg	Audi et al. J Clin Endocrinol Metab 95:1876-1888, 2010			
0298	CAIS	Splice	exon7/intron 7			⇒ <u>tgt</u> ⇒ <u>tat</u>			zero			Subst. at +1 pos of donor splice, - exon7, stop + 10 aa exon 8	Female	Normal	pos	Lim et al; Mol & Cell Endocrinology 131: 205-210, 1997			
0502	CAIS	Splice	exon7/intron 7			⇒ <u>tgt</u> ⇒ <u>tat</u>						Substitution at + 1 position of donor splice site	Female	Normal		Choi et al; Arch Gynecol Obstet 263: 201-205, 2000			
0670	CAIS	Splice	exon7/intron 7			⇒ <u>tgt</u> ⇒ <u>tat</u>			normal	normal		Subst at + 1 pos of donor splice site somtaic mosaicism	Female	Normal		Kohler et al; J Clin endocrinol & Metab 90: 106-111, 2005			
0299	PAIS	Splice	intron 2/exon 3			⇒ <u>gtt</u> ⇒ <u>gat</u>						Subst. -11 pos accept. 2 transc; -exon3, +69 nt. 3 affect sib;var	Male	Normal	pos	Bruggenwirth et al; Am J Hum Genet 61: 1067-1077, 1997			
0800	CAIS	Splice	intron 2/exon 3			⇒ <u>gac</u> ⇒ <u>aac</u>						Subst. -11 pos accept. 2 transc; -exon3, +69 nt.	Male	Normal		Jaaskelainen et al. Hum Mutat 27:291, 2006			
0909	Prostate cancer	Splice	intron 2/exon 3			⇒ <u>gac</u> ⇒ <u>aac</u>						Subst. -11 pos accept. 2 transc; -exon3, +69 nt. found in 5/8 cases	Male	Normal		Steinkamp et al; Cancer Res 69:4434-4442, 2009			
0809	Prostate cancer	Splice	intron 2/exon 3*			⇒ <u>gac</u> ⇒ <u>aac</u>						+ 69 nt insertion = 23 aa affects AR intracellular traffic	Male	Normal		Jagla et al.; Endocrinology 148:4334-43, 2007			
0317	Breast Cancer	Deletion				⇒ ⇒						-exon 3:higher express of mut.var in 7/13 breast cancer	Female	Normal		Zhu et al. Int J of Cancer 72:574-580, 1997			
0594	CAIS	Substitution	intron 2			ag⇒at ⇒								Female	Normal		Avila et al. J Clin Endocrinol Metab 87:182-188, 2002		
0351	CAIS	Substitution	intron 2			gt⇒at ⇒								Female	Normal		Hiort et al; J Pediatrics 132: 939- 943, 1998		
0088	PAIS	Deletion	intron 2			⇒ ⇒			normal	normal		6 kb del at -18 pos of acceptor site 2 transcr: 1wt,1 - exon3	Male	Ambiguous	pos	Ris-Stalpers et al; Am J Hum Genet 54:609, 1994			
0749	PAIS	Deletion	intron 2			⇒ ⇒				normal	high	6 kb del of intron 2 effects splicing	Male	Ambiguous	pos	Boehmer et al; J Clin Endocrinol & Metab 86:4151-4160, 2001			
0750	PAIS	Deletion	intron 2			⇒ ⇒						related to 0750	Male	Ambiguous	pos	Boehmer et al; J Clin Endocrinol & Metab 86:4151-4160, 2001			
0835	PAIS	Substitution	intron 3			g⇒a ⇒						Male to female	Female	Ambiguous		Melo et al; Arq Bras Endocrinol Metab 49:87-97, 2005			
1022	Premature ovarian failure	Substitution	intron 3			tac⇒taa ⇒						Subst. at +9 of donor site. Patient had menopause at 18	Female	Normal		Panda et al. Gynecol Endocrinol 2010			
0312	Prostate Cancer	Substitution	5' UTR			agc⇒atc ⇒						+2 pos from transcription initiation site AR-TIS II	Male	Normal		Crociotto et al. J Urol 158:1599-1601, 1997			
0313	Prostate cancer	5' UTR	5' UTR			gcc⇒gac ⇒						+214 pos from transcription initiation site AR-TIS II	Male	Normal		Crociotto et al. J Urol 158:1599-1601, 1997			

Accession #	Mutation type	Pathogenicity proven	Exon Domain	CpG hot spot	Position Base	Change Amino acid Base	Exon 1 tracts				Androgen Binding			Comments	Sex of rearing	External Genitalia	Family history	Reference
							Poly Gln #	Poly Gly #	Bmax	Kd	Thermolabile k							
0323	Prostate cancer		3' UTR			⇒ ⇒						Som mut. olymorp seq 2820 -36 dwnstrm to transl init. site	Male	Normal		Paz et al. European Urology 31:209-215, 1997		